Descriptor: "Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]"' showing total 82 results

Start Over Descriptor "Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]"

82 results on '"Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]"'

1. Vol. 27, nº 28. Evaluación de la eficacia del programa de cribado de cáncer de mama en la provincia de Granada

Author: Servicio de Vigilancia y Salud Laboral and Secretaría General de Salud Pública y Consumo
Subjects: Granada, Detección precoz del cáncer, Salud poblacional, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Early Diagnosis::Early Detection of Cancer [Medical Subject Headings], Notificación de enfermedades, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiological Monitoring [Medical Subject Headings], Neoplasias de la Mama, Health Care::Environment and Public Health::Public Health::Public Health Practice::Communicable Disease Control::Disease Notification [Medical Subject Headings], Enfermedades transmisibles, Tamizaje masivo, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Vigilancia epidemiológica, Diseases::Bacterial Infections and Mycoses::Infection::Communicable Diseases [Medical Subject Headings]
Abstract: Yes Enfermedades de Declaración Obligatoria por provincias. Semana 27/2022 y acumulado desde la semana 1/2022. Datos provisionales. Incluye además el artículo titulado "Evaluación de la eficacia del programa de cribado de cáncer de mama en la provincia de Granada", de Francisco José Martín Pérez*, con la tutorización de Miguel Rodríguez Barranco** y Óscar Mendoza García**. *Servicio de Medicina Preventiva y Salud Pública del Hospital Universitario Virgen de las Nieves de Granada. **Registro de Cáncer de Granada.
Published: 2022

2. Mutation of SPINOPHILIN (PPP1R9B) found in human tumors promotes the tumorigenic and stemness properties of cells

Author: Daniel Otero-Albiol, Sandra Muñoz-Galván, Eva M. Verdugo-Sivianes, Amancio Carnero, Ana M. Rojas, [Verdugo-Sivianes,EM, Muñoz-Galván,S, Otero-Albiol,D, Carnero,AS] Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del Rocio, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Spain. [Verdugo-Sivianes,EM, Carnero,AS] CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. [Rojas,AM] Centro Andaluz de Biología del Desarrollo (CABD), CSIC-Universidad Pablo de Olavide, Sevilla, Spain., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00 and RTI2018-096735-B-I00grant from AEI-MICIU/FEDER (RED2018-102723-T), from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union), from Consejeria de Salud (PI-0397-2017) and Consejeria of Economía, Conocimiento, Empresas y Universidad of the Junta de Andalucia (P18-RT-2501). Special thanks are also due to the Fundacion AECC and Fundacion Eugenio Rodriguez Pascual for supporting this work., Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Centro de Investigación Biomédica en Red Cáncer (España), Junta de Andalucía, Fundación Científica Asociación Española Contra el Cáncer, and Fundación Eugenio Rodríguez Pascual
Subjects: 0301 basic medicine, Anatomy::Cells::Cells, Cultured::Cell Line::Cell Line, Tumor [Medical Subject Headings], Proteína de retinoblastoma, Carcinogenesis, Mutant, Medicine (miscellaneous), Anatomy::Cells::Stem Cells::Neoplastic Stem Cells [Medical Subject Headings], medicine.disease_cause, environment and public health, Retinoblastoma Protein, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Mice, 0302 clinical medicine, Breast cancer, pRB, Anatomy::Cells::Cells, Cultured::Cell Line [Medical Subject Headings], stem cell phenotype, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Nerve Tissue Proteins [Medical Subject Headings], Protein Phosphatase 1, Organisms::Eukaryota::Animals [Medical Subject Headings], Proteína fosfatasa 1, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Drug Evaluation, Preclinical::Drug Screening Assays, Antitumor::Xenograft Model Antitumor Assays [Medical Subject Headings], Phosphorylation, Phenomena and Processes::Metabolic Phenomena::Metabolism::Phosphorylation [Medical Subject Headings], Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Cycle [Medical Subject Headings], Cell Line, Transformed, Mutation, Chemicals and Drugs::Macromolecular Substances::Polymers::Biopolymers::Microfilament Proteins [Medical Subject Headings], Retinoblastoma, Línea celular, Microfilament Proteins, Proteína 1 de unión a retinoblastoma, Cell cycle, Diseases::Neoplasms::Neoplastic Processes::Carcinogenesis [Medical Subject Headings], PP1, Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Cycle::Cell Cycle Checkpoints::G1 Phase Cell Cycle Checkpoints [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Neoplasm Proteins::Tumor Suppressor Proteins::Tumor Suppressor Protein p53 [Medical Subject Headings], Gene Expression Regulation, Neoplastic, Anatomy::Cells::Cells, Cultured::Cell Line::Cell Line, Transformed [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Eye Neoplasms::Retinal Neoplasms [Medical Subject Headings], SPINOPHILIN, 030220 oncology & carcinogenesis, Neoplasias de la mama, Neoplastic Stem Cells, Cell lines, Female, biological phenomena, cell phenomena, and immunity, Research Paper, Signal Transduction, Carcinogénesis, cancer stem cell, animal structures, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings], Stem cell phenotype, Mice, Nude, Breast Neoplasms, Nerve Tissue Proteins, macromolecular substances, Biology, Resting Phase, Cell Cycle, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Neoplasm Proteins::Tumor Suppressor Proteins::Retinoblastoma Protein [Medical Subject Headings], Dephosphorylation, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Esterases::Phosphoric Monoester Hydrolases::Phosphoprotein Phosphatases::Protein Phosphatase 1 [Medical Subject Headings], 03 medical and health sciences, Cancer stem cell, Cell Line, Tumor, medicine, Animals, Humans, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Células madre neoplásicas, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings], Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Signal Transduction [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice::Mice, Mutant Strains::Mice, Nude [Medical Subject Headings], pocket proteins, medicine.disease, G1 Phase Cell Cycle Checkpoints, Xenograft Model Antitumor Assays, Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation::Gene Expression Regulation, Neoplastic [Medical Subject Headings], enzymes and coenzymes (carbohydrates), tumorigenesis, 030104 developmental biology, Check Tags::Female [Medical Subject Headings], Tumor progression, Cell culture, Retinoblastoma protein, Tumorigenesis, Cancer research, Tumor Suppressor Protein p53, Pocket proteins, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Holoenzymes [Medical Subject Headings]
Abstract: [Rationale] SPINOPHILIN (SPN, PPP1R9B) is an important tumor suppressor involved in the progression and malignancy of different tumors depending on its association with protein phosphatase 1 (PP1) and the ability of the PP1-SPN holoenzyme to dephosphorylate retinoblastoma (pRB)., [Methods] We performed a mutational analysis of SPN in human tumors, focusing on the region of interaction with PP1 and pRB. We explored the effect of the SPN-A566V mutation in an immortalized non-tumorigenic cell line of epithelial breast tissue, MCF10A, and in two different p53-mutated breast cancer cells lines, T47D and MDA-MB-468., [Results] We characterized an oncogenic mutation of SPN found in human tumor samples, SPN-A566V, that affects both the SPN-PP1 interaction and its phosphatase activity. The SPN-A566V mutation does not affect the interaction of the PP1-SPN holoenzyme with pocket proteins pRB, p107 and p130, but it affects its ability to dephosphorylate them during G0/G1 and G1, indicating that the PP1-SPN holoenzyme regulates cell cycle progression. SPN-A566V also promoted stemness, establishing a connection between the cell cycle and stem cell biology via pocket proteins and PP1-SPN regulation. However, only cells with both SPN-A566V and mutant p53 have increased tumorigenic and stemness properties., [Conclusions] SPN-A566V, or other equivalent mutations, could be late events that promote tumor progression by increasing the CSC pool and, eventually, the malignant behavior of the tumor., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00 and RTI2018-096735-B-I00 grant from AEI-MICIU/FEDER (RED2018-102723-T); from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejeria de Salud (PI-0397-2017) and Consejeria of Economía, Conocimiento, Empresas y Universidad of the Junta de Andalucia (P18-RT-2501). Special thanks are also due to the Fundacion AECC and Fundacion Eugenio Rodriguez Pascual for supporting this work.
Published: 2021

3. Efectividad, eficacia y seguridad de la citología con evaluación in situ en punción aspiración con aguja fina y biopsia con aguja gruesa ecoguiadas

Author: Lorena Aguilera-Cobos, Elena Baños-Álvarez, Mª Piedad Rosario-Lozano, Juan Antonio Blasco-Amaro, [Aguilera Cobos, L, Baños Álvarez, E, Rosario Lozano, MP, Blasco Amaro, JA] AETSA Evaluación de Tecnologías Sanitarias de Andalucía, Consejería de Salud y Consumo, Junta de Andalucía, and Este documento ha sido realizado por la AETSA, Evaluación de Tecnologías Sanitarias de Andalucía en el marco de la financiación de la Ministerio de Sanidad para el desarrollo de las actividades del Plan anual de Trabajo de la Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS, aprobado en el Pleno del Consejo Interterritorial del SNS de 06 de mayo de 2021.
Subjects: Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis [Medical Subject Headings], Citodiagnóstico, Lung Neoplasms, Technology Assessment, Biomedical, Neoplasias pulmonares, Cytodiagnosis, Biopsia por Aspiración con Aguja Fina Guiada por Ultrasonido Endoscópico, Breast Neoplasms, Evaluación de la Tecnología Biomédica, Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [Medical Subject Headings], Neoplasias de la mama, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Ultrasonography::Ultrasonography, Interventional::Endoscopic Ultrasound-Guided Fine Needle Aspiration [Medical Subject Headings], Endoscopic Ultrasound-Guided Fine Needle Aspiration, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]
Abstract: Introducción / justificación: La evaluación de la citología in situ (ROSE, del inglés rapid on-site evaluation) se plantea como una posible mejora de la técnica diagnóstica de lesiones oncológicas tras la obtención de la muestra por punción aspirativa con aguja fina o biopsia con aguja gruesa. Esta técnica podría mejorar el método de valoración de la idoneidad de la muestra, e incluso permitir un rápido diagnóstico preliminar. Objetivo: Evaluar la eficacia, efectividad y seguridad de la citología con evaluación in situ en punción aspiración con aguja fina y biopsia con aguja gruesa ecoguiadas con respecto al protocolo de evaluación habitual. Metodología: Revisión sistemática de la literatura, incluyendo informes de evaluación de tecnologías, revisiones sistemáticas y metaanálisis. Para su elaboración se consultaron las siguientes bases de datos referenciales hasta septiembre de 2021 (con lenguaje libre y controlado): Medline (Ovid), Embase (Excerpta Medica DataBase), Cochrane Library (Cochrane Review Database), INAHTA (International HTA Database), WOS (SCI Science Citation Index) y PubMed (Ahead of print/First on line). También se exploraron EvidenceSearch y TripDataBase, así como las principales webs de agencias europeas: National Institute for Health and Care Excellence (NICE), Canadian Agency for Drugs and Technologies in Health (CADTH), Agency for Healthcare Research and Quality (AHRQ) y la Red española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS (RedETS). La selección de los estudios y el análisis de su calidad se realizaron por dos investigadores independientes. La síntesis de los resultados se llevó a cabo de forma cualitativa. La calidad de los estudios fue evaluada mediante las herramientas AMSTAR-2 para revisiones sistemáticas. Resultados: Se incluyeron 2 revisiones sistemáticas con metaanálisis. Se identificaron algunas debilidades en el análisis de la calidad de los trabajos seleccionados y la calidad general fue moderada-baja. Se evaluó la eficacia de la técnica ROSE para la indicación de sospecha de cáncer de mama, gracias a una de las revisiones sistemáticas incluidas. La diferencia en la eficacia entre las intervenciones en las que se usó esta técnica y en las que no se usó, no resultó estadísticamente significativa. Los autores de la revisión destacan que esta diferencia no significativa puede deberse a que la tasa de adecuación de las muestras sin la utilización de ROSE ya es alta por lo que el margen de posible mejora con esta técnica es limitado. Se evaluó la eficacia, la seguridad y la eficiencia de la técnica ROSE para la indicación de sospecha de cáncer de pulmón, gracias a una de las revisiones sistemáticas incluidas. En cuanto a la seguridad de la técnica en esta indicación, no se observaron diferencias significativas en la ratio de complicaciones en pacientes en los que se usó la técnica ROSE frente a pacientes en los que no se usó. En cuanto a la eficacia, todas las variables resultado mostraron valores de mayor eficacia cuando se aplicó la técnica ROSE, aunque cabe destacar la variabilidad de dichos valores entre los diferentes estudios incluidos en la revisión. Conclusiones: La técnica ROSE puede suponer una mejora en la adecuación de las muestras oncológicas y proveer un prediagnóstico de utilidad clínica para el posible tratamiento del paciente. Esta mejora es especialmente significativa en las muestras de sospecha de cáncer de pulmón, a diferencia de las pacientes con sospecha de cáncer de mama en las cuales la eficacia de la técnica no muestra diferencias significativas. Se necesitan más estudios prospectivos, controlados y aleatorizados para ambas indicaciones. Se recomienda que estos estudios homogenicen los parámetros de la técnica ROSE para evitar posibles fuentes de heterogeneidad. Además, se aconseja que estos estudios incluyan aspectos económicos que permitan la evaluación de la eficiencia.
Published: 2022
Full Text: View/download PDF

4. Evidence Update on the Relationship between Diet and the Most Common Cancers from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study: A Systematic Review

Author: Ubago-Guisado, Esther, Rodríguez-Barranco, Miguel, Ching-López, Ana, Petrova, Dafina, Molina-Montes, Esther, Amiano, Pilar, Barricarte-Gurrea, Aurelio, Chirlaque, María-Dolores, Agudo, Antonio, Sánchez, María-José, [Ubago-Guisado,E, Rodríguez-Barranco,M, Ching-López,A, Petrova,D, Sánchez,MJ] Cancer Registry of Granada, Escuela Andaluza de Salud Pública, Granada, Spain. [Ubago-Guisado,E, Molina-Montes,E, Amiano,P, Barricarte-Gurrea,A, Chirlaque,MD, Sánchez,MJ] Epidemiology and Control of Chronic Diseases, CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Ubago-Guisado,E, Sánchez,MJ] Cancer Epidemiology Group, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. [Petrova,D] Department of Experimental Psychology, Mind, Brain and Behavior Research Center (CIMCYC), University of Granada, Granada, Spain. [Molina-Montes,E] Department of Nutrition and Food Science, Campus of Cartuja, University of Granada, Granada, Spain. [Molina-Montes,E] Institute of Nutrition and Food Technology (INYTA) ‘José Mataix’, Biomedical Research Centre, University of Granada, Granada, Spain. [Amiano,P] Public Health Division of Gipuzkoa, BioDonostia Research Institute, Donostia-San Sebastian, Spain. [Barricarte-Gurrea,A] Navarra Public Health Institute, Pamplona, Spain. [Barricarte-Gurrea,A] Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [Chirlaque,MD] Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, Murcia, Spain. [Agudo,A] Unit of Nutrition and Cancer, Catalan Institute of Oncology, L’Hospitalet de Llobregat, Spain. [Agudo,A] Nutrition and Cancer Group, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Bellvitge Biomedical Research Institute—IDIBELL, L’Hospitalet de Llobregat, Spain. [Sánchez,MJ] Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain., and E.U.-G. is supported by the Programa Operativo Fondo Social Europeo (FSE) de Andalucía (2014–2020) and Junta de Andalucía (reference DOC_01618).
Subjects: Metaanalisis, Frutas, Meat, Neoplasias de la próstata, Neoplasias pulmonares, Etanol, Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [Medical Subject Headings], Carne, Fruits, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Ingestión de alimentos, Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms [Medical Subject Headings], Breast cancer, Neoplasias colorrectales, Vegetables, Prospective Studies, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Prostate cancer, Revisión sistemática, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings], Diseases::Neoplasms [Medical Subject Headings], Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena [Medical Subject Headings], Colorectal cancer, Fish, Verduras, Neoplasias de la mama, Intake, Geographical Locations::Geographic Locations::Europe [Medical Subject Headings], Lung cancer, Alcohol
Abstract: The European Prospective Investigation into Cancer and Nutrition (EPIC) is a multicentre prospective study conducted in 23 centres in 10 European countries. Here we review the findings from EPIC on the relationship between diet-related exposures and incidence or mortality from the four most frequent cancers in the European population: colorectal, breast, lung, and prostate cancer. We conducted a systematic review following PRISMA guidelines and identified 110 high-quality studies based on the EPIC cohort. Fruit and vegetable consumption had a protective effect against colorectal, breast, and lung cancer, whereas only fruit had a protective effect against prostate cancer. A higher consumption of fish and lower consumption of red and processed meat were related with a lower risk of colorectal cancer; and higher consumption of fatty fish with lower risk of breast cancer. Calcium and yogurt intake were found to protect against colorectal and prostate cancer. Alcohol consumption increased the risk for colorectal and breast cancer. Finally, adherence to the Mediterranean diet emerged as a protective factor for colorectal and breast cancer. The EPIC study results are in agreement with the latest evidence from leading authorities on cancer prevention and help to inform public prevention policies and strategies. Yes
Published: 2021

5. Editorial: Pathophysiological Interrelationship Between Obesity, Metabolic Diseases, and Cancer

Author: Manuel D. Gahete, Riccarda Granata, Raúl M. Luque, [Gahete,MD, Luque,RM] Maimóinides Institute of Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain. [Gahete,MD, Luque,RM] Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain. [Gahete,MD, Luque,RM] Reina Sofía University Hospital, Córdoba, Spain. [Gahete,MD, and Luque,RM] CIBER Pathophysiology of Obesity and Nutrition (CIBERobn), Córdoba, Spain. [Granata,R] Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Subjects: Síndrome metabólico, cancer, metabolic syndrome, metabolism, obesity, tumor, Cancer Research, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Early Diagnosis::Early Detection of Cancer [Medical Subject Headings], Obesidad, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Fat Distribution::Adiposity [Medical Subject Headings], Bioinformatics, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperinsulinism::Insulin Resistance [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma [Medical Subject Headings], Medicine, Obesity, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], RC254-282, Cancer, Metabolismo, Tumor, business.industry, Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2 [Medical Subject Headings], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Diseases::Neoplasms [Medical Subject Headings], medicine.disease, Metabolic syndrome, Neoplasias, Health Care::Environment and Public Health::Public Health::Epidemiologic Measurements::Biometry::Anthropometry::Body Mass Index [Medical Subject Headings], Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity::Obesity, Abdominal [Medical Subject Headings], Pathophysiology, Metabolism, Oncology, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Somatomedins::Insulin-Like Growth Factor I [Medical Subject Headings], Anatomy::Cells::Myeloid Cells::Macrophages [Medical Subject Headings], business
Abstract: Yes
Published: 2021
Full Text: View/download PDF

6. Metalloproteinases 1 and 3 as Potential Biomarkers in Breast Cancer Development

Author: Amanda Rocío González Ramírez, Sandra Ríos Arrabal, Pablo Torne Poyatos, Alejandro Alonso, Angela Ximena Argote Camacho, María Auxiliadora Olivares Urbano, Juan David Rejón García, María Isabel Núñez, [Argote Camacho,AX] Department of Surgery, Clínico San Cecilio University Hospital, Granada, Spain. [González Ramírez,AR] Bio-Health Research Foundation of Eastern Andalusia—Alejandro Otero (FIBAO), Granada, Spain. [Pérez Alonso,AJ] Department of Surgery, Virgen de las Nieves University Hospital, Granada, Spain. [Rejón García,JD] Andalusian Tumour Bank Network, Granada, Spain. [Olivares Urbano,MA, Ríos Arrabal,S, Nuñez,MI] Department of Radiology and Physical Medicine, University of Granada, Granada, Spain. [Torné Poyatos,P] Department of Surgery and Its Specialties, University of Granada, Granada, Spain. [Nuñez,MI] Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada, Spain. [Nuñez,MI] Biosanitary Research Institute, ibs.Granada, Granada, Spain., and This research was funded by Fundación Progreso Salud, grant number PI-0730-2013, and by ISCIII, grant number PIE16/00045.
Subjects: Oncology, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Endopeptidases::Metalloendopeptidases::Collagenases::Matrix Metalloproteinase 2 [Medical Subject Headings], Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Metalloproteases [Medical Subject Headings], Metaloproteinasas de la matriz, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings], Disease, Matrix metalloproteinase, medicine.disease_cause, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Endopeptidases::Metalloendopeptidases::Collagenases::Matrix Metalloproteinase 1 [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Cohort Studies, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Endopeptidases::Metalloendopeptidases::Matrix Metalloproteinases::Matrix Metalloproteinases, Secreted::Matrix Metalloproteinase 3 [Medical Subject Headings], MMP inhibitors, Medicine, Breast, Biology (General), Spectroscopy, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Aged, 80 and over, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Metalloproteases::Metalloendopeptidases::Collagenases::Matrix Metalloproteinase 9 [Medical Subject Headings], Mortality rate, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Proteinase Inhibitory Proteins, Secretory::Tissue Inhibitor of Metalloproteinases [Medical Subject Headings], Proteolytic enzymes, Tissue Inhibitor of Metalloproteinases, General Medicine, Diseases::Neoplasms::Neoplastic Processes::Carcinogenesis::Cocarcinogenesis [Medical Subject Headings], Middle Aged, Immunohistochemistry, Computer Science Applications, Chemistry, Matrix Metalloproteinase 9, Disease Progression, Matrix Metalloproteinase 2, Female, Matrix Metalloproteinase 3, Matriz extracelular, MMPs, Matrix Metalloproteinase 1, Chemicals and Drugs::Biological Factors::Biological Markers::Biomarkers, Pharmacological [Medical Subject Headings], medicine.medical_specialty, QH301-705.5, extracellular matrix, Breast Neoplasms, Catalysis, Article, metalloproteinases, Inorganic Chemistry, Breast cancer, breast cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings], Internal medicine, Biomarkers, Tumor, Humans, Metaloproteasas, immunohistochemical expression, Physical and Theoretical Chemistry, Molecular Biology, QD1-999, Linfedema del cáncer de mama, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Aged, Retrospective Studies, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [Medical Subject Headings], business.industry, Organic Chemistry, Inhibidores de la metaloproteinasa de la matriz, biomarkers, Retrospective cohort study, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], medicine.disease, Biomarcadores, Persons::Persons::Age Groups::Adult::Aged::Aged, 80 and over [Medical Subject Headings], Spain, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], diagnostic factors, Case-Control Studies, Metalloproteases, business, Carcinogenesis, epithelial-to-mesenchymal transition (EMT)
Abstract: Breast cancer continues to be one of the main causes of morbidity and mortality globally and was the leading cause of cancer death in women in Spain in 2020. Early diagnosis is one of the most effective methods to lower the incidence and mortality rates of breast cancer. The human metalloproteinases (MMP) mainly function as proteolytic enzymes degrading the extracellular matrix and plays important roles in most steps of breast tumorigenesis. This retrospective cohort study shows the immunohistochemical expression levels of MMP-1, MMP-2, MMP-3, and MMP-9 in 154 women with breast cancer and 42 women without tumor disease. The samples of breast tissue are assessed using several tissue matrices (TMA). The percentages of staining (≤50%–&gt, 50%) and intensity levels of staining (weak, moderate, or intense) are considered. The immunohistochemical expression of the MMP-1-intensity (p = 0.043) and MMP-3 percentage (p = 0.018) and intensity, (p = 0.025) present statistically significant associations with the variable group (control–case), therefore, expression in the tumor tissue samples of these MMPs may be related to the development of breast cancer. The relationships between these MMPs and some clinicopathological factors in breast cancer are also evaluated but no correlation is found. These results suggest the use of MMP-1 and MMP-3 as potential biomarkers of breast cancer diagnosis.
Published: 2021

7. Bisphenol-A exposure and risk of breast and prostate cancer in the Spanish European Prospective Investigation into Cancer and Nutrition study

Author: Sandra Colorado, María José Sánchez, Ana Jimenez, Antonio Agudo, Pilar Amiano, Elena Salamanca-Fernández, Marcela Guevara, Nicolás Olea, Fernando Vela, Josu Delfrade, Juan P. Arrebola, Miguel Rodríguez-Barranco, Maria Dolores Chirlaque, [Salamanca-Fernández,E, Rodríguez-Barranco,M, Sánchez,MJ] Andalusian School of Public Health (EASP), Campus Universitario de Cartuja, Granada, Spain. [Salamanca-Fernández,E, Arrebola,JP, Vela,F, Olea,N, Sánchez,MJ] Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain. [Rodríguez-Barranco,M, Amiano,P, Delfrade,J, Chirlaque,MD, Colorado,S, Guevara,M, Sánchez,MJ] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Amiano,P, Jimenez,A] Public Health Division of Gipuzkoa, BioDonostia Research Institute, Donostia-San Sebastian, Spain. [Delfrade,J, Guevara,M] Navarra Public Health Institute, Pamplona, Spain. [Delfrade,J, Guevara,M] Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [Chirlaque,MD, Colorado,S] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Chirlaque,MD] Department of Health and Sciences, University of Murcia, Murcia, Spain. [Colorado,S] Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia. [Arrebola,JP, Sánchez,MJ] Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. [Olea,N] Department of Radiology, University of Granada, Granada, Spain. [Agudo,A] Unit of Nutrition and Cancer, Catalan Institute of Oncology - ICO, Nutrition and Cancer Group, Bellvitge Biomedical Research Institute - IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain., and This work was supported by the Ministry of economy and competitiveness and the National Institute of Health: Instituto de Salud Carlos III (ISCIII). Exps: PI14/00067, PI14/01716, PI14/01880, PI14/00556. BA15/00093. FFIS-CC 2016–06 AECC 'Junta provincial de Murcia'. FEDER and AECC 2015. Dr. J.P. Arrebola is under contract within Ramon y Cajal program (RYC-2016-20155, Ministerio de Economía, Industria y Competitividad, Spain). The EPIC-Spain cohort was supported by the Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), the Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO (Spain).
Subjects: Oncology, Chemicals and Drugs::Chemical Actions and Uses::Toxic Actions::Environmental Pollutants [Medical Subject Headings], Male, Neoplasias de la próstata, Health, Toxicology and Mutagenesis, Endocrine Disruptors, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Cohort Studies, Prostate cancer, Breast cancer, Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Acyclic::Acrylates::Methacrylates::Bisphenol A-Glycidyl Methacrylate [Medical Subject Headings], Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], education.field_of_study, Factors de risc en les malalties, Hazard ratio, Middle Aged, European Prospective Investigation into Cancer and Nutrition, Health Care::Environment and Public Health::Public Health::Environmental Pollution::Environmental Exposure [Medical Subject Headings], Environmental pollutants, Diseases::Male Urogenital Diseases::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms [Medical Subject Headings], Bisphenol a, Endocrine disruptor, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk [Medical Subject Headings], Neoplasias de la mama, Population study, Female, Public aspects of medicine, RA1-1270, Disruptores endocrinos, Adult, Risk, medicine.medical_specialty, endocrine system, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Risk factors in diseases, Population, Estudios de cohortes, Case-cohort, Check Tags::Male [Medical Subject Headings], Breast Neoplasms, Càncer de mama, Phenols, Bisfenol A glicidil metacrilato, Internal medicine, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Benzene Derivatives::Phenols [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings], medicine, Humans, Benzhydryl Compounds, education, Persons::Persons::Age Groups::Adult [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Aged, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], Càncer de pròstata, Proportional hazards model, business.industry, urogenital system, Research, Public Health, Environmental and Occupational Health, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Endocrine Disruptors [Medical Subject Headings], Prostatic Neoplasms, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Benzene Derivatives::Benzhydryl Compounds [Medical Subject Headings], Environmental Exposure, medicine.disease, Industrial medicine. Industrial hygiene, RC963-969, Check Tags::Female [Medical Subject Headings], Spain, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Sensitivity and Specificity::Limit of Detection [Medical Subject Headings], business, Contaminantes ambientales
Abstract: This work was supported by the Ministry of economy and competitiveness and the National Institute of Health: Instituto de Salud Carlos III (ISCIII). Exps: PI14/00067, PI14/01716, PI14/01880, PI14/00556. BA15/00093. FFIS-CC 2016-06 AECC "Junta provincial de Murcia". FEDER and AECC 2015. Dr. J.P. Arrebola is under contract within Ramon y Cajal program (RYC-2016-20155, Ministerio de Economia, Industria y Competitividad, Spain). The EPIC-Spain cohort was supported by the Health Research Fund (FIS) -Instituto de Salud Carlos III (ISCIII), the Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology -ICO (Spain)., Background Bisphenol A (BPA) is an endocrine disruptor that it is present in numerous products of daily use. The aim of this study was to assess the potential association of serum BPA concentrations and the risk of incident breast and prostate cancer in a sub-cohort of the Spanish European Prospective Investigation into Cancer and Nutrition (EPIC). Methods We designed a case-cohort study within the EPIC-Spain cohort. Study population consisted on 4812 participants from 4 EPIC-Spain centers (547 breast cancer cases, 575 prostate cancer cases and 3690 sub-cohort participants). BPA exposure was assessed by means of chemical analyses of serum samples collected at recruitment. Borgan II weighted Cox regression was used to estimate hazard ratios. Results Median follow-up time in our study was 16.9 years. BPA geometric mean serum values of cases and sub-cohort were 1.12 ng/ml vs 1.10 ng/ml respectively for breast cancer and 1.33 ng/ml vs 1.29 ng/ml respectively for prostate cancer. When categorizing BPA into tertiles, a 40% increase in risk of prostate cancer for tertile 1 (p = 0.022), 37% increase for tertile 2 (p = 0.034) and 31% increase for tertile 3 (p = 0.072) was observed with respect to values bellow the limit of detection. No significant association was observed between BPA levels and breast cancer risk. Conclusions We found a similar percentage of detection of BPA among cases and sub-cohort from our population, and no association with breast cancer risk was observed. However, we found a higher risk of prostate cancer for the increase in serum BPA levels. Further investigation is needed to understand the influence of BPA in prostate cancer risk., Ministry of economy and competitiveness, National Institute of Health: Instituto de Salud Carlos III (ISCIII), AECC "Junta provincial de Murcia" PI14/00067- PI14/01716- PI14/01880- PI14/00556- BA15/00093- FFIS-CC 2016-06, Spanish Government RYC-2016-20155, Health Research Fund (FIS) -Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, Catalan Institute of Oncology -ICO (Spain)
Published: 2021

8. Quality indicators for breast cancer care: A systematic review

Author: Maes-Carballo, Marta, Gómez-Fandiño, Yolanda, Reinoso-Hermida, Ayla, Estrada-López, Carlos Roberto, Martín-Díaz, Manuel, Khan, Khalid Saeed, Bueno-Cavanillas, Aurora, [Maes-Carballo,M, Gómez-Fandiño,Y, Reinoso-Hermida,A, Estrada-López,CR] Department of General Surgery, Complexo Hospitalario de Ourense, Ourense, Spain. [Maes-Carballo,M, Khan,KS, Bueno-Cavanillas,A] Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. [Maes-Carballo,M] Department of General Surgery, Hospital de Verín, Ourense, Spain. [Martín-Díaz,CR] Department of General Surgery, Hospital Santa Ana de Motril, Granada, Spain. [Khan,KS, and Bueno-Cavanillas,A] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Bueno-Cavanillas,A] Instituto de Investigacion Biosanitaria IBS, Granada, Spain
Subjects: Information Science::Information Science::Medical Informatics::Medical Informatics Applications::Information Systems::Databases as Topic::Databases, Bibliographic::PubMed::MEDLINE [Medical Subject Headings], Quality care, Geographical Locations::Geographic Locations::Americas::North America [Medical Subject Headings], Health Care::Health Services Administration::Quality of Health Care::Quality Indicators, Health Care [Medical Subject Headings], Indicadores de calidad de la atención de salud, Health care, Quality indicators, Geographical Locations::Geographic Locations::Europe::Italy [Medical Subject Headings], Health Care::Health Care Quality, Access, and Evaluation::Delivery of Health Care [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Health Care::Health Services Administration::Patient Care Management::Critical Pathways [Medical Subject Headings], Check Tags::Female [Medical Subject Headings], Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care [Medical Subject Headings], Breast cancer care, Neoplasias de la mama, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings], Geographical Locations::Geographic Locations::Europe::Belgium [Medical Subject Headings], Information Science::Information Science::Computing Methodologies::Computer Systems::Computer Communication Networks::Internet [Medical Subject Headings], Information Science::Information Science::Communications Media::Publications::Bibliography as Topic::Bibliometrics [Medical Subject Headings], Calidad de la atención de Salud, Atención a la salud, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Standard of Care [Medical Subject Headings], Psychiatry and Psychology::Behavioral Disciplines and Activities::Mental Health Services::Counseling [Medical Subject Headings]
Abstract: Objectives We evaluated breast cancer (BC) care quality indicators (QIs) in clinical pathways and integrated health care processes. Methods Following protocol registration (Prospero no: CRD42021228867), relevant documents were identiﬁed, without language restrictions, through a systematic search of bibliographic databases (EMBASE, Scopus, Web of Science, MEDLINE), health care valuable representatives and the World Wide Web in April 2021. Data concerning QIs, measurement tools and compliance standards were extracted from European and North American sources in duplicate with 98% reviewer agreement. Results There were 89 QIs found from 22 selected documents (QI per document mean 13.5 with standard deviation 11.9). The Belgian (38 QIs) and the EUSOMA (European Society of Breast Cancer Specialists) (34 QIs) documents were the ones that best reported the QIs. No identical QI was identified in all the documents analysed. There were 67/89 QIs covering processes (75.3%) and 11/89 (12.4%) for each structure and outcomes QIs. There were 21/89 QIs for diagnosis (30.3%), 43/89 for treatment (48.3%), and 19/89 for staging, counselling, follow-up and rehabilitation (21.4%). Of 67 process QIs and 11 outcome QIs, 20/78 (26%) did not report a minimum standard of care. Shared decision making was only included as a QI in the Italian document. Conclusion More than half of countries have not established a national clinical pathway or integrated breast cancer care process to achieve the excellence of BC care. There was heterogeneity in QIs for the evaluation of BC care quality. Over two-thirds of the clinical pathways and integrated health care processes did not provide a minimum auditable standard of care for compliance, leaving open the definition of best practice. There is a need for harmonisation of BC care QIs. Yes
Published: 2021

9. Impact of Rowing Training on Quality of Life and Physical Activity Levels in Female Breast Cancer Survivors

Author: José Carlos Fernández-García, Juan Gavala-González, Amanda Torres-Pérez, [Gavala-González,J] Department of Physical Education and Sports, University of Seville, Seville, Spain. [Gavala-González,J, Torres-Pérez,A, Fernández-García,JC] Researching in Sport Science: Research Group (CTS-563) of the Andalusian Research Plan, Malaga, Spain. [Torres-Pérez,A, Fernández-García,JC] Department of Didactics of Languages, Arts and Sport, University of Malaga, Andalucía-Tech, IBIMA, Malaga, Spain., This research was funded by the 'Researching in Sport Sciences' research group (CTS-563) of the Andalusian Research Plan., and Universidad de Sevilla. Departamento de Educación Física y Deporte
Subjects: Longitudinal study, Calidad de vida, Health, Toxicology and Mutagenesis, Rowing, perceived health, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Quality of life, Cancer Survivors, IPAQ-SF, Supervivientes de cáncer, Medicine, 030212 general & internal medicine, Longitudinal Studies, Stage (cooking), Total Mastectomy, Mastectomy, Water Sports, rowing, exercise, Deportes acuáticos, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Questionnaires [Medical Subject Headings], Middle Aged, Ejercicio físico, Encuestas y cuestionarios, Anthropology, Education, Sociology and Social Phenomena::Social Sciences::Quality of Life [Medical Subject Headings], 030220 oncology & carcinogenesis, Neoplasias de la mama, Female, medicine.medical_specialty, SF-36, Physical activity, Breast Neoplasms, Article, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Mastectomy::Mastectomy, Simple [Medical Subject Headings], 03 medical and health sciences, Breast cancer, breast cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies [Medical Subject Headings], Humans, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Health Surveys [Medical Subject Headings], business.industry, Breast cancer survivor, Public Health, Environmental and Occupational Health, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], medicine.disease, Check Tags::Female [Medical Subject Headings], quality of life, Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Musculoskeletal Physiological Processes::Movement::Motor Activity::Exercise [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Mastectomy [Medical Subject Headings], Physical therapy, business
Abstract: The aim of this longitudinal study was to determine whether a rowing training program improved the quality of life and the physical activity levels in female breast cancer survivors (n = 28) (stage 1–4.54%, stage 2–36.36%, stage 3–54.54%, and stage 4–4.54%), diagnosed 4.68 ± 3.00 years previously, who had undergone a subsequent intervention (preservation 56.53% and total mastectomy 43.47%) and had a current mean age of 52.30 ± 3.78 years. The participants (n = 28) engaged in a 12-week training program, each week comprising three sessions and each session lasting 60–90 min. The short form of the International Physical Activity Questionnaire (IPAQ-SF) and the Short Form 36 Health Survey (SF-36) were also administered. The results showed statistically significant improvements in levels of physical activity and in the dimensions of quality of life. We can conclude that a 12-week rowing training program tailored to women who have had breast cancer increases physical activity levels, leading to improved health status and quality of life.
Published: 2021

10. Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study

Author: Esperanza Torres, Emilio Alba, M. Cobo, Inmaculada Ramos, Ana Godoy, Laura Galvez, Nuria Ribelles, Sofia Ruiz-Medina, Begoña Jimenez, Marta Muñoz-Ayllon, Pablo Rodriguez-Brazzarola, Mireya Cazorla, María José Bermejo, Tamara Diaz-Redondo, Antonio Rueda, Carmen Reyna, Silvia Gil, [Ruiz-Medina,S, Gil,S, Jimenez,B, Diaz-Redondo,T, Cazorla,M, Muñoz-Ayllon,M, Ramos,I, Reyna,C, Bermejo,MJ, Godoy,A, Torres,E, Cobo,M, Galvez,L, Rueda,A, Alba,E, and Ribelles,N] Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain. [Rodriguez-Brazzarola,P] Grupo de Inteligencia Computacional en Biomedicina, ETSI Ingeniería Informática, Universidad de Málaga, Málaga, Spain.
Subjects: Cancer Research, Pediatrics, medicine.medical_specialty, Diseases::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms [Medical Subject Headings], Coronavirus disease 2019 (COVID-19), Infecciones por coronavirus, COVID-19 pandemic, Article, 03 medical and health sciences, cancer diagnoses, 0302 clinical medicine, Breast cancer, Pandemic, medicine, 030212 general & internal medicine, Medical diagnosis, Pathological, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], RC254-282, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], Pandemia, SARS-CoV-2, business.industry, COVID-19, Health Care::Environment and Public Health::Public Health::Disease Outbreaks::Epidemics::Pandemics [Medical Subject Headings], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cancer, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings], medicine.disease, Neoplasias, Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings], Hospital care, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings], Oncology, 030220 oncology & carcinogenesis, Population study, business, real data
Abstract: The COVID-19 pandemic has caused a profound change in health organizations at both the primary and hospital care levels. This cross-sectional study aims to investigate the impact of the COVID-19 pandemic in the annual rate of new cancer diagnosis in two university-affiliated hospitals. This study includes all the patients with a pathological diagnosis of cancer attended in two hospitals in Málaga (Spain) during the first year of pandemic. This study population was compared with the patients diagnosed during the previous year 2019. To analyze whether the possible differences in the annual rate of diagnoses were due to the pandemic or to other causes, the patients diagnosed during 2018 and 2017 were also compared. There were 2340 new cancer diagnosis compared to 2825 patients in 2019 which represented a decrease of −17.2% (p = 0.0001). Differences in the number of cancer patients diagnosed between 2018 and 2019 (2840 new cases, 0.5% increase) or 2017 and 2019 (2909 new cases, 3% increase) were not statistically significant. The highest number of patients lost from diagnosis in 2020 was in breast cancer (−26.1%), colorectal neoplasms (−16.9%), and head and neck tumors (−19.8%). The study of incidence rates throughout the first year of the COVID-19 pandemic shows that the diagnosis of new cancer patients has been significantly impaired. Health systems must take the necessary measures to restore pre-pandemic diagnostic procedures and to recover lost patients who have not been diagnosed.
Published: 2021

11. Breast Cancer Care Quality Indicators in Spain: A Systematic Review

Author: Maes-Carballo, Marta, Gómez-Fandiño, Yolanda, Estrada-López, Carlos Roberto, Reinoso-Hermida, Ayla, Khan, Khalid Saeed, Martín-Díaz, Manuel, Bueno-Cavanillas, Aurora, [Maes-Carballo,M, Gómez-Fandiño,Y, Estrada-López,CR, Reinoso-Hermida,A] Department of General Surgery, Complexo Hospitalario de Ourense, Ourense, Spain. [Maes-Carballo,M, Khan,KS, Bueno-Cavanillas,A] Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. [Maes-Carballo,M] Department of General Surgery, Hospital Público de Verín, Ourense, Spain. [Khan,KS, and Bueno-Cavanillas,A] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Martín-Díaz,M] Department of General Surgery, Hospital de Motril, Granada, Spain. [Bueno-Cavanillas,A] Instituto de Investigación Biosanitaria IBS, Granada, Spain.
Subjects: Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], Quality care, Health Care::Health Services Administration::Quality of Health Care [Medical Subject Headings], Health Care::Health Services Administration::Quality of Health Care::Quality Indicators, Health Care [Medical Subject Headings], Indicadores de calidad de la atención de salud, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], España, Revisión sistemática, Health care, Quality indicators, Health Care::Health Services Administration::Organization and Administration::Public Relations::Consumer Satisfaction::Patient Satisfaction [Medical Subject Headings], Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Check Tags::Female [Medical Subject Headings], Breast cancer care, Neoplasias de la mama, Atención al paciente, Spanish quality care, Health Care::Health Services Administration::Quality of Health Care::Quality Indicators, Health Care::Standard of Care [Medical Subject Headings], Metaanálisis, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Calidad de la atención de salud
Abstract: Breast cancer (BC) management care requires an increment in quality. An initiative to improve the BC quality care is registered, and quality indicators (QIs) are studied. We appraised the appearance of QIs and their standards systematically in Spain. A prospective systematic search (Prospero no: CRD42021228867) for clinical pathways and integrated breast cancer care processes was conducted through databases and the World Wide Web in February 2021. Duplicate data extraction was performed with 98% reviewer agreement. Seventy-four QIs (QI per document mean: 11; standard deviation: 10.59) were found in 15 documents. The Catalonian document had the highest number of QIs (n = 30). No QI appeared in all the documents. There were 9/74 QIs covering structure (12.16%), 53/74 covering process (71.62%), and 12/74 covering outcome (16.22%). A total of 22/66 (33.33%) process and outcome QIs did not set a minimum standard of care. QIs related to primary care, patient satisfaction, and shared decision making were deficient. Most of the documents established a BC QI standard for compliance, but the high variability hinders the comparison of outcomes. Establishing a consensus-based set of QIs needs urgent attention. Yes
Published: 2021

12. Cardiac Effects of a Rowing Training Program in Breast Cancer Survivors

Author: Ismael Gálvez-Fernández, José Carlos Fernández-García, Juan Gavala-González, Pere Mercadé-Melé, Universidad de Sevilla. Departamento de Educación Física y Deporte, [Gavala-Gonzalez, Juan] Univ Seville, Dept Phys Educ & Sports, Seville 41013, Spain, [Galvez-Fernandez, Ismael] Univ Malaga, Dept Didact Languages Arts & Sport, Andalucia Tech, IBIMA, Malaga 29010, Spain, [Carlos Fernandez-Garcia, Jose] Univ Malaga, Dept Didact Languages Arts & Sport, Andalucia Tech, IBIMA, Malaga 29010, Spain, [Mercade-Mele, Pere] Univ Malaga, Dept Stat & Econometr, Andalucia Tech, Malaga 29010, Spain, 'Researching in Sport Sciences' research group of the Andalusian Research Plan, [Gavala-González,J] Department of Physical Education and Sports, University of Seville, Seville, Spain. [Gálvez-Fernández,I, Fernández-García,JC] Department of Didactics of Languages, Arts and Sport, University of Malaga, Andalucía-Tech, IBIMA, Malaga, Spain. [Mercadé-Melé,P] Department of Statistics and Econometrics, University of Malaga, Andalucía-Tech, Malaga, Spain., and This research was funded by the 'Researching in Sport Sciences' research group (CTS-563) of the Andalusian Research Plan.
Subjects: Calidad de vida, medicine.medical_treatment, Geography, Planning and Development, Rowing, physical activity, Renewable energy sources, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Supervivientes de cáncer, GE1-350, 030212 general & internal medicine, Mastectomy, education.field_of_study, Environmental effects of industries and plants, Metaanalysis, Ejercicio físico, Health, Anthropology, Education, Sociology and Social Phenomena::Social Sciences::Quality of Life [Medical Subject Headings], 030220 oncology & carcinogenesis, Neoplasias de la mama, Cardiology, Quality of life, Risk, Cardiac function curve, medicine.medical_specialty, Population, Diastole, TJ807-830, Management, Monitoring, Policy and Law, TD194-195, rowing training, Dragon boat, breast cancer survivor, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Mastectomy::Mastectomy, Simple [Medical Subject Headings], 03 medical and health sciences, Internal medicine, Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Hemodynamics::Blood Pressure [Medical Subject Headings], Heart rate, Anatomy::Cardiovascular System [Medical Subject Headings], medicine, Aerobic exercise, Women, Training effects, Mastectomía, education, Exercise, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Physical activity, Renewable Energy, Sustainability and the Environment, business.industry, Breast cancer survivor, Environmental sciences, Blood pressure, Check Tags::Female [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Mastectomy [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Vital Signs::Heart Rate [Medical Subject Headings], Physical-activity, business, Rowing training, training effects
Abstract: The aim of this study was to determine whether a rowing training program could improve cardiac function in women (n = 28) with the mean age of 52.30 ± 3.78 years who survived breast cancer (stage 1: 4.55%, 2: 36.36%, 3: 54.54%, and 4: 4.55%) diagnosed 4.68 ± 3.00 years previously and underwent subsequent surgery (preservation: 56.52%, total mastectomy: 39.13%, and double mastectomy: 4.35%). Participants completed a 12-week training program consisting of three weekly sessions lasting 60–90 min with a progressive intensity increase according to the Börg scale. The assessments performed were blood pressure and pulse measurements both at rest and after performing the six-minute walk test to collect data on cardiac behavior and aerobic performance. The results showed statistically significant differences in cardiovascular system efficiency measured on the basis of heart rate both before (−12.63 ± 14.68 bpm) and after the six-minute walk test (−11.46 ± 28.39 bpm), increase in the distance achieved in the aerobic endurance test (51.56 ± 48.26 m) as well as decrease in diastolic (−13.6 ± 7.85 mm Hg) and systolic (−6.60 ± 9.10 mm Hg) blood pressure. These results suggest that rowing training programs could be a strategy to consider in this population for the benefits observed in heart rate, blood pressure and aerobic performance, which would lead to improved general health and quality of life.
Published: 2021

13. Role of the Holoenzyme PP1-SPN in the Dephosphorylation of the RB Family of Tumor Suppressors During Cell Cycle

Author: Verdugo-Sivianes, Eva M., Carnero, Amancio, [Verdugo-Sivianes,EM, Carnero,A] Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del Rocio, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville, Spain. [Verdugo-Sivianes,EM, Carnero,A] CIBERONC, Instituto de Salud Carlos III, Madrid, Spain., This research was funded by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018-097455-B-I00, grant from AEI-MICIU/FEDER (RED2018-102723-T), from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union), and from Consejeria de Salud (PI-0397-2017) and Consejeria of Economía, Conocimiento, Empresas y Universidad of the Junta de Andalucia (P18-RT-2501). Moreover, a special thanks to the Fundacion AECC and Fundacion Eugenio Rodriguez Pascual for supporting this work.
Subjects: Carcinogénesis, Proteína de retinoblastoma, Dominio catalítico, Células madre, Spinophilin, Anatomy::Cells::Stem Cells::Neoplastic Stem Cells [Medical Subject Headings], Quinasas ciclina-dependientes, Cell cycle, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Neoplasm Proteins::Tumor Suppressor Proteins::Retinoblastoma Protein [Medical Subject Headings], Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Esterases::Phosphoric Monoester Hydrolases::Phosphoprotein Phosphatases::Protein Phosphatase 1 [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Breast cancer, PPP1R9B, Proteína fosfatasa 1, Phosphorylation, Phenomena and Processes::Metabolic Phenomena::Metabolism::Phosphorylation [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Cancer, Holoenzimas, Stem cell, Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Molecular Structure::Binding Sites::Catalytic Domain [Medical Subject Headings], Cyclin-dependent kinases, Diseases::Neoplasms::Neoplastic Processes::Carcinogenesis [Medical Subject Headings], Anatomy::Respiratory System::Lung [Medical Subject Headings], Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases::Cyclin-Dependent Kinases [Medical Subject Headings], Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Cycle::Interphase::G1 Phase [Medical Subject Headings], Neoplasias, Check Tags::Female [Medical Subject Headings], Retinoblastoma protein, Tumorigenesis, Neoplasias de la mama, Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Substrate Specificity [Medical Subject Headings], Catalytic subunit, RB family proteins, Pocket proteins, Holoenzymes, Fosforilación, Phosphatase PP1, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Holoenzymes [Medical Subject Headings]
Abstract: Cell cycle progression is highly regulated by modulating the phosphorylation status of the retinoblastoma protein (pRB) and the other two members of the RB family, p107 and p130. This process is controlled by a balance in the action of kinases, such as the complexes formed by cyclin-dependent kinases (CDKs) and cyclins, and phosphatases, mainly the protein phosphatase 1 (PP1). However, while the phosphorylation of the RB family has been largely studied, its dephosphorylation is less known. Phosphatases are holoenzymes formed by a catalytic subunit and a regulatory protein with substrate specificity. Recently, the PP1-Spinophilin (SPN) holoenzyme has been described as the main phosphatase responsible for the dephosphorylation of RB proteins during the G0/G1 transition and at the end of G1. Moreover, SPN has been described as a tumor suppressor dependent on PP1 in lung and breast tumors, where it promotes tumorigenesis by increasing the cancer stem cell pool. Therefore, a connection between the cell cycle and stem cell biology has also been proposed via SPN/PP1/RB proteins. Yes
Published: 2021

14. Ultrasound use in metastatic breast cancer to measure body composition changes following an exercise intervention

Author: Bella Pajares, Marcos Iglesias-Campos, Cristina Roldán-Jiménez, Adrian Escriche-Escuder, Antonio Cuesta-Vargas, Manuel Trinidad-Fernández, Emilio Alba, [Escriche-Escuder,A, Trinidad-Fernández,M, Cuesta-Vargas,AI, Roldán-Jiménez,C] Department of Physiotherapy, University of Malaga, Málaga, Spain. [Escriche-Escuder,A, Alba,E, Roldán-Jiménez,C] Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain. [Pajares,B, Iglesias-Campos,M, Alba,E] UGCI Oncológica Médica, Hospital Regional Universitario y Virgen de la Victoria, Málaga, Spain. [Cuesta-Vargas,AI] School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia., and Tis research project was partially funded by Contract Nº PS16060 in IBIMA between Novartis-IBIMA (Tra slation Research in Cancer B-01 & Clinimetrics F-14). Tis consisted on a payment for author CRJ as physical therapist in the assessment.
Subjects: Adipose tissue, Biceps, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Neoplasms, 030212 general & internal medicine, Breast, Prospective Studies, Neoplasm Metastasis, Prospective cohort study, Phenomena and Processes::Metabolic Phenomena::Body Composition [Medical Subject Headings], Cancer, Ultrasonography, Multidisciplinary, Ultrasound, Mama, Anatomy::Musculoskeletal System::Muscles::Muscle, Skeletal [Medical Subject Headings], Metastatic breast cancer, Neoplasias, Oncology, 030220 oncology & carcinogenesis, Body Composition, Medicine, Metastatic, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Rehabilitation::Exercise Therapy::Resistance Training [Medical Subject Headings], Female, medicine.medical_specialty, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Strength training, Science, Intervention, Breast Neoplasms, Article, 03 medical and health sciences, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Ultrasonography [Medical Subject Headings], Internal medicine, Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis [Medical Subject Headings], medicine, Aerobic exercise, Humans, Muscle, Skeletal, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], business.industry, Resistance Training, medicine.disease, Biomarcadores, Check Tags::Female [Medical Subject Headings], business, Muscle architecture, Biomarkers
Abstract: Changes in body composition and muscle dysfunction are common in metastatic breast cancer (MBC). Ultrasound imaging (US) offers reliable information about muscle and fat tissue architecture (thickness) and quality (echo-intensity). This study aimed to analyze the responsiveness of thickness and echo-intensity and its possible relationship with functional and patient reported-outcomes (PRO) in MBC patients after an exercise intervention. A prospective study was conducted in 2019. A 12-week exercise program was performed, including aerobic exercise and strength training. Measurements were made at baseline and after intervention. Thickness and echo-intensity were obtained from the quadriceps and biceps brachii and brachialis (BB). Mean differences were calculated using the T-Student parametric test for dependent samples of the differences in the means before and after the intervention (p = 0.05; 95% CI). Data from 13 MBC patients showed that some US muscle variables had significant differences after intervention. Best correlations were found between the quality of life questionnaire (QLQ-BR23) PRO and variables from BB muscle thickness in contraction (r = 0.61, p
Published: 2021

15. Cancer incidence estimation from mortality data: a validation study within a population-based cancer registry

Author: Daniel Redondo-Sánchez, María José Sánchez, F. J. Alonso, Miguel Rodríguez-Barranco, José Juan Jiménez-Moleón, Pablo Fernández-Navarro, Alberto Ameijide, [Redondo-Sánchez,D, Rodríguez-Barranco,M, Sánchez,MJ] Granada Cancer Registry, Andalusian School of Public Health (EASP), Campus Universitario de Cartuja, Granada, Spain. [Redondo-Sánchez,D, Jiménez-Moleón,JJ, Sánchez,MJ] Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), University of Granada, Granada, Spain. [Redondo-Sánchez,D, Fernández-Navarro,P, Sánchez,MJ] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Ameijide,A] Tarragona Cancer Registry, Foundation Society for Cancer Research and Prevention (FUNCA), Pere Virgili Health Research Institute (IISPV), Reus, Spain. [Alonso,FJ] Department of Statistics, Faculty of Sciences, University of Granada, Granada, Spain. [Fernández-Navarro,P] Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain. [Jiménez-Moleón,JJ, Sánchez,MJ] Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain., This research was supported with the subprogram 'Cancer surveillance' of the CIBER of Epidemiology and Public Health (CIBERESP). This work has been also partially supported by grant PGC2018-098860-B-I00 (MINECO/FEDER). M. J. Sánchez is supported by the Andalusian Department of Health Research, Development and Innovation, project grant PI-0152/2017., Ministerio de Economía y Competitividad (España), European Regional Development Fund, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red - CIBERESP (Epidemiología y Salud Pública), and Regional Government of Andalusia
Subjects: Male, Oncology, Anatomy::Urogenital System::Urinary Tract::Urinary Bladder [Medical Subject Headings], Neoplasias de la próstata, Epidemiology, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Markov Chains [Medical Subject Headings], Goodness-of-fit, Anatomy::Digestive System::Gastrointestinal Tract::Intestines::Intestine, Large::Colon [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Goodness-of-fit test, Prostate cancer, 0302 clinical medicine, Information Science::Information Science::Data Collection::Vital Statistics::Mortality [Medical Subject Headings], Information Science::Information Science::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings], Neoplasms, Validation, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Monte Carlo Method [Medical Subject Headings], Registries, education.field_of_study, lcsh:Public aspects of medicine, Incidence, Anatomy::Digestive System::Gastrointestinal Tract::Intestines::Intestine, Large::Rectum [Medical Subject Headings], Neoplasias, medicine.anatomical_structure, Research Design, 030220 oncology & carcinogenesis, lcsh:R858-859.7, Female, Incidencia, medicine.medical_specialty, Neoplasias ováricas, Anatomy::Urogenital System::Genitalia::Genitalia, Female::Uterus [Medical Subject Headings], 030231 tropical medicine, Population, Check Tags::Male [Medical Subject Headings], Rectum, lcsh:Computer applications to medicine. Medical informatics, Estudio de validación, Generalized linear mixed model, Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms [Medical Subject Headings], 03 medical and health sciences, Ovarian cancer, Internal medicine, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Bayes Theorem [Medical Subject Headings], medicine, Humans, education, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Estimation, business.industry, Research, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Stomach Neoplasms [Medical Subject Headings], Public Health, Environmental and Occupational Health, Cancer, lcsh:RA1-1270, Bayes Theorem, Anatomy::Respiratory System::Lung [Medical Subject Headings], medicine.disease, Cancer registry, Diseases::Female Urogenital Diseases and Pregnancy Complications::Female Urogenital Diseases::Genital Diseases, Female::Adnexal Diseases::Ovarian Diseases::Ovarian Neoplasms [Medical Subject Headings], Mortality-to-incidence ratio, Check Tags::Female [Medical Subject Headings], Mortalidad, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings], business, Cancer incidence
Abstract: Background: Population-based cancer registries are required to calculate cancer incidence in a geographical area, and several methods have been developed to obtain estimations of cancer incidence in areas not covered by a cancer registry. However, an extended analysis of those methods in order to confirm their validity is still needed. Methods: We assessed the validity of one of the most frequently used methods to estimate cancer incidence, on the basis of cancer mortality data and the incidence-to-mortality ratio (IMR), the IMR method. Using the previous 15-year cancer mortality time series, we derived the expected yearly number of cancer cases in the period 2004– 2013 for six cancer sites for each sex. Generalized linear mixed models, including a polynomial function for the year of death and smoothing splines for age, were adjusted. Models were fitted under a Bayesian framework based on Markov chain Monte Carlo methods. The IMR method was applied to five scenarios reflecting different assumptions regarding the behavior of the IMR. We compared incident cases estimated with the IMR method to observed cases diagnosed in 2004–2013 in Granada. A goodness-of-fit (GOF) indicator was formulated to determine the best estimation scenario. Results: A total of 39,848 cancer incidence cases and 43,884 deaths due to cancer were included. The relative differences between the observed and predicted numbers of cancer cases were less than 10% for most cancer sites. The constant assumption for the IMR trend provided the best GOF for colon, rectal, lung, bladder, and stomach cancers in men and colon, rectum, breast, and corpus uteri in women. The linear assumption was better for lung and ovarian cancers in women and prostate cancer in men. In the best scenario, the mean absolute percentage error was 6% in men and 4% in women for overall cancer. Female breast cancer and prostate cancer obtained the worst GOF results in all scenarios. Conclusion: A comparison with a historical time series of real data in a population-based cancer registry indicated that the IMR method is a valid tool for the estimation of cancer incidence. The goodness-of-fit indicator proposed can help select the best assumption for the IMR based on a statistical argument., Subprogram "Cancer surveillance" of the CIBER of Epidemiology and Public Health (CIBERESP), MINECO/FEDER PGC2018-098860-B-I00, Andalusian Department of Health Research, Development and Innovation PI-0152/2017
Published: 2021
Full Text: View/download PDF

16. Evaluation of the Use of Shared Decision Making in Breast Cancer: International Survey

Author: Rubén Trigueros, Luciano Mignini, Manuel Martín-Díaz, Aurora Bueno-Cavanillas, Khalid S. Khan, Marta Maes-Carballo, [Maes-Carballo,M] Unidad de Patología Mamaria del Servicio de Cirugía General, Complexo Universitario Hospitalario de Ourense, Ourense, Spain. [Maes-Carballo,M, Khan,KS, Bueno-Cavanillas,A] Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. [Martín-Díaz,M] Hospital Básico Santa Ana de Motril, Granada, Spain. [Mignini,L] Unidad de Mastología del Grupo Oroño, Rosario, Argentina. [Khan,KS, and Bueno-Cavanillas,A] CIBER of Epidimiology and Public Health (CIBERESP), Madrid, Spain. [Trigueros,R] Department of Language and Education, University of Antonio de Nebrija, Madrid, Spain. [Bueno-Cavanillas,A] Instituto de Investigación Biosanitaria (IBS), Granada, Spain.
Subjects: Longitudinal study, Health, Toxicology and Mutagenesis, use of shared decision making, lcsh:Medicine, Computer-assisted web interviewing, Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Thinking::Decision Making [Medical Subject Headings], Estudios longitudinales, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Breast cancer, Surveys and Questionnaires, 030212 general & internal medicine, Survey, health care economics and organizations, Shared decision making, Health Care::Health Care Facilities, Manpower, and Services::Health Services::Community Health Services::Consumer Participation::Patient Participation [Medical Subject Headings], longitudinal study, humanities, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings], Encuestas y cuestionarios, 030220 oncology & carcinogenesis, Scale (social sciences), Neoplasias de la mama, Professional association, Psychology, medicine.medical_specialty, education, shared decision making, Decision Making, Breast Neoplasms, Article, Information Science::Information Science::Data Collection::Questionnaires [Medical Subject Headings], 03 medical and health sciences, breast cancer, Patient satisfaction, Toma de decisiones conjunta, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies [Medical Subject Headings], medicine, Humans, survey, Use of shared decision making, Disadvantage, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Toma de decisiones compartidas, lcsh:R, Public Health, Environmental and Occupational Health, International survey, medicine.disease, Cross-Sectional Studies, Family medicine, Patient Participation, Decision Making, Shared
Abstract: Objectives: To assess shared decision-making (SDM) knowledge, attitude and application among health professionals involved in breast cancer (BC) treatment. Materials and Methods: A cross-sectional study based on an online questionnaire, sent by several professional societies to health professionals involved in BC management. There were 26 questions which combined demographic and professional data with some items measured on a Likert-type scale. Results: The participation (459/541, 84.84%) and completion (443/459, 96.51%) rates were high. Participants strongly agreed or agreed in 69.57% (16/23) of their responses. The majority stated that they knew of SDM (mean 4.43 (4.36–4.55)) and were in favour of its implementation (mean 4.58 (4.51–4.64)). They highlighted that SDM practice was not adequate due to lack of resources (3.46 (3.37–3.55)) and agreed on policies that improved its implementation (3.96 (3.88–4.04)). The main advantage of SDM for participants was patient satisfaction (38%), and the main disadvantage was the patients’ paucity of knowledge to understand their disease (24%). The main obstacle indicated was the lack of time and resources (40%). Conclusions: New policies must be designed for adequate training of professionals in integrating SDM in clinical practice, preparing them to use SDM with adequate resources and time provided.
Published: 2021

17. Selective modulation by PARP-1 of HIF-1α-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions

Author: F. Javier Oliver, Ana Teresa Amaral, Françoise Dantzer, Edurne Berra, Klaudia Dziedzic, Juan Manuel Martí, Ángel García-Díaz, Ariannys González-Flores, José Manuel Rodríguez-Vargas, Onintza Carlevaris, George L. King, Ester M. Hammond, Jean-Christophe Amé, Daniel Delgado-Bellido, Francisco O'Valle, E. de Álava, Junta de Andalucía, Ministerio de Economía y Competitividad (España), Centro de Investigación Biomédica en Red Cáncer (España), Instituto de Salud Carlos III, Eusko Jaurlaritza, Fundación Domingo Martínez, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Institute of Biopathology and Regenerative Medicine (IBIMER), Universidad de Granada, El Centro de Investigación Biomédica (CIBM)-El Centro de Investigación Biomédica (CIBM), Biotechnologie et signalisation cellulaire (BSC), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut de recherche de l'Ecole de biotechnologie de Strasbourg (IREBS), [Martí,JM, Garcia-Diaz,A, Delgado-Bellido,D, González-Flores,A, Oliver,FJ] Institute of Parasitology and Biomedicine López-Neyra, CSIC, and CIBERONC, Granada, Spain. [O'Valle,F] Pathology Department, School of Medicine, IBIMER, CIBM, University of Granada, Spain and Biosanitary Research Institute (IBS. GRANADA), University of Granada, Granada, Spain. [Carlevaris,O, Dziedzic,K, Berra,E] CIC BioGUNE, Parque Tecnológico de Bizkaia, Derio, Spain. [Rodríguez-Vargas,JM, Amé,JC, Dantzer,F] Poly(ADP-ribosyl)ation and Genome Integrity, Laboratoire D’Excellence Medalis, Centre National de La Recherche cientifique/Universit´e de Strasbourg, Institut de Recherche de L’Ecole de Biotechnologie de Strasbourg, Illkirch, France. [King,GL] Section of Vascular Cell Biology and Complications, Dianne Nunnally Hoppes Laboratory for Diabetes Complications, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA. [de Álava,E, Amaral,AT] Institute of Biomedicine of Sevilla (IBiS), Virgen Del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, Seville, Spain. [Hammond,EM] Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., and This work was supported by Junta de Andalucía, project of Excel lence from Junta de Andalucía P10-CTS-0662, P12-CTS-383 to FJO, Spanish Ministry of Economy and Competitiveness SAF2012-40011- C02-01, SAF2015-70520- R, RTI2018-098968-B-I00, RTICC RD12/0036/0026 and CIBER Cáncer ISCIII CB16/12/00421 to FJO. EB1 s lab is supported by the Basque Department of Industry, Tourism and Trade (Etortek) and the MINECO (CB16/12/00421) grants. Fundación Domingo Martínez (call 2019).
Subjects: Secuenciación de inmunoprecipitación de cromatina, 0301 basic medicine, Medicine (General), Clinical Biochemistry, [SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC], Biochemistry, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Hipoxia, Biology (General), Hypoxia, Hypoxia-Responsive Elements, Cell Hypoxia, Chromatin, 3. Good health, Diseases::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms [Medical Subject Headings], ChIP-seq, Tumor microenvironment, Female, medicine.symptom, Research Paper, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Purines::Purine Nucleotides::Adenine Nucleotides::Adenosine Diphosphate::Adenosine Diphosphate Sugars [Medical Subject Headings], QH301-705.5, Poly ADP ribose polymerase, [SDV.CAN]Life Sciences [q-bio]/Cancer, Breast Neoplasms, PARP-1, Biology, Poly(ADP-ribose) Polymerase Inhibitors, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Transcription Factors [Medical Subject Headings], 03 medical and health sciences, R5-920, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Vesicular Transport Proteins::Coat Protein Complex I::ADP-Ribosylation Factor 1 [Medical Subject Headings], Microambiente tumoral, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], medicine, Humans, Transcription factor, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Inhibidores de poli(ADP-Ribosa) polimerasas, Anatomy::Cells::Cellular Structures::Intracellular Space::Cell Nucleus::Cell Nucleus Structures::Intranuclear Space::Chromosomes::Chromosome Structures::Chromatin [Medical Subject Headings], Organic Chemistry, Cancer, Hypoxia (medical), medicine.disease, PARylation, 030104 developmental biology, Check Tags::Female [Medical Subject Headings], Poli ADP ribosilación, Cancer research, Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Respiration::Cell Hypoxia [Medical Subject Headings], Ovarian cancer, 030217 neurology & neurosurgery
Abstract: This work was supported by Junta de Andalucia, project of Excellence from Junta de Andalucia P10-CTS-0662, P12-CTS-383 to FJO, Spanish Ministry of Economy and Competitiveness SAF2012-40011C02-01, SAF2015-70520-R, RTI2018-098968-B-I00, RTICC RD12/0036/0026 and CIBER Cancer ISCIII CB16/12/00421 to FJO. EB1s lab is supported by the Basque Department of Industry, Tourism and Trade (Etortek) and the MINECO (CB16/12/00421) grants. Fundacion Domingo Martinez (call 2019)., We would like to acknowledge Laura L´opez for technical assistance; Eduardo Andr´es and Laura Terr´on (Bioinformatic core IPBLN, CSIC) and Pan Hui (Bioinformatic Core, Joslin Diabetes center, Harvard Medical School)., Background: The adaptation to hypoxia is mainly controlled by the HIF transcription factors. Increased expression/ activity of HIF-1α correlates with poor prognosis in cancer patients. PARP-1 inhibitors are used in the clinic to treat BRCAness breast/ovarian cancer and have been shown to regulate the hypoxic response; therefore, their use could be expanded. Methods: In this work by integrating molecular/cell biology approaches, genome-wide ChIP-seq, and patient samples, we elucidate the extent to which PARP-1 exerts control over HIF-1-regulated genes. Results: In human melanoma, PARP-1 and HIF-1α expression are strongly associated. In response to a hypoxic challenge poly(ADP-ribose) (PAR) is synthesized, HIF-1α is post-transcriptionally modified (PTM) and stabilized by PARylation at specific K/R residues located at its C-terminus. Using an unbiased ChIP-seq approach we demonstrate that PARP-1 dictates hypoxia-dependent HIF-recruitment to chromatin in a range of HIF-regulated genes while analysis of HIF-binding motifs (RCGTG) reveals a restriction on the recognition of hypoxia responsive elements in the absence of PARP-1. Consequently, the cells are poorly adapted to hypoxia, showing a reduced fitness during hypoxic induction. Conclusions: These data characterize the fine-tuning regulation by PARP-1/PARylation of HIF activation and suggest that PARP inhibitors might have therapeutic potential against cancer types displaying HIF-1α overactivation., Junta de Andalucia P10-CTS-0662 P12-CTS-38, Spanish Ministry of Economy and Competitiveness SAF2012-40011-C02-01 SAF2015-70520- R RTI2018-098968-B-I00 RTICC RD12/0036/0026, CIBER Cancer ISCIII CB16/12/00421, Basque Department of Industry, Tourism and Trade (Etortek), MINECO CB16/12/00421, Fundacion Domingo Martinez
Published: 2021
Full Text: View/download PDF

18. Comprehensive genomic profile of heterogeneous long follow-up triple-negative breast cancer and its clinical characteristics shows DNA repair deficiency has better prognostic

Author: Enrique Bargallo-Rocha, Luis I. Terrazas, Clara Díaz-Velásquez, Fernando Vallejo-Lecuona, Fany Iris Porras Reyes, Aldo de la Cruz-Montoya, Javier Oliver, Javier César Mejía-Gómez, Sandra Perdomo, Víctor Pérez-Sánchez, Héctor Martínez Gregorio, Paula Cabrera-Galeana, Cecilia Frecha, Maritza Ramos-Ramírez, Yolanda I. Chirino, Rosalía Quezada-Urban, Felipe Vaca-Paniagua, Luis A. Herrera, Ernesto Rojas-Jiménez, Maybelline Robles-Estrada, Héctor Maldonado-Martinez, [Rojas-Jiménez,E, Díaz-Velásquez,C, Quezada-Urban,R, Martínez Gregorio,H, Vallejo-Lecuona,F, Terrazas,LI, Vaca-Paniagua,F] Laboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Tlalnepantla, Estado de México, Mexico. [Rojas-Jiménez,E, de la Cruz-Montoya,A, Chirino,YI, Vaca-Paniagua,F] Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, UNAM, Tlalnepantla, Estado de México, Mexico. [Mejía-Gómez,JC] Division of Breast Cancer, Department of Medical Oncology, Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada. [Quezada-Urban,R] Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. [Quezada-Urban,R] Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. [Porras Reyes,FI, Pérez-Sánchez,VM, Maldonado-Martínez,HA, Bargalló-Rocha,E, Cabrera-Galeana,P, Ramos-Ramírez,M, Alonso Herrera,L, Vaca-Paniagua,F] Instituto Nacional de Cancerología, CDMX, Mexico. [Robles-Estrada,M] Hospital General de Pachuca SSA, Pachuca, Mexico. [Alonso Herrera,L] Instituto Nacional de Medicina Genómica, CDMX, Mexico. [Alonso Herrera,L] Unidad de Investigación Biomédica en Cáncer, Instituto de Investigaciones Biomédicas-Instituto Nacional de Cancerología, CDMX, Mexico. [Oliver,J] Medical Oncology Service, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga, CIMES, University of Málaga, Málaga, Spain. [Frecha,C] Unidad de Producción Celular del Hospital Regional Universitario de Málaga—IBIMA—Málaga, Málaga, Spain. [Perdomo,S] Instituto de Nutrición, Genética y Metabolismo, Facultad de Medicina, Universidad El Bosque, Bogotá, Colombia. [Perdomo,S] International Agency for Research on Cancer, World Health Organization, Lyon, France., This study was funded by grants from UNAM PAPIIT IN219217 and CONACyT Fondo Sectorial 272573., and Perdomo Lara, Sandra Janneth [0000-0002-4429-3760]
Subjects: 0301 basic medicine, Oncology, Terapéutica, Triple Negative Breast Neoplasms, Kaplan-Meier Estimate, whole exome sequencing, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::DNA Repair-Deficiency Disorders [Medical Subject Headings], somatic mutation, Genetics (clinical), Triple-negative breast cancer, Exome sequencing, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], education.field_of_study, biology, treatment, Middle Aged, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms [Medical Subject Headings], 030220 oncology & carcinogenesis, Neoplasias de la mama, triple-negative breast cancer, WES, Female, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Sequence Analysis::Sequence Analysis, DNA [Medical Subject Headings], Adult, medicine.medical_specialty, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings], lcsh:QH426-470, DNA repair, Population, Mutational signatures, mutational signatures, Article, 03 medical and health sciences, Breast cancer, Germline mutation, Lymphocytes, Tumor-Infiltrating, Internal medicine, Exome Sequencing, Genetics, medicine, PTEN, Humans, education, Persons::Persons::Age Groups::Adult [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Aged, Secuenciación del exoma completo, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Kaplan-Meier Estimate [Medical Subject Headings], Somatic mutation, México, Whole exome sequencing, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Neoplasias de la mama triple negativas, medicine.disease, DNA Repair-Deficiency Disorders, Treatment, lcsh:Genetics, 030104 developmental biology, Geographical Locations::Geographic Locations::Americas::North America::Mexico [Medical Subject Headings], Check Tags::Female [Medical Subject Headings], Genomic Profile, Mutation, biology.protein, Anatomy::Hemic and Immune Systems::Immune System::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::Lymphocytes, Tumor-Infiltrating [Medical Subject Headings]
Abstract: Triple-negative breast cancer (TNBC) presents a marked diversity at the molecular level, which promotes a clinical heterogeneity that further complicates treatment. We performed a detailed whole exome sequencing profile of 29 Mexican patients with long follow-up TNBC to identify genomic alterations associated with overall survival (OS), disease-free survival (DFS), and pathologic complete response (PCR), with the aim to define their role as molecular predictive factors of treatment response and prognosis. We detected 31 driver genes with pathogenic mutations in TP53 (53%), BRCA1/2 (27%), CDKN1B (9%), PIK3CA (9%), and PTEN (9%), and 16 operative mutational signatures. Moreover, tumors with mutations in BRCA1/2 showed a trend of sensitivity to platinum salts. We found an association between deficiency in DNA repair and surveillance genes and DFS. Across all analyzed tumors we consistently found a heterogeneous molecular complexity in terms of allelic composition and operative mutational processes, which hampered the definition of molecular traits with clinical utility. This work contributes to the elucidation of the global molecular alterations of TNBC by providing accurate genomic data that may help forthcoming studies to improve treatment and survival. This is the first study that integrates genomic alterations with a long follow-up of clinical variables in a Latin American population that is an underrepresented ethnicity in most of the genomic studies.
Published: 2020

19. Breast tumor cells promotes the horizontal propagation of EMT, stemness, and metastasis by transferring the MAP17 protein between subsets of neoplastic cells

Author: Amancio Carnero, Sandra Muñoz-Galván, Daniel Otero-Albiol, Elena Pérez-Castejón, José M. García-Heredia, Marco Perez, Universidad de Sevilla. Departamento de Bioquímica Vegetal y Biología Molecular, Ministerio de Ciencia, Innovación y Universidades (MICINN). España, Agencia Estatal de Investigación. España, European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER), entro de Investigación Biomédica en Red (CIBER). España, Junta de Andalucía, [García-Heredia,JM, Otero-Albiol,D, Pérez,M, Pérez-Castejón,E, Muñoz-Galván,S, Carnero,A] Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Consejo Superior de Investigaciones Científicas, Seville, Spain. [García-Heredia,JM] Departamento de Bioquímica Vegetal y Biología Molecular, Universidad de Sevilla, Seville, Spain. [García-Heredia,JM, Carnero,A] CIBER de Cancer, Seville, Spain., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018–097455-B-I00, from AEIMICIU/FEDER (RED2018–102723-T), from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union), from Consejería de Salud (PI-0397–2017) and Consejería of Economía, Conocimiento, Empresas y Universidad de Junta de Andalucía (P18-RT-2501)., Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Red Temática de Investigación Cooperativa en Cáncer (España), Fundación Científica Asociación Española Contra el Cáncer, and Fundación Eugenio Rodríguez Pascual
Subjects: 0301 basic medicine, Cancer Research, Cell, Exosomes, Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression [Medical Subject Headings], Metastasis, Exosomas, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Breast cancer, 0302 clinical medicine, MicroARNs, Cancer stem cells, Desmetilación, Extracellular matrix, Diseases::Neoplasms [Medical Subject Headings], lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Neoplasias, MAP17, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Neoplasias de la mama, Anatomy::Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Organelles::Cytoplasmic Vesicles::Transport Vesicles::Exosomes [Medical Subject Headings], Notch signaling pathway, Biology, lcsh:RC254-282, Article, 03 medical and health sciences, Downregulation and upregulation, Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis [Medical Subject Headings], microRNA, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma [Medical Subject Headings], medicine, Epithelial–mesenchymal transition, Molecular Biology, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Inflammation, Inflamación, Carcinoma, Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation::Epigenesis, Genetic [Medical Subject Headings], medicine.disease, Microvesicles, Demethylation, Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs [Medical Subject Headings], MicroRNAs, 030104 developmental biology, Tumor progression, Cancer research, Neoplasm, Gene expression, Breast neoplasms, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings], Expresión génica
Abstract: MAP17 (PDZK1IP1) is a small protein regulating inflammation and tumor progression, upregulated in a broad range of carcinomas. MAP17 levels increase during tumor progression in a large percentage of advanced tumors. In the present work, we explored the role of this protein shaping tumor evolution. Here we show that in breast cancer, cells increased MAP17 levels in tumors by demethylation induced multiple changes in gene expression through specific miRNAs downregulation. These miRNA changes are dependent on Notch pathway activation. As a consequence, epithelial mesenchymal transition (EMT) and stemness are induced promoting the metastatic potential of these cells both in vitro and in vivo. Furthermore, MAP17 increased the exosomes in tumor cells, where MAP17 was released as cargo, and this horizontal propagation also increased the EMT in the recipient cells. Importantly, an antibody against MAP17 in the media reduces the EMT and stemness alterations promoted by the conditioned media from MAP17-expressing cells. Therefore, MAP17 expression promotes the horizontal propagation of EMT and metastasis by transferring the MAP17 protein between subsets of neoplastic cells. Thus, MAP17 can be used to describe a new mechanism for cell malignity at distance, without the involvement of genetic or epigenetic modifications. MAP17 can also be taken in consideration as new target for metastatic high-grade breast tumors., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, a la Agencia Estatal de Investigación (AEI) y al Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): RTI2018–097455-B-I00; from AEIMICIU/FEDER (RED2018–102723-T); from CIBER de Cáncer (CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejería de Salud (PI-0397–2017) and Consejería of Economía, Conocimiento, Empresas y Universidad de Junta de Andalucía (P18-RT-2501). Also especial thanks to the Fundación AECC and Fundación Eugenio Rodriguez Pascual for supporting this work.
Published: 2020

20. Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment

Author: Laborda-Illanes, Aurora, Sanchez-Alcoholado, Lidia, Dominguez-Recio, María Emilia, Jimenez-Rodriguez, Begoña, Lavado, Rocío, Comino-Méndez, Iñaki, Alba, Emilio, Queipo-Ortuño, María Isabel, [Laborda-Illanes,A, Sanchez-Alcoholado,L, Dominguez-Recio,ME, Jimenez-Rodriguez,B, Lavado,R, Comino-Méndez,I, Alba,E, Queipo-Ortuño,MI] Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA)-CIMES-UMA, Málaga, Spain. [Laborda-Illanes,A, Sanchez-Alcoholado,L] Facultad de Medicina, Universidad de Málaga, Málaga, Spain., and This work was supported in part by PE-0106-2019 from the Consejería de Salud de la Junta de Andalucía, C19047-2018 from Fundación Unicaja and UMA18-FEDERJA-042 from UMA-FEDER. Maria Isabel Queipo-Ortuño is recipient of a 'Miguel Servet Type II' program (CPI13/00003) from ISCIII, co-funded by the Fondo Europeo de Desarrollo Regional-FEDER, Madrid, Spain and also belongs to the regional 'Nicolas Monardes' research program of the Consejería de Salud (C-0030-2018, Junta de Andalucía, Spain. Aurora Laborda-Illanes was recipient of a predoctoral grant PFIS-ISCIII (FI19-00112) co-funded by the Fondo Europeo de Desarrollo Regional-FEDER, Madrid, Spain. Lidia Sanchez-Alcoholado was recipient of a predoctoral grant (PE-0106-2019) from the Consejería de Salud y Familia (co-funded by the Fondo Europeo de Desarrollo Regional-FEDER, Andalucia, Spain).
Subjects: Prebióticos, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Breast cancer, Inmunidad, Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproductive Physiological Processes::Sexual Development::Climacteric::Menopause::Postmenopause [Medical Subject Headings], Estrobolome, Immune responds, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Inflammation, Inflamación, Microbiota, Probiotics, Anticancer therapy, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings], Probióticos, Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation::Epigenesis, Genetic [Medical Subject Headings], Phenomena and Processes::Immune System Phenomena::Immunity [Medical Subject Headings], Antineoplásicos, Prebiotics, Phenomena and Processes::Microbiological Phenomena::Microbiota [Medical Subject Headings], Check Tags::Female [Medical Subject Headings], Neoplasias de la mama, Technology and Food and Beverages::Food and Beverages::Food::Dietary Supplements [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Dysbiosis [Medical Subject Headings], Epigenetic modulation, Chemicals and Drugs::Carbohydrates::Polysaccharides::Polysaccharides, Bacterial::Prebiotics [Medical Subject Headings], Epigénesis genética, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings]
Abstract: In breast cancer (BC) the employment of sequencing technologies for metagenomic analyses has allowed not only the description of the overall metagenomic landscape but also the specific microbial changes and their functional implications. Most of the available data suggest that BC is related to bacterial dysbiosis in both the gut microenvironment and breast tissue. It is hypothesized that changes in the composition and functions of several breast and gut bacterial taxa may contribute to BC development and progression through several pathways. One of the most prominent roles of gut microbiota is the regulation of steroid-hormone metabolism, such as estrogens, a component playing an important role as risk factor in BC development, especially in postmenopausal women. On the other hand, breast and gut resident microbiota are the link in the reciprocal interactions between cancer cells and their local environment, since microbiota are capable of modulating mucosal and systemic immune responses. Several in vivo and in vitro studies show remarkable evidence that diet, probiotics and prebiotics could exert important anticarcinogenic effects in BC. Moreover, gut microbiota have an important role in the metabolism of chemotherapeutic drugs and in the activity of immunogenic chemotherapies since they are a potential dominant mediator in the response to cancer therapy. Then, the microbiome impact in BC is multi-factorial, and the gut and breast tissue bacteria population could be important in regulating the local immune system, in tumor formation and progression and in therapy response and/or resistance. Yes
Published: 2020

21. Quality and reporting of clinical guidelines for breast cancer treatment: A systematic review

Author: Maes-Carballo, Marta, Mignini, Luciano, Martín-Díaz, Manuel, Bueno-Cavanillas, Aurora, Khan, Khalid Saeed, [Maes-Carballo,M] Department of General Surgery, Complexo Hospitalario de Ourense, Ourense, Spain. [Maes-Carballo,M, Bueno-Cavanillas,A, Khan,KS] Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. [Mignini,L] Unidad de Mastología de Grupo Oro~no, Rosario, Argentina. [Martín-Díaz,M] Department of General Surgery, Hospital de Motril, Granada, Spain. [Bueno-Cavanillas,A, and Khan,KS] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Bueno-Cavanillas,A] Instituto de Investigación Biosanitaria IBS, Granada, Spain.
Subjects: RIGHT, Consensus, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus [Medical Subject Headings], Terapéutica, Revisión sistemática, Guidelines, AGREE II, Health Care::Health Services Administration::Quality of Health Care::Quality Assurance, Health Care::Guidelines as Topic::Practice Guidelines as Topic [Medical Subject Headings], Treatment, Guía de práctica clínica, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Breast cancer, Information Science::Information Science::Medical Informatics::Medical Informatics Applications::Information Systems::Databases as Topic::Databases, Bibliographic [Medical Subject Headings], Consenso, Check Tags::Female [Medical Subject Headings], Neoplasias de la mama, Appraisal instruments, Guías como asunto, Quality of guidelines, Clinical practice guidelines, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]
Abstract: Background: High-quality, well-reported clinical practice guidelines (CPGs) and consensus statements (CSs) underpinned by systematic reviews are needed. We appraised the quality and reporting of CPGs and CSs for breast cancer (BC) treatment. Methods: Following protocol registration (Prospero no: CRD42020164801), CPGs and CSs on BC treatment were identiﬁed, without language restrictions, through a systematic search of bibliographic databases (MEDLINE, EMBASE, Web of Science, Scopus, CDSR) and online sources (12 guideline databases and 51 professional society websites) from January 2017 to June 2020. Data were extracted in duplicate assessing overall quality using AGREE II (% of maximum score) and reporting compliance using RIGHT (% of total 35 items); reviewer agreement was 98% and 96% respectively. Results: There were 59 relevant guidance documents (43 CPGs, 16 CSs), of which 20 used systematic reviews for evidence synthesis. The median overall quality was 54.0% (IQR 35.9-74.3) and the median overall reporting compliance was 60.9% (IQR 44.5-84.4). The correlation between quality and reporting was 0.9. Compared to CSs, CPGs had better quality (55.4% vs 44.2%; p = 0.032) and reporting (67.18% vs 44.5%; p = 0.005). Compared to subjective methods of evidence analysis, guidance documents that used systematic reviews had better quality (76.3% vs 51.4%; p = 0.001) and reporting (87.1% vs 59.4%; p = 0.001). Conclusion: The quality and reporting of CPGs and CSs in BC treatment were moderately strong. Systematic reviews should be used to improve the quality and reporting of CPGs and CSs. Yes
Published: 2020

22. Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors

Author: Chica-Parrado, María Rosario, Godoy-Ortiz, Ana, Jiménez, Begoña, Ribelles, Nuria, Barragan, Isabel, Alba, Emilio, [Chica-Parrado,MR, Godoy-Ortiz,A, Jiménez,B, Ribelles,N, Barragan,I, Alba,E] Institute of Biomedical Research in Malaga (IBIMA), Regional and Virgen de la Victoria University Hospitals, Málaga, Spain. [Chica-Parrado,MR, Alba,E] Cancer Molecular Biology Group, Medical Research Center, University of Málaga (UMA), Málaga, Spain. [Godoy-Ortiz,A, Alba,E] Medical Oncology Service Intercentros, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain. [Barragan,I] Group of Pharmacoepigenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., and This research was funded by the Instituto de Salud Carlos III Grant PI15/01823 (to Emilio Alba, María Rosario Chica-Parrado, and Begoña Jiménez), the European Commission MSCA Grant 799,818 (to Isabel Barragán.), and the Grant for Research Support of Clinical Units of the Andalusian Health System SA0263/2017 (to Isabel Barragán). The APC was funded by the Institute of Biomedical Research in Malaga Instituto de investigación Biomédica de Málaga (IBIMA).
Subjects: Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings], Pathological complete response, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings], Residual disease, Trastuzumab, Predictive markers, Neoadjuvant chemotherapy, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy [Medical Subject Headings], Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Breast cancer, Terapia neoadyuvante, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized [Medical Subject Headings], Check Tags::Female [Medical Subject Headings], Neoplasias de la mama, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Anthropometry::Body Weights and Measures::Tumor Burden [Medical Subject Headings], Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis::Neoplasm Micrometastasis [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], Chemicals and Drugs::Biological Factors::Biological Markers::Tumor Markers, Biological::Receptor, erbB-2 [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]
Abstract: Neoadjuvant Chemotherapy (NAC) in Breast Cancer (BC) has proved useful for the reduction in tumor burden prior to surgery, allowing for a more extensive breast preservation and the eradication of subjacent micrometastases. However, the impact on prognosis is highly dependent on the establishment of Pathological Complete Response (pCR), in particular for Triple Negative (TN) and Hormonal Receptor negative/Human Epidermal growth factor Receptor 2 positive (HR-/HER2+) subtypes. Several pCR predictors, such as PAM50, Integrative Cluster (IntClust), mutations in PI3KCA, or the Trastuzumab Risk model (TRAR), are useful molecular tools for estimating response to treatment and are prognostic. Major evolution events during BC NAC that feature the Residual Disease (RD) are the loss of HR and HER2, which are prognostic of bad outcome, and stemness and immune depletion-related gene expression aberrations. This dynamic nature of the determinants of response to BC NAC, together with the extensive heterogeneity of BC, raises the need to discern the individual and subtype-specific determinants of resistance. Moreover, refining the current approaches for a comprehensive monitoring of tumor evolution during treatment, RD, and eventual recurrences is essential for identifying new actionable alterations and the integral best management of the disease. Yes
Published: 2020

23. Rowing Training in Breast Cancer Survivors: A Longitudinal Study of Physical Fitness

Author: José Carlos Fernández-García, Juan Gavala-González, Pere Mercadé-Melé, Ismael Gálvez-Fernández, Universidad de Sevilla. Departamento de Educación Física y Deporte, Junta de Andalucía. Plan de Investigación, [Gavala-González,J] Department of Physical Education and Sports, University of Seville, Seville, Spain. [Gálvez-Fernández,I, Fernández-García,JC] Department of Didactics of Languages, Arts and Sport, University of Malaga, Andalucia-Tech, IBIMA, Malaga, Spain. [Mercadé-Melé,P] Department of Statistics and Econometrics, University of Malaga, Andalucia-Tech, Malaga, Spain., and This research was funded by the 'Researching in Sport Sciences' research group (CTS-563) of the Andalusian Research Plan.
Subjects: Longitudinal study, Health, Toxicology and Mutagenesis, Rowing, Physical fitness, lcsh:Medicine, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Quality of life, heart rate, 030212 general & internal medicine, Longitudinal Studies, Survivors, Mastectomy, Water Sports, education.field_of_study, anthropometry, rowing, Hand Strength, Middle Aged, fitness, Anthropology, Education, Sociology and Social Phenomena::Social Sciences::Quality of Life [Medical Subject Headings], 030220 oncology & carcinogenesis, Neoplasias de la mama, Female, Persons::Persons::Survivors [Medical Subject Headings], medicine.medical_specialty, Population, Breast Neoplasms, Article, 03 medical and health sciences, breast cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies [Medical Subject Headings], Heart rate, Deportes Acuáticos, medicine, Humans, education, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Muscle Strength::Hand Strength [Medical Subject Headings], business.industry, Health Care::Population Characteristics::Health::Physical Fitness [Medical Subject Headings], lcsh:R, Public Health, Environmental and Occupational Health, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Anthropometry, Antropometría, Check Tags::Female [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Mastectomy [Medical Subject Headings], Physical Fitness, Physical therapy, Lean body mass, Quality of Life, business, human activities
Abstract: The aim of this study was to determine whether a rowing training program leads to improvements in physical fitness and body composition in women who have survived breast cancer (53.70 &plusmn, 7.88 years). The participants (n = 30) completed a twelve-week training program consisting of three sessions per week, with each session lasting from sixty to ninety minutes. An anthropometric and general physical fitness assessment was performed before and after the program. The results showed statistically significant improvements in all the physical fitness tests performed: sit and reach (2.82 cm), back scratch, dominant (3.29 cm), back scratch, non-dominant (4.59 cm), counter movement jump (1.91 cm), hand grip, dominant (2.54 kgf), hand grip, non-dominant (2.53 kgf), chair stand (2.56 rep), and six-minute walk (51.56 m). In addition, a significant improvement was observed in the efficiency of the cardiovascular system measured by heart rate, in beats per minute (bpm), both before (&minus, 12.63 bpm) and after the six-minute walk test (&minus, 11.46 bpm). The evaluated body composition parameters also improved, specifically total lean mass (2.18 kg) and the percentage of total body fat (&minus, 2.63%). We can therefore conclude that rowing training programs can be a strategy to be considered for improving physical fitness in this population given the improvement obtained in both anthropometric and physical fitness variables, thus leading to better health and quality of life.
Published: 2020

24. ZNF577 Methylation Levels in Leukocytes From Women With Breast Cancer Is Modulated by Adiposity, Menopausal State, and the Mediterranean Diet

Author: Paula M. Lorenzo, Andrea G. Izquierdo, Angel Diaz-Lagares, Marcos C. Carreira, Manuel Macias-Gonzalez, Juan Sandoval, Juan Cueva, Rafael Lopez-Lopez, Felipe F. Casanueva, Ana B. Crujeiras, [Lorenzo,PM, Izquierdo,AG, Crujeiras,AB] Laboratory of Epigenomics in Endocrinology and Nutrition (EpiEndoNut), Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela (CHUS/SERGAS), Santiago de Compostela, Spain. [Izquierdo,AG, Carreira,MC, Macias-Gonzalez,M, Casanueva,FF, Crujeiras,AB] CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEOBN), Instituto de Salud Carlos III, Madrid, Spain. [Diaz-Lagares,A] Cancer Epigenetics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain. [Diaz-Lagares,A, Lopez-Lopez,R] CIBER de Oncologia (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. [Carreira,MC, Casanueva,FF] Laboratory of Molecular and Cellular Endocrinology, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela (CHUS/SERGAS) and Santiago de Compostela University (USC), Santiago de Compostela, Spain. [Macias-Gonzalez,M] Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, University of Malaga (IBIMA) and CIBEROBN, Málaga, Spain. [Sandoval,J] Biomarkers and Precision Medicine Unit and Epigenomics Core Facility, Health Research Institute La Fe, Valencia, Spain. [Cueva,J, Lopez-Lopez,R] Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain., and This study was supported by the Centro de Investigacion Biomedica en Red de Fisiopatologia de la Obesidad y Nutricion.
Subjects: 0301 basic medicine, Epigenomics, obesity, Ciencias de la nutrición, Mediterranean diet, Endocrinology, Diabetes and Metabolism, Células sanguíneas, Obesidad, Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings], Physiology, Overweight, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Fat Distribution::Adiposity [Medical Subject Headings], Diet, Mediterranean, lcsh:Diseases of the endocrine glands. Clinical endocrinology, Body Mass Index, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Endocrinology, Phenomena and Processes::Genetic Phenomena::Genetic Processes::DNA Methylation [Medical Subject Headings], Anatomy::Cells::Blood Cells::Leukocytes [Medical Subject Headings], Leukocytes, Promoter Regions, Genetic, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Overweight::Obesity [Medical Subject Headings], Original Research, Adiposity, Phenomena and Processes::Genetic Phenomena::Genetic Structures::Base Sequence::GC Rich Sequence::CpG Islands [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Nutrition Therapy::Diet Therapy::Diet, Mediterranean [Medical Subject Headings], Methylation, Middle Aged, Prognosis, Neoplasias, DNA-Binding Proteins, nutrition, Metilación, Neoplasias de la mama, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins [Medical Subject Headings], Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause [Medical Subject Headings], Female, medicine.symptom, Menopause, Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Molecular Structure::Base Sequence::Regulatory Sequences, Nucleic Acid::Promoter Regions, Genetic [Medical Subject Headings], Adult, 030209 endocrinology & metabolism, Breast Neoplasms, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Transcription Factors [Medical Subject Headings], Phenomena and Processes::Chemical Phenomena::Chemical Processes::Organic Chemistry Processes::Alkylation::Methylation [Medical Subject Headings], 03 medical and health sciences, Breast cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings], medicine, Biomarkers, Tumor, cancer, Humans, Epigenetics, Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology::Genomics::Epigenomics [Medical Subject Headings], Persons::Persons::Age Groups::Adult [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], lcsh:RC648-665, epigenetics, business.industry, Cancer, biomarkers, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], DNA Methylation, medicine.disease, Obesity, 030104 developmental biology, Biomarcadores, Check Tags::Female [Medical Subject Headings], Spain, Epigenómica, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], CpG Islands, blood cells, business, Body mass index, Follow-Up Studies, Transcription Factors
Abstract: The methylation levels of ZNF577 in breast tumors has been previously identified as a possible epigenetic mark of breast cancer associated with obesity. The aim of the current study was to investigate differences in methylation levels of ZNF577 depending on obesity, menopausal state and dietary pattern in blood leukocytes, a non-invasive sample. The methylation levels of ZNF577 of two CpG sites (CpGs) located in promoter and island previously identified as differentially methylated according to adiposity and menopausal state by 450 k array (cg10635122, cg03562414) were evaluated by pyrosequencing in DNA from the blood leukocytes of breast cancer patients [n = 90; n = 64 (71.1%) overweight/obesity and n = 26 (28.9%) normal-weight] and paired tumor tissue biopsies (n = 8 breast cancer patients with obesity; n = 3/5 premenopausal/postmenopausal women). Differences in methylation levels were evaluated at each CpGs individually and at the mean of the two evaluated CpGs. Adherence to the Mediterranean diet was evaluated using the MEDAS-validated questionnaire, and the consumption of food groups of interest was also evaluated using the recommended intakes of the Sociedad Española de Nutricion Comunitaria. The methylation levels of ZNF577 were correlated between paired leukocytes and breast tumor biopsies (r = 0.62; p = 0.001). Moreover, higher methylation was found in leukocytes from patients with obesity (p = 0.002) and postmenopausal patients (p = 0.022) than patients with normal-weight or premenopausal, respectively. After adjusting for the body mass index and age, higher levels of ZNF577 methylation were also found in women with greater adherence to the Mediterranean diet (p = 0.017) or specific foods. Relevantly, the methylation levels of ZNF577 showed a good ability for fish consumption detection [area under the ROC curve (AUC) = 0.72; p = 0.016]. In conclusion, the association between methylation of ZNF577 and adiposity, menopausal state, and adherence to the Mediterranean diet can be detected in the blood leukocytes. The results guarantee the need of performing further studies in longer longitudinal cohorts in order to elucidate the role of ZNF577 methylation in the association between breast cancer, adiposity and dietary patterns. Yes
Published: 2020

25. Physical activity and risks of breast and colorectal cancer : a Mendelian randomisation analysis

Author: Michael O. Woods, Fränzel J.B. van Duijnhoven, Tilman Kühn, Graham G. Giles, Temitope O. Keku, Konstantinos K. Tsilidis, Andrew T. Chan, Mingyang Song, Michael Hoffmeister, Gad Rennert, Tabitha A. Harrison, Anna H. Wu, Kenneth Offit, Mark A. Jenkins, Elizabeth A Platz, Sabina Sieri, Noralane M Lindor, John D. Potter, D Timothy Bishop, Barbara L. Banbury, Anne M. May, Sonja I. Berndt, José María Huerta, Antonia Trichopoulou, Paul D.P. Pharoah, Niki Dimou, Christopher I. Li, Roger L. Milne, Marc J. Gunter, Hermann Brenner, Martha L. Slattery, Catherine M. Tangen, Gianluca Severi, Richard M. Martin, Nabila Kazmi, Ruth C. Travis, Sanford D. Markowitz, Jeroen R. Huyghe, Heather Hampel, Ulrike Peters, John L. Hopper, Brigid M. Lynch, Krasimira Aleksandrova, Alicja Wolk, Merete Ellingjord-Dale, Li Li, Bethany Van Guelpen, Sergi Castellví-Bel, Edward Giovannucci, Steven J Gallinger, Annika Lindblom, Cornelia M. Ulrich, Stephen B. Gruber, Stephanie L. Schmit, Jenny Chang-Claude, Lorena Moreno, Victor Moreno, Nikos Papadimitriou, Stephen N. Thibodeau, Elio Riboli, Sophia Harlid, Polly A. Newcomb, Pavel Vodicka, Demetrius Albanes, Bas Bueno-de-Mesquita, Maria J. Sánchez, Sarah J Lewis, Timothy Robinson, Daniel D Buchanan, Loic Le Marchand, Carlo La Vecchia, Robert E Schoen, Neil Murphy, Giovanna Masala, Evelyn M. Monninkhof, Jane C. Figueiredo, Andrea Gsur, Jochen Hampe, Vittorio Perduca, Li Hsu, Emily White, Peter T. Campbell, School of Public Health - Department of Epidemiology and Biostatistics, Imperial College London, University of Bristol [Bristol], National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), Department of Epidemiology, German Institute of Human Nutrition, Division of Cancer Epidemiology and Genetics [Bethesda, MD, États-Unis], National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH), Division of Clinical Epidemiology and Aging Research, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment [Bilthoven] (RIVM), The Cancer, Ageing and Somatic Mutation Programme [Cambridgeshire, UK], The Wellcome Trust Sanger Institute [Cambridge], Division of Cancer Epidemiology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital [Toronto, Canada] (MSH), University of Melbourne, Harvard School of Public Health, Department of Internal Medicine, Epidemiology, Human Genetics, University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, Medical Department 1 [Dresden, Germany], Technische Universität Dresden = Dresden University of Technology (TU Dresden), Ohio State University [Columbus] (OSU), FESTO, Universität Stuttgart [Stuttgart], Centre for MEGA Epidemiology, The University of Melbourne, Victoria, Australia, CIBER de Epidemiología y Salud Pública (CIBERESP), Department of Medical Genetics, HMNC Brain Health, Department of Clinical Sciences and Community Health [Milan, Italy], Università degli Studi di Milano [Milano] (UNIMI), University of Hawai‘i [Mānoa] (UHM), Chinese Center for Disease Control and Prevention, Department of Clinical Genetics, Karolinska University Hospital [Stockholm], Mayo Clinic, Case Western Reserve University [Cleveland], Cancer Risk Factors and LifeStyle Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Julius Center for Health Sciences and Primary Care, University Medical Center [Utrecht], Cancer Epidemiology Centre, Cancer Council Victoria, Biomedical Research Centre Network for Rare Diseases, CIBER de Enfermedades Raras (CIBERER), Memorial Sloane Kettering Cancer Center [New York], Mathématiques Appliquées Paris 5 (MAP5 - UMR 8145), Université Paris Descartes - Paris 5 (UPD5)-Institut National des Sciences Mathématiques et de leurs Interactions (INSMI)-Centre National de la Recherche Scientifique (CNRS), Department of Oncology, University of Cambridge [UK] (CAM), Johns Hopkins Bloomberg School of Public Health [Baltimore], Johns Hopkins University (JHU), Department of Community Medicine and Epidemiology, CHS National Cancer Control Center, School of Public Health [London, UK] (Faculty of Medicine), Andalusian School of Public Health [Granada], Istituto Nazionale dei Tumori, Fred Hutchinson Cancer Research Center [Seattle] (FHCRC), Mayo Clinic [Rochester], University of Oxford [Oxford], WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School [Athens]-University of Athens Medical School [Athens], Helmholtz Centre for Ocean Research [Kiel] (GEOMAR), Department of Medical Biosciences and Pathology, Umeå University, Institute of Experimental Medicine, Czech Academy of Sciences [Prague] (CAS), Karolinska Institutet [Stockholm], Nutrition and Metabolism Section, International Agency for Research on Cancer, [Papadimitriou,N, Dimou,N, Gunter,MJ, Murphy,N] Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France. [Tsilidis,KK] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. [Tsilidis,KK, Ellingjord-Dale,M, Riboli,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Banbury,B, Harrison,TA, Hsu,L, Huyghe,JR, Li,CI, Newcomb,PA, Potter,JD, White,E, Peters,U] Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. [Martin,RM, Kazmi,N] MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. [Martin,RM, Lewis,SJ, Robinson,TM] Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK. [Martin,RM] National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, UK. [Albanes,D, Berndt,SI] Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MA, USA. [Aleksandrova,K] German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. [Bishop,DT] Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK. [Brenner,H, Hoffmeister,M] Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Brenner,H] Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. [Brenner,H] German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. [Buchanan,DD, Giles,GG, Hopper,JL, Jenkins,MA, Lynch,B, Milne,R] Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia. [Buchanan,DD] Colorectal Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC, Australia. [Buchanan,DD] Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, VIC, Australia [Bueno-de-Mesquita,B] Former senior scientist, Dept. for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), BA Bilthoven, Netherlands. [Bueno-de-Mesquita,B] Former associate professor, Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, Netherlands. [Bueno-de-Mesquita,B] ormer visiting professor, Dept. of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, St Mary’s Campus, Norfolk Place, London, London, UK. [Bueno-de-Mesquita,B] Former academic Icon / visiting professor, Dept. of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Pantai Valley, Kuala Lumpur, Malaysia. [Campbell,PT] Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA. [Castellví-Bel,S, Moreno,L] Gastroenterology Department, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain. [Chan,AT, Song,M] Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. [Chan,AT, Song,M] Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. [Chang-Claude,J, Kühn,T] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Chang-Claude,J] University Medical Centre Hamburg-Eppendorf, University Cancer Centre Hamburg (UCCH), Hamburg, Germany. [Figueiredo,JC] Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. [Figueiredo,JC] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. [Gallinger,SJ] Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. [Giles,GG, Milne,R] Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia. [Giovannucci,E, Song,M] Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. [Giovannucci,E, Song,M] Department of Nutrition, T.H. H, Chan School of Public Health, Boston, MA, USA. [Giovannucci,E] Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA. [Gruber,SB, Schmit,SL] Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. [Gsur,A] Institute of Cancer Research, Department of Medicine I, Medical University Vienna, Vienna, Austria. [Hampe,J] Department of Medicine I, University Hospital Dresden, Technische Universität Dresden (TU Dresden), Dresden, Germany. [Hampel,H] Division of Human Genetics, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. [Harlid,S] Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden. [Hopper,JL] Department of Epidemiology, School of Public Health and Institute of Health and Environment, Seoul National University, Seoul, South Korea. [Hsu,L] Department of Biostatistics, University of Washington, Seattle, WA, USA. [Huerta,JM, Moreno,V, Sánchez,MJ] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Keku,TO] Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, USA. [La Vecchia,C, Trichopoulou,A] Hellenic Health Foundation, Athens, Greece. [La Vecchia,C] Dept. of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy. [Le Marchand,L] University of Hawaii Cancer Center, Honolulu, HI, USA. [Li,L] Department of Family Medicine, University of Virginia, Charlottesville, VA, USA. [Lindblom,A] Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. [Lindblom,A] Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. [Lindor,NM] Department of Health Science Research, Mayo Clinic, Scottsdale, AZ, USA. [Lynch,B] Physical Activity Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. [Markowitz,SD] Departments of Medicine and Genetics, Case Comprehensive Cancer Center, Case Western Reserve University, and University Hospitals of Cleveland, Cleveland, OH, USA. [Masala,G] Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy. [May,AM, Monninkhof,E] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, GA UTRECHT, Netherlands. [Milne,R] Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, VIC, Australia. [Moreno,V] Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Moreno,V] Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain. [Newcomb,PA] School of Public Health, University of Washington, Seattle, WA, USA. [Offit,K] Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [Offit,K] Department of Medicine, Weill Cornell Medical College, New York, NY, USA. [Perduca,V, Severi,G] CESP, Fac. de médecine - Univ. ParisSud, Fac. de médecine - UVSQ I, Université Paris-Saclay, Villejuif, France. [Perduca,V, Severi,G] Gustave Roussy, Villejuif, France. [Perduca,V] Laboratoire de Mathématiques Appliquées MAP5 (UMR CNRS 8145), Université Paris Descartes, Paris, France. [Pharoah,PDP] Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. [Platz,EA] Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. [Rennert,G] Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel. [Rennert,G] 7Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. [Rennert,G] Clalit National Cancer Control Center, Haifa, Israel. [Sánchez,MJ] Andalusian School of Public Health, Biomedical Research Institute ibs.GRANADA, University of Granada, Granada, Spain. [Schmit,SL] Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. [Schoen,RE] Department of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. [Sieri,S] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Slattery,ML] Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. [Tangen,CM] SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. [Thibodeau,SN] Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. [Travis,RC] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Ulrich,CM] Huntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA. [van Duijnhoven,FJB] Division of Human Nutrition, Wageningen University and Research, Wageningen, Netherlands. [Van Guelpen,B] Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden. [Van Guelpen,B] Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden. [Vodicka,P] Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. [Vodicka,P] Faculty of Medicine and Biomedical Center in Pilsen, Charles University, Pilsen, Czech Republic. [Vodicka,P] Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. [White,E, Peters,U] Department of Epidemiology, University of Washington, Seattle, WA, USA. [Wolk,A] Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. [Woods,MO] Memorial University of Newfoundland, Discipline of Genetics, St. John’s, Canada. [Wu,AH] University of Southern California, Preventative Medicine, Los Angeles, CA, USA., This work was supported by the National Cancer Institute, the International Agency for Research on Cancer and a Cancer Research UK program grant (C18281/A19169 to RMM, SJL & NK). RMM was supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The funding sources for BCAC, CCFR, GECCO, and CORECT consortia are presented in detail in the appendix in the Supplementary material., Tsilidis, Konstantinos K [0000-0002-8452-8472], Martin, Richard M [0000-0002-7992-7719], Lewis, Sarah J [0000-0003-4311-6890], Robinson, Timothy M [0000-0003-0933-646X], Timothy Bishop, D [0000-0002-8752-8785], Buchanan, Daniel D [0000-0003-2225-6675], Chan, Andrew T [0000-0001-7284-6767], Giles, Graham G [0000-0003-4946-9099], Gsur, Andrea [0000-0002-9795-1528], Hampe, Jochen [0000-0002-2421-6127], Hampel, Heather [0000-0001-7558-9794], Harlid, Sophia [0000-0001-8540-6891], Harrison, Tabitha A [0000-0002-4173-7530], María Huerta, José [0000-0002-9637-3869], Huyghe, Jeroen R [0000-0001-6027-9806], Jenkins, Mark A [0000-0002-8964-6160], La Vecchia, Carlo [0000-0003-1441-897X], Masala, Giovanna [0000-0002-5758-9069], Milne, Roger [0000-0001-5764-7268], Moreno, Victor [0000-0002-2818-5487], Newcomb, Polly A [0000-0001-8786-0043], Perduca, Vittorio [0000-0003-0339-0473], Pharoah, Paul D P [0000-0001-8494-732X], Potter, John D [0000-0001-5439-1500], Rennert, Gad [0000-0002-8512-068X], Riboli, Elio [0000-0001-6795-6080], Schmit, Stephanie L [0000-0001-5931-1194], Schoen, Robert E [0000-0001-7153-2766], Van Guelpen, Bethany [0000-0002-9692-101X], Wolk, Alicja [0000-0001-7387-6845], Peters, Ulrike [0000-0001-5666-9318], Murphy, Neil [0000-0003-3347-8249], Apollo - University of Cambridge Repository, Tsilidis, Konstantinos K. [0000-0002-8452-8472], Martin, Richard M. [0000-0002-7992-7719], Lewis, Sarah J. [0000-0003-4311-6890], Timothy Bishop, D. [0000-0002-8752-8785], Buchanan, Daniel D. [0000-0003-2225-6675], Chan, Andrew T. [0000-0001-7284-6767], Giles, Graham G. [0000-0003-4946-9099], Harrison, Tabitha A. [0000-0002-4173-7530], Huyghe, Jeroen R. [0000-0001-6027-9806], Jenkins, Mark A. [0000-0002-8964-6160], Newcomb, Polly A. [0000-0001-8786-0043], Pharoah, Paul D. P. [0000-0001-8494-732X], Potter, John D. [0000-0001-5439-1500], Schmit, Stephanie L. [0000-0001-5931-1194], Schoen, Robert E. [0000-0001-7153-2766], and Pharoah, Paul DP [0000-0001-8494-732X]
Subjects: Oncology, Epidemiology, Colorectal cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Accelerometry [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Molecular Epidemiology::Mendelian Randomization Analysis [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Breast cancer, Epidemiology of cancer, Accelerometry, Odds Ratio, lcsh:Science, skin and connective tissue diseases, Cancer genetics, ComputingMilieux_MISCELLANEOUS, Cancer, 0303 health sciences, Biobank, 3. Good health, 030220 oncology & carcinogenesis, ICEP, Factores de riesgo, medicine.medical_specialty, Science, 631/67/2324, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Colorectal Neoplasms, Hereditary Nonpolyposis [Medical Subject Headings], Breast Neoplasms/genetics, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Càncer colorectal, Anthropology, Education, Sociology and Social Phenomena::Human Activities::Exercise [Medical Subject Headings], Humans, Epidemiologia, Exercise, VLAG, Cancer och onkologi, 45, 631/67/1347, Odds ratio, Mendelian Randomization Analysis, medicine.disease, Colorectal Neoplasms/genetics, 030104 developmental biology, Analyses, Risk factors, Check Tags::Female [Medical Subject Headings], Cancer and Oncology, lcsh:Q, Breast neoplasms, 0301 basic medicine, 631/67/1504/1885, Nutrition and Disease, General Physics and Astronomy, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Risk Factors, Neoplasias colorrectales, Voeding en Ziekte, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Odds Ratio [Medical Subject Headings], Multidisciplinary, article, Public Health, Global Health, Social Medicine and Epidemiology, Polymorphism, Single Nucleotide/genetics, Ejercicio físico, Neoplasias de la mama, Female, Colorectal Neoplasms, 631/67, 141, Breast Neoplasms, 45/23, Polymorphism, Single Nucleotide, Colorectal neoplasms, Càncer de mama, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease [Medical Subject Headings], Cancer epidemiology, 631/67/68, Internal medicine, Mendelian randomization, medicine, Journal Article, Life Science, Genetic Predisposition to Disease, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], 030304 developmental biology, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic::Polymorphism, Single Nucleotide [Medical Subject Headings], business.industry, General Chemistry, Physical fitness, Confidence interval, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Condició física
Abstract: Physical activity has been associated with lower risks of breast and colorectal cancer in epidemiological studies; however, it is unknown if these associations are causal or confounded. In two-sample Mendelian randomisation analyses, using summary genetic data from the UK Biobank and GWA consortia, we found that a one standard deviation increment in average acceleration was associated with lower risks of breast cancer (odds ratio [OR]: 0.51, 95% confidence interval [CI]: 0.27 to 0.98, P-value = 0.04) and colorectal cancer (OR: 0.66, 95% CI: 0.48 to 0.90, P-value = 0.01). We found similar magnitude inverse associations for estrogen positive (ER+ve) breast cancer and for colon cancer. Our results support a potentially causal relationship between higher physical activity levels and lower risks of breast cancer and colorectal cancer. Based on these data, the promotion of physical activity is probably an effective strategy in the primary prevention of these commonly diagnosed cancers., United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Cancer Institute (NCI), International Agency for Research on Cancer, Cancer Research UK C18281/A19169, National Institute for Health Research (NIHR)
Published: 2020
Full Text: View/download PDF

26. Shared decision making in breast cancer treatment guidelines: Development of a quality assessment tool and a systematic review

Author: Maes-Carballo, Marta, Muñoz-Núñez, Isabel, Martín-Díaz, Manuel, Mignini, Luciano, Bueno-Cavanillas, Aurora, Khan, Khalid Saeed, [Maes-Carballo,M] Department of General Surgery, Complexo Hospitalario de Ourense, Ourense, Spain. [Maes-Carballo,M, Bueno-Cavanillas,A, Khan,KS] Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. [Muñoz-Núñez,I, Martín-Díaz,M] Department of General Surgery, Hospital de Motril, Granada, Spain. [Mignini,L] Unidad de Mastología de Grupo Oroño, Rosario, Argentina [Bueno-Cavanillas,A, and Khan,KS] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Bueno-Cavanillas,A] Instituto de Investigación Biosanitaria IBS, Granada, Spain.
Subjects: Breast cancer treatment, Consensus, Neoplasias de la Mama, Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Thinking::Decision Making::Consensus [Medical Subject Headings], Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Thinking::Decision Making [Medical Subject Headings], Guía de práctica clínica, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Breast cancer, Toma de decisiones conjunta, Consenso, Check Tags::Female [Medical Subject Headings], Information Science::Information Science::Communications Media::Publications::Bibliography as Topic::Bibliometrics [Medical Subject Headings], Clinical practice guidelines, Shared decision making, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]
Abstract: Background: It is not clear whether clinical practice guidelines (CPGs) and consensus statements (CSs) are adequately promoting shared decision making (SDM). Objective: To evaluate the recommendations about SDM in CPGs and CSs concerning breast cancer (BC) treatment. Search strategy: Following protocol registration (Prospero no.: CRD42018106643), CPGs and CSs on BC treatment were identified, without language restrictions, through systematic search of bibliographic databases (MEDLINE, EMBASE, Web of Science, Scopus, CDSR) and online sources (12 guideline databases and 51 professional society websites) from January 2010 to December 2019. Inclusion criteria: CPGs and CSs on BC treatment were selected whether published in a journal or in an online document. Data extraction and synthesis: A 31-item SDM quality assessment tool was developed and used to extract data in duplicate. Main results: There were 167 relevant CPGs (139) and CSs (28); SDM was reported in only 40% of the studies. SDM was reported more often in recent publications after 2015 (42/101 (41.6 %) vs 46/66 (69.7 %), P = .0003) but less often in medical journal publications (44/101 (43.5 %) vs 17/66 (25.7 %), P = .009). In CPGs and CSs with SDM, only 8/66 (12%) met one-fifth (6 of 31) of the quality items; only 14/66 (8%) provided clear and precise SDM recommendations. Discussion and conclusions: SDM descriptions and recommendations in CPGs and CSs concerning BC treatment need improvement. SDM was more frequently reported in CPGs and CSs in recent years, but surprisingly it was less often covered in medical journals, a feature that needs attention. Yes
Published: 2020

27. Vigilancia del cáncer en Andalucía: incidencia, mortalidad y tendencias temporales

Author: Barrera Tenorio, Carlos, Duran Pla, Enric, Rodríguez Romero, Elisa, Secretaría General de Salud Pública y Consumo, [Barrera Tenorio,C, Duran Pla, E, and Rodríguez Romero,E] Servicio de Vigilancia y Salud Laboral, Dirección general del Salud Pública y Ordenación Farmacéutica, Consejería de Salud y Familias
Subjects: Diseases::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms::Otorhinolaryngologic Neoplasms::Laryngeal Neoplasms [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Stomach Neoplasms [Medical Subject Headings], Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiological Monitoring [Medical Subject Headings], Andalucía, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings], Cáncer, Estadísticas, Diseases::Neoplasms [Medical Subject Headings], Informe, Health Care::Population Characteristics::Demography::Vital Statistics::Mortality [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [Medical Subject Headings], Neoplasias, Vigilancia epidemiológica, Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Uterine Cervical Neoplasms [Medical Subject Headings], Mortalidad, Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Urinary Bladder Neoplasms [Medical Subject Headings], Diseases::Male Urogenital Diseases::Genital Diseases, Male::Genital Neoplasms, Male::Prostatic Neoplasms [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]
Abstract: Yes El presente informe tiene como objetivo general presentar los resultados disponibles del Registro de Cáncer de Andalucía, así como la mortalidad por cáncer y sus tendencias, y como objetivos específicos el describir: • La incidencia y el patrón de presentación del cáncer de mama observado en Andalucía de en los periodos de 2008 a 2011 y de 2012 a 2014. • Incidencia y patrón de presentación observado del cáncer colorrectal, pulmón, próstata, estomago, vejiga urinaria, laringe y cérvix uterino en Andalucía para el total del periodo de 2009 a 2014. • Tendencia de la incidencia de las distintas localizaciones en la provincia de Granada desde 1985 a 2014. • La mortalidad, mortalidad prematura desde el año 2008 hasta el 2017 y las tendencias de las mismas, para cada una de las localizaciones, desde 1999 hasta 2017.
Published: 2020

28. Serum phospholipids fatty acids and breast cancer risk by pathological subtype

Author: Antonio Antón, Beatriz Pérez-Gómez, Manuel Ramos-Vázquez, Inmaculada Criado-Navarro, Blanca Hernando, Angel Guerrero-Zotano, Raquel Andrés, Rosalia Caballero, Antonio Llombart-Cussac, Ana M. Casas, Miguel Martín, José Manuel Baena-Cañada, Begoña Bermejo, Virginia Lope, Montserrat Muñoz, Feliciano Priego-Capote, Ana de Juan, Adela Castelló, José A. García-Sáenz, Marina Pollán, Rosa María Franquesa, Pedro Sánchez-Rovira, Silvia Antolín, Asociación Española Contra el Cáncer, Sociedad Española de Oncología Médica, Ministerio de Economía y Competitividad (España), Federación Española de Cáncer de Mama, Medicina, Fundación Científica AECC, [Lope,V, Pérez-Gómez,B, Castelló,A, Pollán,M] Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain. [Lope,V, Pollán,M] Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain. [Lope,V, Guerrero-Zotano,Á, Casas,A, Baena-Cañada,JM, Bermejo,B, Antolí,S, Sánchez-Rovira,P, Ramos-Vázquez,M, Antón,A, García-Saénz,JÁ, Muñoz,M, de Juan,A, Andrés,R, Llombart-Cussac,A, Hernando,B, Franquesa,RM, Caballero,R, Martín,M, Pollán,M] GEICAM Spanish Breast Cancer Group, Madrid, Spain. [Guerrero-Zotano,Á] Instituto Valenciano de Oncología, Valencia, Spain. [Casas,A] Hospital Universitario Virgen Del Rocio, Sevilla, Spain. [Baena-Cañada,JM] Hospital Universitario Puerta del Mar, Cádiz, Spain. [Baena-Cañada,JM] Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), Cádiz, Spain. [Bermejo,B] Hospital Clínico Universitario de Valencia, Valencia, Spain. [Bermejo,B] Biomedical Research Institute INCLIVA, Valencia, Spain. [Bermejo,B, Martín,M] CIBERONC, ISCIII, Madrid, Spain. [Criado-Navarro,I, Priego-Capote,F] Analytical Chemistry Department, Universidad de Córdoba, Córdoba, Spain. [Criado-Navarro,I, Priego-Capote,F] Maimónides Institute of Biomedical Research (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain. [Criado-Navarro,I, Priego-Capote,F] CIBERFES, ISCIII, Madrid, Spain. [Antolín,S] Medical Oncology Unit, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain. [Sánchez-Rovira,P] Complejo Hospitalario de Jaén, Jaén, Spain. [Ramos-Vázquez,M] Centro Oncológico de Galicia, A Coruña, Spain. [Antón,A] Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón, Zaragoza, Spain. [Castell,A] Faculty of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain. [García-Saénz,JÁ] Hospital Clínico San Carlos, Madrid, Spain. [Muñoz,M] Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain. [Muñoz,M] Translational Genomics and Targeted Therapeutics, Institut d’Investigacions Biomèdiques Pi i Sunyer-IDIBAPS, Barcelona, Spain. [de Juan,A] Hospital Marqués de Valdecilla, Santander, Spain. [Andrés,R] Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [Llombart-Cussac,A] Hospital Arnau de Vilanova, Valencia, Spain. [Hernando,B] Hospital General Yagüe, Burgos, Spain. [Franquesa,RM] Hospital General de Vic, Barcelona, Spain. [Martín,M] Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Martín,M] Instituto Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain., and This study was funded by the Fundación Científica Asociación Española Contra el Cancer (AECC) (Scientific Foundation of the Spanish Association against Cancer 2006 & 2016), Sociedad Española de Oncología Médica (SEOM) (Spanish Society of Medical Oncology), Ministerio de Economía y Competitividad (Spanish Ministry of Economy and Coiveness. IJCI-2014-20900), Fundación Cerveza y Salud 2005 (Beer and Health Foundation 2005) and Federación de Asociaciones de Mujeres con Cáncer de Mama (FECMA) (Spanish Federation of Associations of Women with Breast Cancer). This article presents independent research. The views expressed are those of the authors and not necessarily those of the Carlos III Institute of Health.
Subjects: 0301 basic medicine, Àcids grassos, Grasas, Gastroenterology, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Fats, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, EpiGEICAM, Surveys and Questionnaires, Fosfolípidos, Palmitoleic acid, Ácidos grasos, Phospholipids, desaturation indices, Nutrition and Dietetics, Estudios de casos y controles, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], Breast neoplasm, Fatty Acids, Chemicals and Drugs::Lipids::Fatty Acids [Medical Subject Headings], Middle Aged, Elaidic acid, 030220 oncology & carcinogenesis, Neoplasias de la mama, Female, Stearic acid, Chemicals and Drugs::Biological Factors::Biological Markers::Biomarkers, Pharmacological [Medical Subject Headings], lcsh:Nutrition. Foods and food supply, Adult, Risk, medicine.medical_specialty, fats, Phenomena and Processes::Mathematical Concepts::Probability::Risk [Medical Subject Headings], Linoleic acid, Breast cancer subtypes, Breast Neoplasms, lcsh:TX341-641, Desaturation indices, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Feeding Behavior [Medical Subject Headings], Article, Information Science::Information Science::Data Collection::Questionnaires [Medical Subject Headings], Càncer de mama, 03 medical and health sciences, breast neoplasm, Internal medicine, Biomarkers, Tumor, medicine, Humans, Fatty acids, Persons::Persons::Age Groups::Adult [Medical Subject Headings], Chemicals and Drugs::Lipids::Phospholipids [Medical Subject Headings], Life Style, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], business.industry, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Feeding Behavior, Odds ratio, medicine.disease, Confidence interval, breast cancer subtypes, 030104 developmental biology, Check Tags::Female [Medical Subject Headings], chemistry, Spain, Case-Control Studies, business, Body mass index, Food Science
Abstract: This study evaluates whether serum phospholipids fatty acids (PL-FAs) and markers of their endogenous metabolism are associated with breast cancer (BC) subtypes. EpiGEICAM is a Spanish multicenter matched case-control study. A lifestyle and food frequency questionnaire was completed by 1017 BC cases and healthy women pairs. Serum PL-FA percentages were measured by gas chromatography-mass spectrometry. Conditional and multinomial logistic regression models were used to quantify the association of PL-FA tertiles with BC risk, overall and by pathological subtype (luminal, HER2+ and triple negative). Stratified analyses by body mass index and menopausal status were also performed. Serum PL-FAs were measured in 795 (78%) pairs. Women with high serum levels of stearic acid (odds ratio (OR)T3vsT1 = 0.44, 95% confidence interval (CI) = 0.30&ndash, 0.66), linoleic acid (ORT3vsT1 = 0.66, 95% CI = 0.49&ndash, 0.90) and arachidonic to dihomo-&gamma, linolenic acid ratio (OR T3vsT1 = 0.64, 95% CI = 0.48&ndash, 0.84) presented lower BC risk. Participants with high concentrations of palmitoleic acid (ORT3vsT1 = 1.65, 95% CI = 1.20&ndash, 2.26), trans-ruminant palmitelaidic acid (ORT3vsT1 = 1.51, 95% CI = 1.12&ndash, 2.02), trans-industrial elaidic acid (ORT3vsT1 = 1.52, 95% CI = 1.14&ndash, 2.03), and high oleic to stearic acid ratio (ORT3vsT1 = 2.04, 95% CI = 1.45&ndash, 2.87) showed higher risk. These associations were similar in all BC pathological subtypes. Our results emphasize the importance of analyzing fatty acids individually, as well as the desaturase activity indices.
Published: 2020

29. GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain

Author: Martín, Miguel, Guerrero-Zotano, Ángel, Montero, Ángel, Jara, Carlos, Filipovich, Elena, Rojo, Federico, Moreno, Fernando, García-Sáenz, Jose Ángel, Alés, Jose Enrique, Chacón, José Ignacio, Cruz, Josefina, Giménez, Julia, Cruz-Merino, Luis, Algara López, Manuel-Ignacio, Santisteban, Marta, López Tarruella, Sara, GEICAM Spanish Breast Cancer Group Steering Committee, GEICAM Spanish Breast Cancer Group Steering Committee, [Martin,M, López Tarruella,S] Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Departamento de Medicina, Universidad Complutense, Madrid, Spain. [Martin,M, Rojo,F, García-Sáenz,JA, López Tarruella,S] Centro de Investigación Biomedica en Red de Oncologia, CIBERONC-ISCIII, Spain. [Guerrero-Zotano,A] Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain. [Montero,A] Radiation Oncology, Hospital HM Sanchinarro, Madrid, Spain. [Jara,C] Medical Oncology, Universidad Rey Juan Carlos, Hospital Fundación Alcorcón, Madrid, Spain. [Filipovich,E, Alés,JE] Medical Oncology, Complejo Asistencial de Ávila, Ávila, Spain. [Rojo,F] Pathology, Hospital Fundación Jimenez Díaz de Madrid, Madrid, Spain. [Moreno,F, and García-Sáenz,JA] Medical Oncology, Hospital Universitario Clínico San Carlos de Madrid, Madrid, Spain. [Chacón,JI] Medical Oncology, Hospital Virgen de la Salud de Toledo, Toledo, Spain. [Cruz,J] Medical Oncology, Hospital Universitario de Canarias, Tenerife, Spain. [Gimenez,J] Surgery, Instituto Valenciano de Oncología, Valencia, Spain. [Cruz-Merino,L] Medical Oncology, Hospital Virgen de Macarena de Sevilla, Seville, Spain. [Algara,M] Radiation Oncology, Hospital del Mar de Barcelona, Barcelona, Spain. [Santisteban,M] Medical Oncology, Clínica Universidad de Navarra, Navarra, Spain.
Subjects: Cancer Research, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), España, Clinical Decision-Making, Context (language use), Breast Neoplasms, Medical Oncology, SARS‐CoV‐2, Expert recommendations, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Patient Admission, COVID‐19, Pandemic, Health care, Breast Cancer, medicine, Humans, 030212 general & internal medicine, skin and connective tissue diseases, Intensive care medicine, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], Pandemia, business.industry, SARS-CoV-2, Neoplasias de la Mama, Health Care::Environment and Public Health::Public Health::Disease Outbreaks::Epidemics::Pandemics [Medical Subject Headings], Cancer, COVID-19, medicine.disease, Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings], Treatment efficacy, Coronavirus, Oncology, Spain, 030220 oncology & carcinogenesis, Female, business, Delivery of Health Care
Abstract: GEICAM Spanish Breast Cancer Group Steering Committee.-- This article also appears in: COVID-19 and Cancer Article Collection., Breast cancer (BC) is the most common cancer in women in Spain. During the COVID‐19 pandemic caused by the SARS‐CoV‐2 virus, patients with BC still require timely treatment and follow‐up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in‐hospital visit to minimize pandemic‐associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID‐19 pandemic. Owing to the lack of evidence about COVID‐19 infection, these recommendations are mainly based on expert opinion, medical organizations' and societies' recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing.
Published: 2020

30. Vol. 24, nº 52. INCIDENCIA DEL CÁNCER EN ANDALUCÍA

Author: Servicio de Vigilancia y Salud Laboral and Secretaría General de Salud Pública y Consumo
Subjects: Diseases::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms::Otorhinolaryngologic Neoplasms::Laryngeal Neoplasms [Medical Subject Headings], Neoplasia, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiological Monitoring [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms [Medical Subject Headings], Andalucía, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings], Enfermedades transmisibles, Diseases::Neoplasms [Medical Subject Headings], Indicadores (estadística), Vigilancia epidemiológica, Gripe humana, Neoplasias laríngeas, Neoplasias gastrointestinales, Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Uterine Cervical Neoplasms [Medical Subject Headings], Neoplasias colorrectales, Notificación de enfermedades, Neoplasias de la mama, Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Urinary Bladder Neoplasms [Medical Subject Headings], Neoplasias del cuello uterino, Health Care::Environment and Public Health::Public Health::Public Health Practice::Communicable Disease Control::Disease Notification [Medical Subject Headings], Neoplasias de la vejiga urinaria, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Diseases::Bacterial Infections and Mycoses::Infection::Communicable Diseases [Medical Subject Headings]
Abstract: Yes Enfermedades de Declaración Obligatoria por provincias. Semana 51/2019 y acumulado desde la semana 1/2019. Datos provisionales y el informe de la 'Gripe' de la semana 51/2019. Incluye además el artículo titulado 'INCIDENCIA DEL CÁNCER EN ANDALUCÍA', de Carlos Barrera Tenorio, Josefa Ruiz Gomiz, Enric Durán Pla, Alberto Carmona Ubago, Rafael Ruiz Montero, Javier Guillén Enríquez, Nicola Lorusso. Servicio de Vigilancia y Salud Laboral.
Published: 2019

31. Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort

Author: Christina C. Dahm, Marc J. Gunter, Carlotta Sacerdote, Carmen Santiuste, Sabine Rohrmann, Merete Ellingjord-Dale, Cecilie Kyrø, Anika Hüsing, Renée T. Fortner, Eva Ardanaz, Antonia Trichopoulou, María Dolores López, Claudia Agnoli, Elisabete Weiderpass, Virginia Menéndez, Rudolf Kaaks, Signe Borgquist, Marina Kvaskoff, Patrick Arveux, Anne Tjønneland, Carlo La Vecchia, Helene Tilma Vistisen, Marije F. Bakker, Antonio Agudo, María José Sánchez, Agnès Fournier, Laure Dossus, Kay-Tee Khaw, Timothy J. Key, Guri Skeie, Eleni Peppa, Rosario Tumino, Elio Riboli, Salma Butt, Carla H. van Gils, Nena Karavasiloglou, Kostantinos K. Tsilidis, Tilman Kühn, Giovanna Masala, Inge Huybrechts, Matthias B. Schulze, Domenico Palli, Anna Karakatsani, Jenny Chang-Claude, Salvatore Panico, Apollo - University of Cambridge Repository, [Karavasiloglou,N, Rohrmann,S] Division of Chronic Disease Epidemiology, Institute for Epidemiology, Biostatistics and Prevention, University of Zurich, Zurich, Switzerland. [Karavasiloglou,N, Rohrmann,S] Cancer Registry Zurich and Zug, University Hospital Zurich, Zurich, Switzerland. [Karavasiloglou,N, Hüsing,A, Turzanski Fortner,R, Chang-Claude,J, Kaaks,R, Kühn,T] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Masala,G, Palli,D] Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy. [van Gils,CH, Bakker,MF] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. [Huybrechts,I, Weiderpass,E, Dossus,L] International Agency for Research on Cancer, Lyon, France. [Weiderpas,E, Skeie,G] Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. [Arveux,P, Fournier,A, Kvaskoff,M] CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France. [Arveux,P, Kvaskoff,M] Gustave Roussy, Villejuif, France. [Arveux,P] Breast and Gynaecologic Cancer Registry of Côte d’Or, Georges-François Leclerc Cancer Centre, UNICANCER, Dijon, France. [Tjønneland,A] Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. [Tjønneland,A, Kyrø,C] Danish Cancer Society Research Center, Copenhagen, Denmark. [Dahm,CC, Vistisen,HT] Department of Public Health, Aarhus University, Aarhus, Denmark. [Sánchez,MJ] Andalusian School of Public Health (EASP), Granada, Spain. [Sánchez,MJ] Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain. [Sánchez,MJ, Chirlaque López,MD, Santiuste,C, Ardanaz,E] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Sánchez,MJ] Universidad de Granada, Granada, Spain. [Chirlaque López,MD, Santiuste,C] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Chirlaque López,MD] Department of Health and Social Sciences, Murcia University, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Ardanaz,E] IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. [Menéndez,V] Public Health Directorate, Asturias, Spain. [Agudo,A] Unit of Nutrition and Cancer, Catalan Institute of Oncology - ICO, Nutrition and Cancer Group, Bellvitge Biomedical Research Institute - IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Trichopoulou,A, Karakatsani,A, La Vecchia,C, Peppa,E] Hellenic Health Foundation, Athens, Greece. [Karakatsani,A] 2nd Pulmonary Medicine Department, School of Medicine, 'ATTIKON' University Hospital, National and Kapodistrian University of Athens, Haidari, Greece. [La Vecchia,C] Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy. [Agnoli,C] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Panico,S] Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy. [Tumino,R] Cancer Registry and Histopathology Department, Azienda Sanitaria Provinciale (ASP), Ragusa, Italy. [Sacerdote,C] Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy. [Butt,ST] Department of Clinical Sciences, Lund University, Malmö, Sweden. [Butt,ST] Department of Surgery, Skåne University Hospital, Malmö, Sweden. [Borgquist,S] Department of Oncology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark. [Borgquist,S] Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden. [Skeie,G] Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Leeds, UK. [Schulze,M] Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany. [Key,T] Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Khaw,KT] Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. [Tsilidis,KK, Ellingjord-Dale,M, Riboli,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Tsilidis,KK] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece., The coordination of the European Prospective Investigation into Cancer and Nutrition (EPIC) is supported financially by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (France), German Cancer Aid, German Cancer Research Center (German Cancer Research Center), Federal Ministry of Education and Research (Federal Ministry of Education and Research), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany), Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (Ministry of Health, Welfare and Sport), Netherlands Cancer Registry (Netherlands Cancer Registry), LK Research Funds, Dutch Prevention Funds, Dutch Zorg Onderzoek Nederland, World Cancer Research Fund, Statistics Netherlands (the Netherlands), Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), the Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO, Swedish Cancer Society, Swedish Research Council, and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (14136 to EPIC-Norfolk, C570/A16491 and C8221/A19170 to EPIC-Oxford), and the Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK)., Tjønneland, Anne [0000-0003-4385-2097], Dahm, Christina C [0000-0003-0481-2893], Tumino, Rosario [0000-0003-2666-414X], and Borgquist, Signe [0000-0001-7938-8893]
Subjects: 0301 basic medicine, Male, Breastfeeding, lcsh:Medicine, Breast carcinoma in situ, GUIDELINES, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Cohort Studies, 0302 clinical medicine, Breast cancer, Risk Factors, Medicine, Prospective Studies, Prospective cohort study, 11 Medical and Health Sciences, Medicine(all), Geographical Locations::Geographic Locations::Americas::North America::United States [Medical Subject Headings], Hazard ratio, Academies and Institutes, Cohort, General Medicine, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Lifestyle Score, Europe, POSTMENOPAUSAL WOMEN, 030220 oncology & carcinogenesis, Female, CONCORDANCE, Life Sciences & Biomedicine, PROJECT, In situ breast cancer, Cohort study, Research Article, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Estudios de cohortes, RECREATIONAL PHYSICAL-ACTIVITY, Check Tags::Male [Medical Subject Headings], Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Data Collection::Nutrition Assessment [Medical Subject Headings], Breast Neoplasms, Estilo de vida, Càncer de mama, 03 medical and health sciences, Medicine, General & Internal, Medicina preventiva, DIETARY, General & Internal Medicine, Journal Article, Humans, VDP::Medisinske Fag: 700, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Carcinoma de mama in situ, Preventive medicine, 030109 nutrition & dietetics, Cancer prevention, Science & Technology, business.industry, Prevention, lcsh:R, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], medicine.disease, Lifestyle, United States, VDP::Medical disciplines: 700, Nutrition Assessment, Health Care::Health Care Economics and Organizations::Organizations::Academies and Institutes [Medical Subject Headings], Check Tags::Female [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], Cancer research, Life style, Geographical Locations::Geographic Locations::Europe [Medical Subject Headings], business
Abstract: Background Even though in situ breast cancer (BCIS) accounts for a large proportion of the breast cancers diagnosed, few studies have investigated potential risk factors for BCIS. Their results suggest that some established risk factors for invasive breast cancer have a similar impact on BCIS risk, but large population-based studies on lifestyle factors and BCIS risk are lacking. Thus, we investigated the association between lifestyle and BCIS risk within the European Prospective Investigation into Cancer and Nutrition cohort. Methods Lifestyle was operationalized by a score reflecting the adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations. The recommendations utilized in these analyses were the ones pertinent to healthy body weight, physical activity, consumption of plant-based foods, energy-dense foods, red and processed meat, and sugary drinks and alcohol, as well as the recommendation on breastfeeding. Cox proportional hazards regression was used to assess the association between lifestyle score and BCIS risk. The results were presented as hazard ratios (HR) and corresponding 95% confidence intervals (CI). Results After an overall median follow-up time of 14.9 years, 1277 BCIS cases were diagnosed. Greater adherence to the WCRF/AICR cancer prevention recommendations was not associated with BCIS risk (HR = 0.98, 95% CI 0.93–1.03; per one unit of increase; multivariable model). An inverse association between the lifestyle score and BCIS risk was observed in study centers, where participants were recruited mainly via mammographic screening and attended additional screening throughout follow-up (HR = 0.85, 95% CI 0.73–0.99), but not in the remaining ones (HR = 0.99, 95% CI 0.94–1.05). Conclusions While we did not observe an overall association between lifestyle and BCIS risk, our results indicate that lifestyle is associated with BCIS risk among women recruited via screening programs and with regular screening participation. This suggests that a true inverse association between lifestyle habits and BCIS risk in the overall cohort may have been masked by a lack of information on screening attendance. The potential inverse association between lifestyle and BCIS risk in our analyses is consistent with the inverse associations between lifestyle scores and breast cancer risk reported from previous studies.
Published: 2019
Full Text: View/download PDF

32. Estudio observacional post-introducción de las pruebas predictivo/pronósticas en cáncer de mama del Sistema Sanitario Público de Andalucía (SSPA)

Author: Benot López, Soledad, Noriega Barreda, Covadonga, Martínez Ferez, Isabel, Bayo Lozano, Eloísa, Márquez Peláez, Sergio, Abu Omar, Nadia, Aldana Espinal, Josefa M.ª, [Benot López,S, Martínez Ferez,I, Márquez Peláez,S] AETSA Evaluación de Tecnologías Sanitarias de Andalucía. [Noriega Barreda,C, Aldana Espinal,JM] Servicio Andaluz de Salud. [Bayo Lozano, E, and Abu Omar, N] Hospital Virgen Macarena.
Subjects: Evaluación de la tecnología biomédica, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings], Biología molecular, Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biology::Genetics::Molecular Biology [Medical Subject Headings], Evaluación de tecnologias sanitaria de Andalucía, Pruebas genómicas, Neoplasias de la mama, Recurrencia, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Genetic Testing [Medical Subject Headings], Pruebas genéticas, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Riesgo de recurrencia
Abstract: Este trabajo se lleva a cabo para dar respuesta a las siguientes preguntas de investigación: 1. ¿Se han seleccionado de manera adecuada a las pacientes candidatas a las pruebas genómicas en función de los criterios de inclusión establecidos? 2. ¿Los resultados de las plataformas genómicas modifican la decisión terapéutica del profesional? 3. ¿Qué implicaciones económicas suponen la incorporación de estas plataformas a la cartera de Servicios del SSPA? Yes
Published: 2019

33. Prospective analysis of circulating metabolites and breast cancer in EPIC

Author: José María Huerta, Salvatore Panico, Antonia Trichopoulou, Joseph A. Rothwell, Sabina Sieri, Anja Olsen, Christina C. Dahm, Ruth C. Travis, Audrey Gicquiau, Pilar Amiano, Elisabete Weiderpass, N. Charlotte Onland-Moret, Antonio Agudo, Anna Karakatsani, Isabelle Romieu, Paolo Vineis, Mathilde His, Elio Riboli, Marc J. Gunter, Guri Skeie, Tilman Kühn, Augustin Scalbert, Carla H. van Gils, Georgia Martimianaki, Therese Haugdahl Nøst, Anne Tjønneland, Heiner Boeing, Laure Dossus, Pietro Ferrari, Julie A. Schmidt, Rosario Tumino, Konstantinos K. Tsilidis, David Achaintre, Torkjel M. Sandanger, Agnès Fournier, Sofia Christakoudi, María José Sánchez, Vivian Viallon, Renée T. Fortner, Kim Overvad, Giovanna Masala, Sabina Rinaldi, J. Ramón Quirós, Gianluca Severi, Eva Ardanaz, [His,M, Viallon,V, Dossus,L, Gicquiau,A, Achaintre,D, Scalbert,A, Ferrari,P, Weiderpass,E, Gunter,MJ, Rinaldi,S] International Agency for Research on Cancer, Lyon, France. [Romieu,I] Centre for Research on Population Health, National Institute of Public Health, Cuernavaca, Mexico. [Onland-Moret,NC, van Gils,CH] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. [Dahm,CC, Overvad,K] Department of Public Health, Aarhus University, Aarhus, Denmark. [Overvad,K] Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. [Olsen,A, Tjønneland,A] Danish Cancer Society Research Center, Copenhagen, Denmark. [Tjønneland,A] University of Copenhagen, Copenhagen, Denmark. [Fournier,A, Rothwell,JA, Severi,G] CESP, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France. [Fournier,A, Severi,G] Gustave Roussy, Villejuif, France. [Kühn,T, Fortner,R] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Boeing,H] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. [Trichopoulou,A, Karakatsani,A, Martimianaki,G] Hellenic Health Foundation, Athens, Greece. [Karakatsani,A] Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, 'ATTIKON' University Hospital, Haidari, Greece. [Masala,G] Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network – ISPRO, Florence, Italy. [Sieri,S] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. [Tumino,R] Cancer Registry and Histopathology Department, 'M.P.Arezzo'Hospital, ASP Ragusa, Ragusa, Italy. [Vineis,P] Italian Institute for Genomic Medicine (IIGM), Turin, Italy. [Vineis,P] MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK. [Panico,S] Dipartimento di medicina clinica e chirurgia, Federico II University, Naples, Italy. [Nøst,TH, Sandanger,TM, Skeie,G] Department of Community Medicine, UiT the Arctic University of Norway, Tromso, Norway. [Skeie,G] Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Leeds, UK. [Quirós,JR] Public Health Directorate, Asturias, Spain. [Agudo,A] Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Sánchez,MJ] Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Universidad de Granada, Granada, Spain. [Sánchez,MJ, Amiano,P, Huerta,JM, Ardanaz,E] CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain. [Amiano,P] Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Ardanaz,E] IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. [Schmidt,JA, Travis,RC] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Riboli,E, Tsilidis,KK, Christakoudi,S] Department of Epidemiology and Biostatistics, Imperial College London, St Mary’s Campus, Norfolk Place, London, UK. [Tsilidis,KK] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. [Christakoudi,S] MRC Centre for Transplantation, King’s College London, Great Maze Pond, London, SE1 9RT, UK, This work was funded by the French National Cancer Institute (grant number 2015-166). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), European Research Council (ERC-2009-AdG 232997), and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236), Navarra, and the CERCA Program (Generalitat de Catalunya) (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), and Cancer Research UK (14136 to EPIC-Norfolk, and C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom).
Subjects: 0301 basic medicine, Oncology, lcsh:Medicine, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Mass Spectrometry, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Cohort Studies, 0302 clinical medicine, Breast cancer, Information Science::Information Science::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings], Risk Factors, Estudios prospectivos, Prospective Studies, Prospective cohort study, 11 Medical and Health Sciences, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], education.field_of_study, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, Incidence, Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biochemistry::Metabolomics [Medical Subject Headings], General Medicine, Metabolómica, Middle Aged, metabolomics, 3. Good health, Research Design, 030220 oncology & carcinogenesis, Cohort, Neoplasias de la mama, Female, Chemicals and Drugs::Biological Factors::Biological Markers::Biomarkers, Pharmacological [Medical Subject Headings], Cohort study, Research Article, prospective study, Adult, medicine.medical_specialty, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Population, Breast Neoplasms, Càncer de mama, 03 medical and health sciences, breast cancer, Internal medicine, Cell Line, Tumor, General & Internal Medicine, medicine, Journal Article, Metabolomics, Humans, Prospective study, education, Persons::Persons::Age Groups::Adult [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Aged, business.industry, lcsh:R, Case-control study, Cancer, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Odds ratio, medicine.disease, 030104 developmental biology, Check Tags::Female [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], Case-Control Studies, VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, business, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Chemistry Techniques, Analytical::Mass Spectrometry [Medical Subject Headings], Biomarkers
Abstract: BackgroundMetabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk.MethodsA nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression.ResultsAmong women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70–0.90), asparagine (OR = 0.83 (0.74–0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76–0.90)), aa C36:3 (OR = 0.84 (0.77–0.93)), ae C34:2 (OR = 0.85 (0.78–0.94)), ae C36:2 (OR = 0.85 (0.78–0.88)), and ae C38:2 (OR = 0.84 (0.76–0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11–1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06–1.24)) and PC ae C36:3 (OR = 0.88 (0.82–0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity.ConclusionsThese findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies.
Published: 2019
Full Text: View/download PDF

34. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy

Author: Francisco G. Ortega, Christian Rolfo, José Expósito, Diego de Miguel-Pérez, Jose L. Garcia-Puche, Alba Rodríguez-Martínez, Jordi Martorell-Marugán, María del Carmen Garrido-Navas, Marta Legueren, María José Serrano, José A. Lorente, Inmaculada Robles-Fernandez, Hugh Ilyine, Pedro Carmona-Sáez, [Rodriguez-Martinez,A, de Miguel-Perez,D, Ortega,FG, Garcia-Puche,JL, Robles-Fernandez,I, Garrido-Navas,MC, Lorente,JA, Serrano,MJ] Liquid biopsy and metastasis research group, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government PTS, Granada, Spain. [Rodriguez-Martinez,A, Lorente,JA] Laboratory of Genetic Identification, Legal Medicine and Toxicology Department, Faculty of Medicine, University of Granada, Spain. [García-Puche,JL, Exposito,J, Legueren,M, Serrano,MJ] Comprehensive oncology division, Clinical University Hospital, Virgen de las Nieves-San Cecilio, Granada, Spain. [Martorell-Marugan,J, Carmona-Sáez,P] Bioinformatics Unit, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government PTS. Granada, Spain. [Rolfo,C] Thoracic Medical Oncology, Early Clinical Trials, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), Baltimore, USA. [Ilyine,H] DestiNA Genomics Ltd, Edinburgh, UK., and This work was supported by 'Granada Research of Excellence Initiative on BioHealth (GREIB)', the PhD grant from the University of Granada and the PhD grant from the Spanish Government (FPU) 2014, REF FPU14/05461.
Subjects: Oncology, medicine.medical_treatment, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Feasibility Studies [Medical Subject Headings], Exosomes, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy [Medical Subject Headings], Anatomy::Body Regions::Breast [Medical Subject Headings], Exosomas, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Localized breast cancer, 0302 clinical medicine, Circulating tumor cell, Surgical oncology, Positron Emission Tomography Computed Tomography, Medicine, Breast, Prospective Studies, Neoadjuvant therapy, Anatomy::Cells::Neoplastic Cells, Circulating [Medical Subject Headings], microRNA, Diagnóstico, Conservative surgery, Pronóstico, MicroRNA, Cancer diagnosis, Middle Aged, Progesterone Receptor Status, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Neoplastic Cells, Circulating, Prognosis, Metastatic breast cancer, Neoadjuvant Therapy, Treatment Outcome, 030220 oncology & carcinogenesis, Neoplasias de la mama, Female, Anatomy::Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Organelles::Cytoplasmic Vesicles::Transport Vesicles::Exosomes [Medical Subject Headings], Research Article, medicine.medical_specialty, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Antineoplastic Agents, Breast Neoplasms, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Gene Expression Profiling [Medical Subject Headings], lcsh:RC254-282, Neoadjuvant chemotherapy, 03 medical and health sciences, Breast cancer, Terapia neoadyuvante, Internal medicine, Biomarkers, Tumor, Humans, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings], Chemotherapy, Cancer prognosis, business.industry, Gene Expression Profiling, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings], Liquid Biopsy, Circulating tumor cells, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], medicine.disease, Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs [Medical Subject Headings], MicroRNAs, Check Tags::Female [Medical Subject Headings], Feasibility Studies, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], business, Células neoplásicas circulantes
Abstract: Background: Breast cancer patients under neoadjuvant chemotherapy includes a heterogeneous group of patients who eventually develop distal disease, not detectable by current methods. We propose the use of exosomal miRNAs and circulating tumor cells as diagnostic and predictive biomarkers in these patients. Methods: Fifty-three breast cancer women initially diagnosed with localized breast cancer under neoadjuvant chemotherapy were prospectively enrolled in this study. However, six of them were later re-evaluated and diagnosed as metastatic breast cancer patients by PET-CT scan. Additionally, eight healthy donors were included. Circulating tumor cells and serum exosomal miRNAs were isolated from blood samples before and at the middle of neoadjuvant therapy and exosomal miRNA levels analyzed by qPCR. Results: Before neoadjuvant therapy, exosomal miRNA-21 and 105 expression levels were higher in metastatic versus non-metastatic patients and healthy donors. Likewise, higher levels of miRNA-222 were observed in basal-like (p = 0.037) and in luminal B versus luminal A (p = 0.0145) tumor subtypes. Exosomal miRNA-222 levels correlated with clinical and pathological variables such as progesterone receptor status (p = 0.017) and Ki67 (p = 0.05). During neoadjuvant treatment, exosomal miRNA-21 expression levels directly correlated with tumor size (p = 0.039) and inversely with Ki67 expression (p = 0.031). Finally, higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155 were significantly associated with the presence of circulating tumor cells. Conclusion: Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementary clinical tool for improving breast cancer diagnosis and prognosis., This work was supported by “Granada Research of Excellence Initiative on BioHealth (GREIB)”, the PhD grant from the University of Granada and the PhD grant from the Spanish Government (FPU) 2014, REF FPU14/05461
Published: 2019

35. Restoration of MHC-I on Tumor Cells by Fhit Transfection Promotes Immune Rejection and Acts as an Individualized Immunotherapeutic Vaccine

Author: Alba S-Montalvo, Federico Garrido, Antonia Collado, Angel M. Garcia-Lora, María Pulido, Irene Romero, Virginia Chamorro, Ignacio Algarra, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, [Pulido,M, Chamorro,V, S-Montalvo,A, Garrido,F, Garcia-Lora,AM] Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio Clínico, Hospital Universitario Virgen de las Nieves, Granada, Spain. [Pulido,M, Garcia-Lora,AM] Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. [Romero,I] UGC Laboratorios, Complejo Hospitalario de Jaén, Jaén, Spain. [Algarra,I] Departamento de Ciencias de la Salud, Universidad de Jaén, Jaén, Spain. [Collado,A] Unidad de Biobanco, Hospital Universitario Virgen de las Nieves, Granada, Spain. [Garrido,F] Departamento de Bioquímica, Biología Molecular e Inmunología III, Universidad de Granada, Granada, Spain., and This work was supported by grants cofinanced by FEDER funds (EU) from the Instituto de Salud Carlos III (PI12/02031, PI14/01978, PI15/00528, PI17/00197, PI19/01179, PT13/0010/0039 and PT17/0015/0041), Worldwide Cancer Research project 15-1166, Junta de Andalucía (Group CTS-143, CTS-3952, CVI-4740 grants). A.M.G.L. was supported by Contract I3-SNS from Junta de Andalucía and ISCIII, I. R. by Rio-Hortega Contract CM12/00033 from ISCIII, and M. P. by ibs.Granada Fellowship 496.
Subjects: Anatomy::Cells::Cells, Cultured::Cell Line::Cell Line, Tumor [Medical Subject Headings], 0301 basic medicine, Cancer Research, Ratones, medicine.medical_treatment, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Mice, Chemicals and Drugs::Biological Factors::Antigens::Antigens, Surface::Histocompatibility Antigens::Histocompatibility Antigens Class I [Medical Subject Headings], 0302 clinical medicine, Cancer immunotherapy, FHIT, vaccine, Organisms::Eukaryota::Animals [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [Medical Subject Headings], Cytotoxic T cell, Chemicals and Drugs::Complex Mixtures::Biological Products::Vaccines [Medical Subject Headings], Vaccines, biology, Vacuna, Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Signal Transduction [Medical Subject Headings], immune profile, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Tumor antigen, Oncology, 030220 oncology & carcinogenesis, Linfocitos t citotóxicos, immunotherapy, antitumor immunity, Check Tags::Male [Medical Subject Headings], chemical and pharmacologic phenomena, Tumor cells, cytotoxic T lymphocytes, Major histocompatibility complex, lcsh:RC254-282, Article, MHC-I restoration, 03 medical and health sciences, Immune system, MHC class I, medicine, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Cytokine-Induced Killer Cells::T-Lymphocytes, Cytotoxic [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings], Fhit, Immunotherapy, Chemicals and Drugs::Biological Factors::Antigens::Antigens, Neoplasm [Medical Subject Headings], 030104 developmental biology, Cancer research, biology.protein, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Gene Transfer Techniques::Transfection [Medical Subject Headings]
Abstract: The authors thank I. Linares, V. Sanz, A.B. Rodriguez, A.I. Rodriguez and E. Arias for technical advice and R. Davies for editorial assistance., The capacity of cytotoxic-T lymphocytes to recognize and destroy tumor cells depends on the surface expression by tumor cells of MHC class I molecules loaded with tumor antigen peptides. Loss of MHC-I expression is the most frequent mechanism by which tumor cells evade the immune response. The restoration of MHC-I expression in cancer cells is crucial to enhance their immune destruction, especially in response to cancer immunotherapy. Using mouse models, we recovered MHC-I expression in the MHC-I negative tumor cell lines and analyzed their oncological and immunological profile. Fhit gene transfection induces the restoration of MHC-I expression in highly oncogenic MHC-I-negative murine tumor cell lines and genes of the IFN-γ transduction signal pathway are involved. Fhit-transfected tumor cells proved highly immunogenic, being rejected by a T lymphocyte-mediated immune response. Strikingly, this immune rejection was more frequent in females than in males. The immune response generated protected hosts against the tumor growth of non-transfected cells and against other tumor cells in our murine tumor model. Finally, we also observed a direct correlation between FHIT expression and HLA-I surface expression in human breast tumors. Recovery of Fhit expression on MHC class I negative tumor cells may be a useful immunotherapeutic strategy and may even act as an individualized immunotherapeutic vaccine., FEDER funds (EU) from the Instituto de Salud Carlos III PI12/02031 PI14/01978 PI15/00528 PI17/00197 PI19/01179 PT13/0010/0039 PT17/0015/0041, Worldwide Cancer Research 15-1166, Junta de Andalucia CTS-143 CTS-3952 CVI-4740, Instituto de Salud Carlos III, Rio-Hortega Contract from ISCIII CM12/00033, ibs.Granada Fellowship 496
Published: 2020
Full Text: View/download PDF

36. Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study

Author: María Teresa Sánchez-Barrón, Ana I. Álvarez-Mercado, Carmen M Ruiz-Marín, Cándido Robles-Sánchez, Saturnino Reyes Lartategui, María José Sáez-Lara, María Belén Sánchez-Andujar, Mariana F. Fernández, Alejandro J. Pérez-Alonso, Ana Moreno-Delgado, Tania Gallart-Aragón, Natalia Chueca, Katia Torres-Martínez, Julio Plaza-Díaz, Federico García, Iris Reina-Pérez, Luis Fontana, Pablo Torné, [Plaza-Díaz,J, Álvarez-Mercado,AI, Robles-Sánchez,C, Fontana,L] Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071, Granada, Spain. [Plaza-Díaz,J, Sáez-Lara,MJ, Fontana,L] Institute of Nutrition and Food Technology 'José Mataix', Biomedical Research Center, Parque Tecnológico Ciencias de la Salud, University of Granada, Granada, Spain. [Plaza-Díaz,J, García,F, Chueca,N, Fernández,MF, Fontana,L] Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. [Plaza-Díaz,J] Spanish Consortium for Research on Physiopathology of Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. [Ruiz-Marín,CM, Pérez-Alonso,AJ, Sánchez-Andujar,MB] Unit of Mammary Pathology, General Surgery Service, University Hospital of Jaén, Jaén, Spain. [Reina-Pérez,I, Fernández,MF] Department of Radiology, School of Medicine, University of Granada, Granada, Spain. [Fernández,MF] Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. [Pérez-Alonso,AJ, Torné,P] Department of Surgery, School of Medicine, University of Granada, Granada, Spain. [Torné,P, Gallart-Aragón,T, Sánchez-Barrón,MT, Reyes Lartategui,S] Unit of Mammary Pathology, General Surgery Service, University Hospital Campus de la Salud, Granada, Spain. [García,F, Chueca,N] Department of Microbiology, University Hospital Campus de la Salud, Granada, Spain. [Moreno-Delgado,A, Torres-Martínez,K] Clínica Ana Moreno, Calle Doctor Alejandro Otero, Granada, Spain. [Sáez-Lara,MJ] Department of Biochemistry and Molecular Biology I, School of Sciences, University of Granada, Granada, Spain. [Fernández,MF] Laboratory 207, Biomedical Research Center, Parque Tecnológico Ciencias de la Salud, Granada, Spain., and Biomedical Research Networking Center-CIBER de Epidemiología y Salud Pública (CIBERESP) of the Institute of Health Carlos III -supported by European Regional Development Fund/FEDER (FIS-PI16/01812) (to MFF)
Subjects: 0301 basic medicine, Cancer Research, medicine.medical_treatment, Biopsy, Physiology, Disease, Gut flora, Hongos, Metastasis, Anatomy::Body Regions::Breast [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Study Protocol, Feces, 0302 clinical medicine, Breast cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Biopsy [Medical Subject Headings], Surveys and Questionnaires, Breast, Breast augmentation, Neoadjuvant therapy, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Phenomena and Processes::Metabolic Phenomena::Metabolome [Medical Subject Headings], biology, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], Microbioma sastrointestinal, Organisms::Viruses [Medical Subject Headings], Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Health Care::Environment and Public Health::Public Health::Environmental Pollution::Environmental Exposure [Medical Subject Headings], Environmental pollutants, Virus, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Estrogens [Medical Subject Headings], Oncology, 030220 oncology & carcinogenesis, Neoplasias de la mama, Metabolome, Breast microbiota, Female, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Dysbiosis [Medical Subject Headings], Disruptores endocrinos, Adult, Anatomy::Fluids and Secretions::Feces [Medical Subject Headings], Breast Neoplasms, Gut microbiota, lcsh:RC254-282, 03 medical and health sciences, Genetics, medicine, Humans, Persons::Persons::Age Groups::Adult [Medical Subject Headings], Endocrine disruptors, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Aged, Organisms::Archaea [Medical Subject Headings], Phenomena and Processes::Genetic Phenomena::Genetic Processes::DNA Damage [Medical Subject Headings], Bacteria, business.industry, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Endocrine Disruptors [Medical Subject Headings], Fungi, Cancer, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Estrogens, Environmental Exposure, medicine.disease, biology.organism_classification, Archaea, Organisms::Eukaryota::Fungi [Medical Subject Headings], Gastrointestinal Microbiome, 030104 developmental biology, Check Tags::Female [Medical Subject Headings], Case-Control Studies, Dysbiosis, business, Contaminantes ambientales, DNA Damage
Abstract: We would like to thank M Luisa Puertas-Martin and Isabel Manzano-Jimenez, nurses at the Unit of Mammary Pathology, General Surgery Service, San Cecilio University Hospital (Granada), without whose enthusiasm the enrolment of participants in Granada would still be stalled. We are indebted to all the women taking part in the study., The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Trial registration ClinicalTrials.gov NCT03885648, 03/25/2019. Retrospectively registered., Background Breast cancer ranks first in women, and is the second cause of death in this gender. In addition to genetics, the environment contributes to the development of the disease, although the factors involved are not well known. Among the latter is the influence of microorganisms and, therefore, attention is recently being paid to the mammary microbiota. We hypothesize that the risk of breast cancer could be associated with the composition and functionality of the mammary/gut microbiota, and that exposure to environmental contaminants (endocrine disruptors, EDCs) might contribute to alter these microbiota. Methods We describe a case-control clinical study that will be performed in women between 25 and 70 years of age. Cases will be women diagnosed and surgically intervened of breast cancer (stages I and II). Women with antecedents of cancer or advanced tumor stage (metastasis), or who have received antibiotic treatment within a period of 3 months prior to recruitment, or any neoadjuvant therapy, will be excluded. Controls will be women surgically intervened of breast augmentation or reduction. Women with oncological, gynecological or endocrine history, and those who have received antibiotic treatment within a period of 3 months prior to recruitment will also be excluded. Blood, urine, breast tissue and stool samples will be collected. Data regarding anthropometric, sociodemographic, reproductive history, tumor features and dietary habits will be gathered. Metabolomic studies will be carried out in stool and breast tissue samples. Metagenomic studies will also be performed in stool and breast tissue samples to ascertain the viral, fungal, bacterial and archaea populations of the microbiota. Quantitation of estrogens, estrogen metabolites and EDCs in samples of serum, urine and breast tissue will also be performed. Discussion: This is the first time that the contribution of bacteria, archaea, viruses and fungi together with their alteration by environmental contaminants to the risk of breast cancer will be evaluated in the same study. Results obtained could contribute to elucidate risk factors, improve the prognosis, as well as to propose novel intervention studies in this disease., This work is funded by grants PI-0538-2017 (Junta de Andalucía, Spain, to LF) and Biomedical Research Networking Center-CIBER de Epidemiología y Salud Pública (CIBERESP) of the Institute of Health Carlos III -supported by European Regional Development Fund/FEDER (FIS-PI16/01812) (to MFF).
Published: 2019
Full Text: View/download PDF

37. Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles

Author: Consolación Melguizo, José Manuel Entrena, Jose Prados, Laura Cabeza, Raquel Luque, Raúl Ortiz, María Adolfina Ruiz Martínez, José L. Arias, [Cabeza,L, Ortiz,R, Prados,J, Melguizo,C] Institute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain. [Ortiz,R] Department of Health Science, University of Jaén, Jaén, Spain. [Arias,JL, Ruiz Martínez,MA] Department of Pharmacy and Pharmaceutical Technology, University of Granada, Granada, Spain. [Prados,J, Melguizo,C] Biosanitary Institute of Granada (ibs GRANADA), SAS-Universidad de Granada, Granada, Spain. [Entrena,JM] Institute of Neuroscience, Biomedical Research Center. Animal Behavior Research Unit, Scientific Instrumentation Center, University of Granada, Armilla, Granada, Spain. [Luque,R] Service of Medical Oncology, Virgen de las Nieves Hospital, Granada, Spain., and This investigation was funded by FEDER, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I + D + I), Instituto de Salud Carlos III (FIS) through projects Nos PI11/01862 and PI11/02571, and by the Consejería de Salud de la Junta de Andalucía through project No PI-0338.
Subjects: Anatomy::Cells::Cells, Cultured::Cell Line::Cell Line, Tumor [Medical Subject Headings], Nanopolymer, Chemicals and Drugs::Pharmaceutical Preparations::Dosage Forms::Delayed-Action Preparations [Medical Subject Headings], Doxorrubicina, Cytotoxicity, Pharmaceutical Science, Pharmacology, carcinoma, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Mice, International Journal of Nanomedicine, Enbucrilato, Drug Discovery, Biodegradable polymer, nanopolymer, Organisms::Eukaryota::Animals [Medical Subject Headings], polycyclic compounds, Medicine, Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Acyclic::Acrylates::Cyanoacrylates [Medical Subject Headings], Adsorción, Original Research, Drug Carriers, Preparaciones de acción retardada, Nanopartículas, General Medicine, Enbucrilate, Metastatic breast cancer, Humanos, Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Acyclic::Acrylates::Cyanoacrylates::Enbucrilate [Medical Subject Headings], Phenomena and Processes::Chemical Phenomena::Physicochemical Phenomena::Physicochemical Processes::Adsorption [Medical Subject Headings], Drug delivery, Neoplasias de la mama, cytotoxicity, Female, medicine.drug, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Polycyclic Hydrocarbons, Aromatic::Naphthacenes::Anthracyclines::Daunorubicin::Doxorubicin [Medical Subject Headings], Technology, Industry, Agriculture::Technology, Industry, and Agriculture::Manufactured Materials::Nanostructures::Nanoparticles [Medical Subject Headings], Cell Survival, Biophysics, Bioengineering, Antineoplastic Agents, Breast Neoplasms, macromolecular substances, Biomaterials, In vivo, Cell Line, Tumor, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Toxicity Tests::Inhibitory Concentration 50 [Medical Subject Headings], Organisms::Eukaryota::Animals::Animal Population Groups::Animals, Inbred Strains::Mice, Inbred Strains::Mice, Inbred C57BL [Medical Subject Headings], Animals, Humans, Doxorubicin, IC50, Chemotherapeutic drug, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], chemotherapeutic drug, Línea celular tumoral, business.industry, Concentración 50 inhibidora, Organic Chemistry, Carcinoma, technology, industry, and agriculture, biodegradable polymer, Cianoacrilatos, Ratones consanguíneos C57BL, medicine.disease, In vitro, carbohydrates (lipids), Cancer cell, Animales, drug delivery, Nanoparticles, business
Abstract: The use of doxorubicin (DOX), one of the most effective antitumor molecules in the treatment of metastatic breast cancer, is limited by its low tumor selectivity and its severe side effects. Colloidal carriers based on biodegradable poly(butylcyanoacrylate) nanoparticles (PBCA NPs) may enhance DOX antitumor activity against breast cancer cells, thus allowing a reduction of the effective dose required for antitumor activity and consequently the level of associated toxicity. DOX loading onto PBCA NPs was investigated in this work via both drug entrapment and surface adsorption. Cytotoxicity assays with DOX-loaded NPs were performed in vitro using breast tumor cell lines (MCF-7 human and E0771 mouse cancer cells), and in vivo evaluating antitumor activity in immunocompetent C57BL/6 mice. The entrapment method yielded greater drug loading values and a controlled drug release profile. Neither in vitro nor in vivo cytotoxicity was observed for blank NPs. The 50% inhibitory concentration (IC50) of DOX-loaded PBCA NPs was significantly lower for MCF-7 and E0771 cancer cells (4 and 15 times, respectively) compared with free DOX. Furthermore, DOX-loaded PBCA NPs produced a tumor growth inhibition that was 40% greater than that observed with free DOX, thus reducing DOX toxicity during treatment. These results suggest that DOX-loaded PBCA NPs have great potential for improving the efficacy of DOX therapy against advanced breast cancers., This investigation was funded by FEDER, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I + D + I), Instituto de Salud Carlos III (FIS) through projects Nos PI11/01862 and PI11/02571, and by the Consejería de Salud de la Junta de Andalucía through project No PI-0338. The authors wish to express their gratitude to G Ortiz Ferron (CIC, University of Granada, Spain) for his skillful assistance with cytometry experiments.
Published: 2015

38. Prognostic genomic tests in early breast cancer: up-date of evidence. Executive summary

Author: Martínez-Férez, Isabel M., Viguera-Guerra, Isabel, Rosario-Lozano, María Piedad, Benot-López, Soledad, [Martínez-Férez,IM, Viguera-Guerra,I, Benot-López,S] AETSA Evaluación de Tecnologías Sanitarias de Andalucía., and Este documento ha sido realizado por la Agencia de Evaluación de Tecnologías Sanitarias de Andalucía en el marco de la financiación del Ministerio de Sanidad, Servicios Sociales e Igualdad para el desarrollo de las actividades del Plan anual de Trabajo de la Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS, aprobado en el Pleno del Consejo Interterritorial del SNS de 8 de noviembre de 2017 (conforme al Acuerdo del Consejo de Ministros de 1 de diciembre de 2017)
Subjects: Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Early Diagnosis::Early Detection of Cancer [Medical Subject Headings], Perfilación de la expresión génica, Revisión sistemática, Quimioterapia adyuvante, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Gene Expression Profiling [Medical Subject Headings], Gene expression profiling, Detección precoz del cáncer, Early detection of cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures [Medical Subject Headings], Neoplasias de la mama, Diagnostic techniques and procedures, Técnicas y procedimientos diagnósticos, Breast neoplasms, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]
Abstract: El informe es una revisión sistemática de la literatura cuyo objetivo es la actualización de dos informes publicados con anterioridad por la Agencia de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA) que valoraban la validez y utilidad clínica de las pruebas genéticas (MammaPrint®, Oncotype DX™, EndoPredict® y Prosigna™) como pruebas pronóstico y/o predictivas del cáncer de mama en estadios tempranos. La nueva evidencia sobre las pruebas EndoPredict® y Prosigna™ se ha limitado a estudios sobre su validez clínica como factores pronóstico pero no se dispone de información sobre su utilidad clínica en términos de salud. De las pruebas MammaPrint® y Oncotype DX™ se han incluido y valorado los primeros resultados publicados de los estudios sobre su utilidad clínica . En general, en la revisión se ha observado que la realización de las pruebas de expresión génica impacta en la toma de decisión modificando la recomendación terapéutica y reduciendo en general el número de pacientes tratados con quimioterapia adyuvante. Yes
Published: 2018

39. Ribociclib en el tratamiento del cáncer de mama localmente avanzado o metastásico. Eficacia y Seguridad

Author: Valle Corpas, Margarita, Ubago Pérez, Ruth, and [Valle Corpas,M] Hospital Universitario San Cecilio, Granada. [Ubago Pérez,R] AETSA Evaluación de Tecnologías Sanitarias de Andalucía, Consejería de Salud y Consumo, Junta de Andalucía.
Subjects: Neoplasm metastasis, Evaluación de medicamentos, Drug evaluation, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Drug Evaluation [Medical Subject Headings], Metástasis de la neoplasia, Neoplasias de la mama, Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis [Medical Subject Headings], Quimioterapia, Drug therapy, Resultado del tratamiento, Breast neoplasms, Treatment outcome, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]
Abstract: La combinación ribociclib más letrozol administrada en ciclos de 28 días a mujeres postmenopáusicas con cáncer de mama localmente avanzado o metastásico ER positivo HER 2 negativo, que no han sido tratadas anteriormente para la enfermedad avanzada, ha demostrado ser más eficaz, en términos de supervivencia libre de progresión, que letrozol en monoterapia. No obstante, no se conoce si esta mejora en la SLP conlleva un beneficio en la supervivencia global. Respecto a la calidad de vida de los pacientes, no se encontró mejora significativa del tratamiento con ribociclib más letrozol en relación a letrozol según la escala EORTC QLQ-30. En relación a los comparadores a evaluar, letrozol es una opción válida, aunque sería deseable la realización de ensayos clínicos en los que se comparara de forma directa palbociclib en combinación con letrozol y ribociclib en la misma combinación. Por otra parte, para SLP, la superioridad de ribociclib + letrozol fue consistente entre los diferentes subgrupos estratificados. La combinación ribociclib más letrozol ha resultado más tóxica que letrozol, en especial en relación a la toxicidad hematológica (principalmente neutropenia y leucopenia) así como alteraciones de la función hepática (elevación grado 3-4 de ASAT y ALAT) y prolongación del intervalo QT. Yes
Published: 2018

40. Digital tomosynthesis in breast cancer. Meta-analysis

Author: Llanos-Méndez, Aurora, Benot-López, Soledad, [Llanos-Méndez,A, Benot-López,S] AETSA Evaluación de Tecnologías Sanitarias de Andalucía., and Este documento ha sido realizado por la Agencia de Evaluación de Tecnologías Sanitarias de Andalucía en el marco de la financiación del Ministerio de Sanidad, Servicios Sociales e Igualdad para el desarrollo de las actividades del Plan anual de Trabajo de la Red Española de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS, aprobado en el Pleno del Consejo Interterritorial del SNS de 8 de noviembre de 2017 (conforme al Acuerdo del Consejo de Ministros de 1 de diciembre de 2017)
Subjects: Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Early Diagnosis::Early Detection of Cancer [Medical Subject Headings], Revisión sistemática, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Mass Screening [Medical Subject Headings], Mamografía, Mass screening, Diagnostico precoz del cáncer, Early detection of cancer, Neoplasias de la mama, Systematic review, Breast neoplasms, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Radiography::Mammography [Medical Subject Headings], Tamizaje masivo, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Mammography
Abstract: El objetivo de este metanálisis fue establecer la eficacia –en términos de validez diagnóstica y precisión–, efectividad –en términos de reducción de la mortalidad– y seguridad de la tomosíntesis digital de mama más la mamografía digital en el cribado y diagnóstico del cáncer de mama. La combinación de imagen 2D+3D en el cribado se mostró como una prueba excelente. Aunque en el diagnóstico la especificidad fue menor que en el cribado, el rendimiento global de la prueba fue muy bueno. No obstante, no se disponen de estudios que analicen el efecto que tendría añadir la tomosíntesis a la mamografía en el cribado o diagnóstico sobre los resultados en salud Yes
Published: 2018

41. Validation of suitable normalizers for miR expression patterns analysis covering tumour heterogeneity

Author: Macarena Perán, Houria Boulaiz, Cynthia Morata-Tarifa, Juan A. Marchal, Carmen Griñán-Lisón, María Ángel García, Manuel Picon-Ruiz, [Morata-Tarifa,C, Picon-Ruiz,M, Griñan-Lison,C, Boulaiz,H, Perán,M, Garcia,MA, Marchal,JA] Biopathology and Medicine Regenerative Institute (IBIMER), University of Granada, Granada, Spain. [Morata-Tarifa,C, Marchal,JA] Biosanitary Institute of Granada (ibs.GRANADA), University Hospitals of Granada-University of Granada, Granada, Spain. [Morata-Tarifa,C, Picón-Ruiz,M] Braman Family Breast Cancer Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA. [Boulaiz,H, Marchal,JA] Department of Human Anatomy and Embryology, University of Granada, Granada, Spain. [Perán,M] Department of Health Sciences, University of Jaén, Jaén, Spain. [Garcia,MA] Virgen de las Nieves University Hospital, Oncology Department, Oncology Unit, Granada, Spain., and This work was supported in part by grants from the Fundación Pública Andaluza Progreso y Salud, Consejería de Salud Junta de Andalucía in collaboration with JANNSSEN CILAG,S.A. (project numbers PI-0533-2014, PI-0441-2014), from the Ministerio de Economía y Competitividad (MINECO, FEDER funds, grant number MAT2015-62644-C2-2-R) from the Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (FEDER funds, project DTS15/00174) and from the Chair 'Doctors Galera-Requena in cancer stem cell research'.
Subjects: 0301 basic medicine, Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Nuclear::RNA, Small Nuclear [Medical Subject Headings], Colorectal cancer, medicine.disease_cause, Bioinformatics, 0302 clinical medicine, Anatomy::Cells::Cells, Cultured::Cell Line [Medical Subject Headings], Neoplasms, ARN nucleolar pequeño, Small nucleolar RNA, MicroARNs, Multidisciplinary, Línea celular, Diseases::Neoplasms::Neoplastic Processes::Carcinogenesis [Medical Subject Headings], Housekeeping gene, Gene Expression Regulation, Neoplastic, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Research Design::Reproducibility of Results [Medical Subject Headings], Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology [Medical Subject Headings], 030220 oncology & carcinogenesis, Neoplasias de la mama, Biología computacional, Carcinogénesis, Tumour heterogeneity, Chemicals and Drugs::Biological Factors::Biomarkers [Medical Subject Headings], Computational biology, Biology, Real-Time Polymerase Chain Reaction, Article, 03 medical and health sciences, Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Essential [Medical Subject Headings], Cell Line, Tumor, microRNA, Biomarkers, Tumor, medicine, Humans, Neoplasias del colon, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Reacción en cadena en tiempo real de la polimerasa, Reproducibilidad de resultados, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Nucleic Acid Amplification Techniques::Polymerase Chain Reaction::Real-Time Polymerase Chain Reaction [Medical Subject Headings], Computational Biology, Cancer, Oncogenes, medicine.disease, Antineoplásicos, Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs [Medical Subject Headings], MicroRNAs, 030104 developmental biology, Biomarcadores, Cancer cell, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Colonic Neoplasms [Medical Subject Headings], Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Neoplasm::Oncogenes [Medical Subject Headings], Carcinogenesis, Genes esenciales
Abstract: Oncogenic microRNAs (miRs) have emerged as diagnostic biomarkers and novel molecular targets for anti-cancer drug therapies. Real-time quantitative PCR (qPCR) is one of the most powerful techniques for analyzing miRs; however, the use of unsuitable normalizers might bias the results. Tumour heterogeneity makes even more difficult the selection of an adequate endogenous normalizer control. Here, we have evaluated five potential referenced small RNAs (U6, rRNA5s, SNORD44, SNORD24 and hsa-miR-24c-3p) using RedFinder algorisms to perform a stability expression analysis in i) normal colon cells, ii) colon and breast cancer cell lines and iii) cancer stem-like cell subpopulations. We identified SNORD44 as a suitable housekeeping gene for qPCR analysis comparing normal and cancer cells. However, this small nucleolar RNA was not a useful normalizer for cancer stem-like cell subpopulations versus subpopulations without stemness properties. In addition, we show for the first time that hsa-miR-24c-3p is the most stable normalizer for comparing these two subpopulations. Also, we have identified by bioinformatic and qPCR analysis, different miR expression patterns in colon cancer versus non tumour cells using the previously selected suitable normalizers. Our results emphasize the importance of select suitable normalizers to ensure the robustness and reliability of qPCR data for analyzing miR expression.
Published: 2017

42. Osteoprotegerin and breast cancer risk by hormone receptor subtype: A nested case-control study in the EPIC cohort

Author: Miren Dorronsoro, Marc J. Gunter, Mathilde His, Helena Schock, Sabina Sieri, Maria Dolores Chirlaque, Aurélie Affret, Rudolf Kaaks, Elisabete Weiderpass, H. Bas Bueno-de-Mesquita, Philippos Orfanos, Melissa A. Merritt, Anne Tjønneland, Domenico Palli, J. Ramón Quirós, María José Sánchez, Theron Johnson, Danja Sarink, Eva Ardanaz, Antonio Agudo, Renée T. Fortner, Laure Dossus, Timothy J. Key, Kim Overvad, Rosario Tumino, Androniki Naska, Petra H.M. Peeters, Heiner Boeing, Amalia Mattiello, Anja Olsen, Sabina Rinaldi, Eiliv Lund, Antonia Trichopoulou, Carla H. van Gils, Marie-Christine Boutron-Ruault, Kay-Tee Khaw, Elio Riboli, Fulvio Ricceri, Khaw, Kay-Tee [0000-0002-8802-2903], Apollo - University of Cambridge Repository, University Medical Center Utrecht, Imperial College Trust, [Fortner,RT, Sarink,D, Schock,H, Johnson,T, Kaaks,R] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Tjønneland,A, Olsen,A] Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark. [Overvad,K] Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark. [Affret,A, His,M, Boutron-Ruault,MC] Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France. [Affret,A, Boutron-Ruault,MC] Villejuif, France. [Boeing,H] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. [Trichopoulou,A, Naska,A, Orfanos,P] Hellenic Health Foundation, Athens, Greece. [Trichopoulou,A, Orfanos,P] WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece. [Palli,D] Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy. [Sieri,S] Epidemiology and Prevention Unit, Department of Preventive & Predictive Medicine Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Mattiello,A] Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy. [Tumino,R] Cancer Registry and Histopathology Unit, 'Civic - M.p.Arezzo' Hospital, ASP Ragusa, Italy. [Ricceri,F] Unit of Epidemiology, Regional Health Service ASL TO3, Grugliasco (TO), Italy. [Ricceri,F] Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy. [Bueno-de-Mesquita,HB] Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. [Bueno-de-Mesquita,HB, Merritt,MA, Riboli,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Bueno-de-Mesquita,HB] Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. [Peeters,PH, Van Gils,CH] Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands. [Peeters,PH] MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK. [Weiderpass,E, Lund,E] Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. [Weiderpass,E] Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway. [Weiderpass,E] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. [Weiderpass,E] Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland. [Quirós,JR] Public Health Directorate, Asturias, Spain. [Agudo,A] Unit of Nutrition and Cancer. Cancer Epidemiology Research Program. Catalan Institute of Oncology-IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain. [Sánchez,MJ] Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs. GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. [Sánchez,MJ, Chirlaque,MD, Ardanaz,E] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Chirlaque,MD] Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Chirlaque,MD] Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Ardanaz,E] IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. [Dorronsoro,M] Public Health Direction and Biodonostia Research Institute CIBERESP, Basque Regional Health Department, San Sebastian, Spain. [Key,T] Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Khaw,KT] Cancer Epidemiology Unit, University of Cambridge, Cambridge, UK. [Rinaldi,S, Dossus,L, Gunter,M] International Agency for Research on Cancer, Lyon, France., This project was funded by research grant 111454 from the Deutsche Kresbshilfe. RT Fortner was supported by a Marie Curie International Incoming Fellowship of the European Commission’s Seventh Framework Programme (MC-IIF-623984). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and the National Research Council (Italy), the Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (The Netherlands), ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, and Navarra, and ISCIII RETIC (RD06/0020) (Spain), the Swedish Cancer Society, Swedish Research Council, and County Councils of Skåne and Västerbotten (Sweden), and Cancer Research UK (14136 to EPIC-Norfolk, and C570/A16491 and C8221/A19170 to EPIC-Oxford), and the Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK).
Subjects: 0301 basic medicine, Oncology, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Transcription Factors::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Progesterone [Medical Subject Headings], Estrogen receptor, Progesterone receptor, Cohort Studies, 0302 clinical medicine, Breast cancer, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Tumor Necrosis Factor::Receptor Activator of Nuclear Factor-kappa B [Medical Subject Headings], Risk Factors, Prospective Studies, Prospective cohort study, Medicine(all), Osteoprotegerina, biology, VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, 11 Medical And Health Sciences, General Medicine, Middle Aged, Necrosi, 3. Good health, European Prospective Investigation into Cancer and Nutrition, RANK axis, RANKL, 030220 oncology & carcinogenesis, Neoplasias de la mama, Female, Research Article, musculoskeletal diseases, medicine.medical_specialty, Receptores estrogénicos, Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings], Breast Neoplasms, Receptores de progesterona, Receptores de hormonas, Hormone receptor, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Estrogen [Medical Subject Headings], Càncer de mama, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], Necrosis, 03 medical and health sciences, Osteoprotegerin, General & Internal Medicine, Internal medicine, Journal Article, medicine, Humans, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], business.industry, Case-control study, medicine.disease, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Prospective Studies [Medical Subject Headings], 030104 developmental biology, Endocrinology, Case-Control Studies, Nested case-control study, Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause::Postmenopause [Medical Subject Headings], biology.protein, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Tumor Necrosis Factor::Tumor Necrosis Factor Decoy Receptors::Osteoprotegerin [Medical Subject Headings], VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, business
Abstract: All Author: Renée T. Fortner, Danja Sarink, Helena Schock, Theron Johnson, Anne Tjønneland, Anja Olsen, Kim Overvad, Aurélie Affret, Mathilde His, Marie-Christine Boutron-Ruault, Heiner Boeing, Antonia Trichopoulou, Androniki Naska, Philippos Orfanos, Domenico Palli, Sabina Sieri, Amalia Mattiello, Rosario Tumino, Fulvio Ricceri, H. Bas Bueno-de-Mesquita, Petra H. M. Peeters, Carla H. Van Gils, Elisabete Weiderpass, Eiliv Lund, J. Ramón Quirós, Antonio Agudo, Maria-José Sánchez, María-Dolores Chirlaque, Eva Ardanaz, Miren Dorronsoro, Tim Key, Kay-Tee Khaw, Sabina Rinaldi, Laure Dossus, Marc Gunter, Melissa A. Merritt, Elio Riboli and Rudolf Kaaks, Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study. Methods: A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER–, n = 386), matched 1:1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Results: The associations between OPG and ER+ and ER– breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER– breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24–3.02]; ptrend = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER– disease did not differ by menopausal status at blood collection (phet = 0.97), and we observed no heterogeneity by HT use at blood collection (phet ≥ 0.43) or age at breast cancer diagnosis (phet ≥ 0.30). Conclusions: This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER– breast cancer., This project was funded by research grant 111454 from the Deutsche Kresbshilfe. RT Fortner was supported by a Marie Curie International Incoming Fellowship of the European Commission’s Seventh Framework Programme (MC-IIF-623984). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and the National Research Council (Italy); the Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, and Navarra, and ISCIII RETIC (RD06/0020) (Spain); the Swedish Cancer Society, Swedish Research Council, and County Councils of Skåne and Västerbotten (Sweden); and Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), and the Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK).
Published: 2017
Full Text: View/download PDF

43. Geographical and Temporal Variations in Female Breast Cancer Mortality in the Municipalities of Andalusia (Southern Spain)

Author: Carmen Montaño-Remacha, José María Mayoral-Cortés, Ricardo Ocaña-Riola, [Ocaña-Riola,R] Escuela Andaluza de Salud Pública, Spain. [Ocaña-Riola,R] Instituto de Investigación Biosanitaria de Granada, Spain. [Montaño-Remacha,C, Mayoral-Cortés,JM] Servicio de Epidemiología y Salud Laboral, Dirección General de Salud Pública y Ordenación Farmacéutica, Secretaría General de Salud Pública y Consumo, Consejería de Salud de la Junta de Andalucía, Spain., [Ocana-Riola, Ricardo] Escuela Andaluza Salud Publ, Cuesta Observ 4, Granada 18011, Spain, [Ocana-Riola, Ricardo] Inst Invest Biosanitaria Granada, Doctor Azpitarte 4,4 Planta, Granada 18012, Spain, [Montano-Remacha, Carmen] Consejeria Salud Junta Andalucia, Secretaria Gen Salud Publ & Consumo, Direcc Gen Salud Publ & Ordenac Farmaceut, Serv Epidemiol & Salud Laboral, Ave Innovac S-N,Edificio Arena 1, Seville 41020, Spain, and [Mayoral-Cortes, Jose Maria] Consejeria Salud Junta Andalucia, Secretaria Gen Salud Publ & Consumo, Direcc Gen Salud Publ & Ordenac Farmaceut, Serv Epidemiol & Salud Laboral, Ave Innovac S-N,Edificio Arena 1, Seville 41020, Spain
Subjects: Health, Toxicology and Mutagenesis, España, Bayesian analysis, lcsh:Medicine, Rate ratio, spatial statistics, 0302 clinical medicine, Breast cancer, 030212 general & internal medicine, Patterns, Andalusia, Aged, 80 and over, Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings], education.field_of_study, Geography, Spatial statistics, Mortality rate, small areas, Middle Aged, Europe, Trend analysis, Health, Information Science::Information Science::Information Storage and Retrieval::Databases as Topic::Databases, Factual::Geographic Information Systems [Medical Subject Headings], 030220 oncology & carcinogenesis, Neoplasias de la mama, Female, Seasons, Adult, Adolescent, Population, Sistemas de Información Geográfica, Breast Neoplasms, Spatial distribution, Article, Geographical Information System, Young Adult, 03 medical and health sciences, breast cancer, medicine, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Bayes Theorem [Medical Subject Headings], Humans, Teorema de Bayes, Mortality, education, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Aged, Female breast cancer, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], lcsh:R, Public Health, Environmental and Occupational Health, Ecological study, Bayes Theorem, medicine.disease, mortality, Small areas, Check Tags::Female [Medical Subject Headings], Spain, Disciplines and Occupations::Natural Science Disciplines::Earth Sciences::Geography [Medical Subject Headings], Mortalidad, trend analysis, Trends, Demography
Abstract: The last published figures have shown geographical variations in mortality with respect to female breast cancer in European countries. However, national health policies need a dynamic image of the geographical variations within the country. The aim of this paper was to describe the spatial distribution of age-specific mortality rates from female breast cancer in the municipalities of Andalusia (southern Spain) and to analyze its evolution over time from 1981 to 2012. An ecological study was devised. Two spatio-temporal hierarchical Bayesian models were estimated. One of these was used to estimate the age-specific mortality rate for each municipality, together with its time trends, and the other was used to estimate the age-specific rate ratio compared with Spain as a whole. The results showed that 98% of the municipalities exhibited a decreasing or a flat mortality trend for all the age groups. In 2012, the geographical variability of the age-specific mortality rates was small, especially for population groups below 65. In addition, more than 96.6% of the municipalities showed an age-specific mortality rate similar to the corresponding rate for Spain, and there were no identified significant clusters. This information will contribute towards a reflection on the past, present and future of breast cancer outcomes in Andalusia Yes
Published: 2016

44. Radiation-induced breast angiosarcoma: a case report

Author: Sara Pabón-Fernández, Manolo La Calle-Marcos, Diego Núñez-García, Rosa Albalat-Fernández, Sara Tato-Varela, [Tato-Varela,s, Albalat-Fernández,R, and La Calle-Marcos,M] Clinical Management Unit of Gynaecology and Obstetrics, Hospital Universitario Virgen Macarena, Seville, Spain. [Pabón-Fernández,S] Pathological Anatomy Service, Hospital Universitario Virgen Macarena, Seville, Spain. [Núñez-García,D] Family and Community Medicine, Hospital Universitario Virgen Macarena, Seville, Spain.
Subjects: Cancer Research, medicine.medical_specialty, Neoplasias inducidas por radiación, medicine.medical_treatment, Hemangiosarcoma, Radiation induced, Case Report, Secondary angiosarcoma, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 03 medical and health sciences, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma::Hemangiosarcoma [Medical Subject Headings], 0302 clinical medicine, Breast cancer, breast cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Reconstructive Surgical Procedures::Mammaplasty [Medical Subject Headings], medicine, breast reconstruction, Breast reconstruction, Diseases::Neoplasms::Neoplasms, Radiation-Induced [Medical Subject Headings], Anodyne, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Radiation, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Survival Rate [Medical Subject Headings], business.industry, Incidence (epidemiology), Breast angiosarcoma, Analgésicos, medicine.disease, Surgery, Radiation therapy, radiation, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Peripheral Nervous System Agents::Sensory System Agents::Analgesics [Medical Subject Headings], Oncology, Mamoplastia, 030220 oncology & carcinogenesis, Neoplasias de la mama, secondary angiosarcoma, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], 030211 gastroenterology & hepatology, Radiology, business
Abstract: Radiation-induced breast angiosarcoma is a severe but rare late complication in the breast-preserving management of breast cancer through surgery and radiotherapy [1]. Often the initial diagnosis of this entity is complex given its relatively anodyne nature and usually being present in the form of typically multifocal reddish-purple papular skin lesions [2]. Because of the low incidence of this tumour, there is a limited number of studies regarding its optimal therapeutic management [3]. The preferred treatment is aggressive surgical removal and the prognosis is poor with an overall survival rate of 12-20% at five years [4]. Yes
Published: 2016

45. Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group

Author: Jesús Alfaro, José Miramón, José Gómez-Codina, Rut Álvarez, Javier Lavernia, Esteban Nogales, Mariano Provencio, Francisco Ramon Garcia Arroyo, David Aguiar-Bujanda, Natividad Martínez, Fernando Fabio Franco Pérez, Francisco Menarguez, Mayte Delgado, Maria Torrente, Miguel Ángel Marín, Ana Royuela, Delvys Rodriguez Abreu, Cristina Quero, Josep Gumá, Marta Llanos, [Franco Perez, Fernando] Hosp Univ Puerta Hierro, Dept Med Oncol, Majadahonda, Spain, [Torrente, Maria] Hosp Univ Puerta Hierro, Dept Med Oncol, Majadahonda, Spain, [Provencio, Mariano] Hosp Univ Puerta Hierro, Dept Med Oncol, Majadahonda, Spain, [Lavernia, Javier] Inst Valenciano Oncolog, Dept Med Oncol, Valencia, Spain, [Aguiar-Bujanda, David] Hosp Univ Gran Canaria Doctor Negr, Dept Med Oncol, Las Palmas Gran Canaria, Spain, [Miramon, Jose] Hosp Serrania Ronda, Dept Med Oncol, Malaga, Spain, [Guma, Josep] Hosp Univ Sant Joan Reus, Dept Med Oncol, Reus, Spain, [Alvarez, Rut] Hosp Univ Virgen Salud, Dept Med Oncol, Toledo, Spain, [Gomez-Codina, Jose] Hosp Univ Politecn Le Fe, Dept Med Oncol, Valencia, Spain, [Garcia Arroyo, Francisco] Complejo Hospitalario Pontevedra, Dept Med Oncol, Pontevedra, Spain, [Llanos, Marta] Hosp Univ Canarias, Dept Med Oncol, San Cristobal la Laguna, Spain, [Marin, Miguel] Hosp Clinico Univ Virgen La Arrixaca, Dept Med Oncol, Murcia, Spain, [Alfaro, Jesus] Inst Oncol Kurxa, Dept Med Oncol, Donistia, Spain, [Quero, Cristina] Hosp Univ Virgen La Victoria, Dept Med Oncol, Malaga, Spain, [Delgado, Mayte] Hosp Univ San Cecilio, Dept Med Oncol, Granada, Spain, [Nogales, Esteban] Hosp Univ Virgen La Macarena, Dept Med Oncol, Seville, Spain, [Menarguez, Francisco] Hosp Gen Univ Elche, Dept Med Oncol, Alicante, Spain, [Martinez, Natividad] Hosp Gen Univ Elche, Dept Med Oncol, Alicante, Spain, [Royuela, Ana] Hosp Univ Puerta Hierro, Dept Biostat, Majadahonda, Spain, [Abreu, Delvys] Hosp Univ Insular Gran Canaria, Dept Med Oncol, Las Palmas Gran Canaria, Spain, [Franco Pérez,F, Torrente,M, Provencio,M] Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Lavernia,J] Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain. [Aguiar-Bujanda,D] Department of Medical Oncology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canarias, Spain. [Miramón,J] Department of Medical Oncology, Hospital Serranía de Ronda, Málaga, Spain. [Gumá,J] Department of Medical Oncology, Hospital Universitari Sant Joan de Reus, Reus, Spain. [Álvarez,R] Department of Medical Oncology, Hospital Universitario Virgen de la Salud, Toledo, Spain. [Gómez-Codina,J] Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. [García Arroyo,F] Department of Medical Oncology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain. [Llanos,M] Department of Medical Oncology, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain. [Marin,M] Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. [Alfaro,J] Department of Medical Oncology, Instituto Oncológico de Kutxa, Donostia, Spain. [Quero,C] Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Delgado,M] Department of Medical Oncology, Hospital Universitario San Cecilio, Granada, Spain. [Nogales,E] Department of Medical Oncology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain. [Menarguez,F, and Martinez,N] Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain. [Royuela,A] Department of Biostatistics, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Abreu,D] Department of Medical Oncology, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canarias, Spain.
Subjects: 0301 basic medicine, Oncology, Male, Cancer Research, Survival, Lymphoma, medicine.medical_treatment, Anatomy::Body Regions::Breast::Mammary Glands, Human [Medical Subject Headings], neoplasias de la mama, cancer de mama, oncología médica, Medical Oncology, radioterapia, Supervivencia sin rnfermedad, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Diseases::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin [Medical Subject Headings], immune system diseases, hemic and lymphatic diseases, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [Medical Subject Headings], Breast, Neoplasms of the breast, Stage (cooking), Multicenter, Lymph node, inmunoterapia, Aged, 80 and over, Patient, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Remission Induction [Medical Subject Headings], B-cell lymphoma, Incidence (epidemiology), Follow-up, Lymphoma, Non-Hodgkin, Lumpectomy, Ganglios linfáticos, Diseases::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma [Medical Subject Headings], Hematology, Middle Aged, Prognosis, medicine.anatomical_structure, Treatment Outcome, Consenso, Non-hodgkins-lymphoma, mama, 030220 oncology & carcinogenesis, Rituximab, Female, Immunotherapy, Incidencia, medicine.drug, Adult, medicine.medical_specialty, tumores de mama, Antineoplastic Agents, Breast Neoplasms, Outcomes, Disease-Free Survival, Breast Neoplasms, Male, 03 medical and health sciences, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings], Internal medicine, medicine, Chemotherapy, Humans, Extranodal lymphoma, linfoma, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Aged, linfoma no Hodgkin, Radiotherapy, business.industry, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus [Medical Subject Headings], Prognostic-factors, medicine.disease, Radiation therapy, 030104 developmental biology, Check Tags::Female [Medical Subject Headings], Glándulas mamarias humanas, Quimioterapia, Lymph Nodes, business, Anatomy::Tissues::Lymphoid Tissue::Lymph Nodes [Medical Subject Headings], Clinicopathological features
Abstract: We reviewed 55 patients diagnosed with primary breast lymphoma, stages IE and IIE, in 16 Spanish institutions. Of the 55 cases, 96.4% corresponded to non-Hodgkin lymphoma. Results of 5-year progression-free and overall survival were 73% and 76%, respectively. Current treatments achieve good control of the disease, with an overall survival of 5 years in 80% of the patients.Introduction: Primary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary glands unilaterally or bilaterally, and can also affect the regional lymph nodes. Materials and Methods: We reviewed 55 patients, with disease stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were calculated. Results: Of the 55 patients, 96.4% were women with an average age of 69 years. A total of 53 patients corresponded to non-Hodgkin lymphoma (NHL), of whom 36.3% had lymph node involvement upon diagnosis. Of the patients, 58.2% were stage IE, and 41.8% were stage IIE. Treatments received included radiotherapy (36.3%), chemotherapy (85.5%), and rituximab (in 38 of the 45 patients with NHL treated with chemotherapy). In all, 82.2% of complete responses were achieved. OS and progression-free survival at 5 years in NHL patients was 76% and 73%, respectively. Conclusion: Current treatments (chemotherapy, immunotherapy, and radiotherapy) achieve good control of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the scarce incidence of these lymphomas. (C) 2016 The Authors. Published by Elsevier Inc.
Published: 2016

46. The INSIG2 rs7566605 polymorphism is not associated with body mass index and breast cancer risk

Author: Olga M. Sinilnikova, Rudolf Kaaks, Pilar Amiano, Anne Tjønneland, José Ramón Quirós, Eiliv Lund, Daniele Campa, Carla H. van Gils, Göran Hallmans, Kay-Tee Khaw, H. Bas Bueno-de-Mesquita, Anika Hüsing, Sabina Rinaldi, Nicholas J. Wareham, Nathalie Chabbert-Buffet, Kim Overvad, Eva Ardanaz, Sabine Rohrmann, Vittorio Krogh, Federico Canzian, Giovanna Masala, Françoise Clavel-Chapelon, María Dolores Chirlaque, Per Lenner, Carlotta Sacerdote, Esther Molina-Montes, Guy Fagherazzi, Jakob Stegger, James McKay, N. Charlotte Onland-Moret, Salvatore Panico, Rosario Tumino, Afshan Siddiq, Birgit Teucher, Timothy J. Key, Erifili Oustoglou, Ruth C. Travis, Veronique Chajes, Dimosthenis Zylis, Ulla Vogel, Antonia Trichopoulou, Elio Riboli, Nadia Slimani, Heiner Boeing, Núria Sala, Eva Fisher, Wareham, Nicholas [0000-0003-1422-2993], Khaw, Kay-Tee [0000-0002-8802-2903], Apollo - University of Cambridge Repository, Campa, D, Hüsing, A, Mckay, Jd, Sinilnikova, O, Vogel, U, Tjønneland, A, Overvad, K, Stegger, J, Clavel Chapelon, F, Chabbert Buffet, N, Fagherazzi, G, Trichopoulou, A, Zylis, D, Oustoglou, E, Rohrmann, S, Teucher, B, Fisher, E, Boeing, H, Masala, G, Krogh, V, Sacerdote, C, Panico, Salvatore, Tumino, R, Onland Moret, Nc, van Gils, Ch, Bueno de Mesquita, Hb, Lund, E, Chirlaque, Md, Sala, N, Quirós, Jr, Ardanaz, E, Amiano, P, Molina Montes, E, Hallmans, G, Lenner, P, Travis, Rc, Key, Tj, Wareham, N, Khaw, Kt, Rinaldi, S, Slimani, N, Chajes, V, Siddiq, A, Riboli, E, Kaaks, R, Canzian, F., and [Campa D, Hüssing A, Rohrmann S, Teucher B, Kaaks R, Canzian F] German Cancer Research Center (DKFZ), Heidelberg, Germany. [McKay JD, Slimani N, Chajes V] International Agency for Research on Cancer, Lyon, France. [Sinilnikova O] Hospices Civils de Lyon/Centre Léon Bérard, UMR5201 CNRS-Université Claude Bernard, Lyon, France. [Vogel U] National Food Institute Technical University of Denmark, Denmark. [Tjønneland A] Danish Cancer Society, Copenhagen, Denmark. [Overvad K] Aarhus University Hospital, Aalborg, Denmark. [Stegger J] Department of Cardiology, Cardiovascular Research Centre, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. [Clavel-Chapelon F, Chabbert-Buffet N, Fagherazzi G] Institut Gustave Roussy, Villejuif, France. [Trichopoulou A, Zylis D] WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece. [Trichopoulou A, Oustoglou E] Hellenic Health Foundation, Athens, Greece. [Fisher E, Boeing H] German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany. [Masala G] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy. [Krogh V] Istituto Nazionale dei Tumori (IRCCS), Milan, Italy. [Sacerdote C] CPO Piemonte, Turin, Italy. [Panico S] Department of Clinical and Experimental Medicine Federico II University, Naples, Italy. [Tumino R] Azienda Ospedaliera 'Civile M.P.Arezzo' Ragusa, Italy. [Onland-Moret NC, van Gils CH] Julius Center, University Medical Center, Utrecht, The Netherlands. [Bueno-de-Mesquita HB] National Institute for Public Health and the Environment, Bilthoven, The Netherlands. [Lund E] Institute of Community Medicine University of Tromsø, Tromsø, Norway. [Chirlaque MD] Murcia Regional Health Council, Murcia, Spain. [Sala N] Catalan Institute of Oncology, Barcelona, Spain. [Quirós JR] Consejería de Salud y Servicios Sanitarios Principado de Asturias, Oviedo, Spain. [Ardanaz E] Public Health Institute of Navarra, Pamplona, Spain. [Amiano P] Public Health Department of Gipuzkoa, San Sebastian, Spain. [Molina-Montes E] Andalusian School of Public Health, Granada, Spain. [Chirlaque MD, Amiano P, Molina-Montes E] CIBER de Epidemiología y Salud Pública (CIBERESP), Spain. [Hallmans G, Lenner2 P] Umeå University, Umeå, Sweden. [Travis RC, Key TJ] Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK OX3 7LF. [Wareham N, Khaw KT] University of Cambridge, Cambridge, UK. [Siddiq A, Riboli E] Imperial College, London, UK.
Subjects: Oncology, Aging, Cancer Research, Genome-wide association study, 32 Biomedical and Clinical Sciences, Body Mass Index, Cohort Studies, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Research Design::Genome-Wide Association Study [Medical Subject Headings], 0302 clinical medicine, 2.1 Biological and endogenous factors, membrane protein, POPULATION, Cancer, 2. Zero hunger, 2 Aetiology, 0303 health sciences, education.field_of_study, Intracellular Signaling Peptides and Proteins, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 4203 Health Services and Systems, 3. Good health, Índice de masa muscular, INSIG2 protein, Adipose Tissue, Neoplasias de la mama, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins [Medical Subject Headings], Female, Life Sciences & Biomedicine, Cohort study, Research Article, Adult, Risk, medicine.medical_specialty, VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk genetikk: 714, Genotype, Estudios de cohortes, Population, Polimorfismo Genético, COMMON GENETIC VARIANT, PHENOTYPES, 030209 endocrinology & metabolism, Single-nucleotide polymorphism, Breast Neoplasms, VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical genetics: 714, lcsh:RC254-282, Estudio de Asociación del Genoma Completo, 03 medical and health sciences, Breast cancer, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], SDG 3 - Good Health and Well-being, Clinical Research, Internal medicine, Breast Cancer, POLYGENIC CONTRIBUTION, medicine, Genetics, Humans, signal peptide, Neoplasm Invasiveness, Obesity, human, education, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], 030304 developmental biology, Nutrition, Aged, Science & Technology, Polymorphism, Genetic, Models, Genetic, business.industry, VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762, Prevention, Case-control study, 42 Health Sciences, Membrane Proteins, DNA, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic [Medical Subject Headings], medicine.disease, 3211 Oncology and Carcinogenesis, Health Care::Environment and Public Health::Public Health::Epidemiologic Measurements::Biometry::Anthropometry::Body Mass Index [Medical Subject Headings], VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762, Case-Control Studies, Immunology, INSIG2 protein, human, business, Body mass index, Genome-Wide Association Study
Abstract: Background The single nucleotide polymorphism rs7566605, located in the promoter of the INSIG2 gene, has been the subject of a strong scientific effort aimed to elucidate its possible association with body mass index (BMI). The first report showing that rs7566605 could be associated with body fatness was a genome-wide association study (GWAS) which used BMI as the primary phenotype. Many follow-up studies sought to validate the association of rs7566605 with various markers of obesity, with several publications reporting inconsistent findings. BMI is considered to be one of the measures of choice to evaluate body fatness and there is evidence that body fatness is related with an increased risk of breast cancer (BC). Methods we tested in a large-scale association study (3,973 women, including 1,269 invasive BC cases and 2,194 controls), nested within the EPIC cohort, the involvement of rs7566605 as predictor of BMI and BC risk. Results and Conclusions In this study we were not able to find any statistically significant association between this SNP and BMI, nor did we find any significant association between the SNP and an increased risk of breast cancer overall and by subgroups of age, or menopausal status.
Published: 2016
Full Text: View/download PDF

47. Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid

Author: Alberto Jiménez-Burkhardt, Ana-Belén Marín-Fernández, Blas García Medina, Antonio Aguilar-Salvatierra, Gerardo Gómez-Moreno, [Marín-Fernández,AB, García Medina,B] Oral and Maxillofacial Surgery Service, Virgen de las Nieves University Hospital, Granada, Spain. [Aguilar-Salvatierra,A] Faculty of Dentistry, University of Granada, Granada, Spain. [Jiménez-Burkhardt,A, and Gómez-Moreno,G] Department of Special Care in Dentistry, Faculty of Dentistry, University of Granada, Granada, Spain.
Subjects: Peri-implantitis, Bone disease, medicine.medical_treatment, Difosfonatos, Dentistry, Case Report, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Dental implant, Chemicals and Drugs::Organic Chemicals::Organophosphorus Compounds::Diphosphonates [Medical Subject Headings], Implantes dentales, Anatomy::Cells::Connective Tissue Cells::Macrophages::Osteoclasts [Medical Subject Headings], Imidazoles, Osteonecrosis, Bisphosphonates, Diseases::Neoplasms [Medical Subject Headings], CIENCIAS MÉDICAS [UNESCO], Ciencias de la salud, Neoplasias, Humanos, medicine.anatomical_structure, Neoplasias de la mama, Chemicals and Drugs::Biomedical and Dental Materials::Dental Materials::Dental Implants [Medical Subject Headings], UNESCO::CIENCIAS MÉDICAS, Maxillectomy, Diseases::Stomatognathic Diseases::Mouth Diseases::Peri-Implantitis [Medical Subject Headings], Oral Surgery, Resorción ósea, medicine.drug, medicine.medical_specialty, Odontología, Diseases::Musculoskeletal Diseases::Bone Diseases::Osteonecrosis [Medical Subject Headings], Bone resorption, Breast cancer, Osteoclast, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Imidazoles [Medical Subject Headings], medicine, Periimplantitis, General Dentistry, Zoledronic acid, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Osteonecrosis of the jaw, business.industry, Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Musculoskeletal Physiological Processes::Bone Remodeling::Bone Resorption [Medical Subject Headings], Osteoclastos, medicine.disease, Surgery, Check Tags::Female [Medical Subject Headings], business
Abstract: Journal Article; Bisphosphonates (BP) are a type of drug known to inhibit bone resorption through complex interventions. Their primary mechanism of action is aimed at the cellular level, inhibiting osteoclast activity and so bone resorption. BPs are widely used, with many patients receiving continuous treatment for years. But it is well known that these drugs can produce osteonecrosis of the jaw (ONJ). Zoledronic acid (ZA) is an intravenous BP used in the treatment and prophylaxis of bone disease in patients with malignant tumors with bone implication. ZA is the most potent BP in clinical development. This report describes the case of a 62-year-old woman with breast cancer antecedents which relapsed, who had received a maxillary dental implant two years before the start of therapy with zoledronic acid. She later developed osteonecrosis of the jaw (ONJ), which began in the peri-implant area, and was treated for stage 3 ONJ by sub-total maxillectomy. Key words:Bisphosphonates, zoledronic acid, osteonecrosis of the jaw, peri-implantitis, maxillectomy. Yes
Published: 2015
Full Text: View/download PDF

48. Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Author: Miguel, Martín, Alvaro, Rodríguez-Lescure, Amparo, Ruiz, Emilio, Alba, Lourdes, Calvo, Manuel, Ruiz-Borrego, Blanca, Munárriz, César A, Rodríguez, Carmen, Crespo, Enrique, de Alava, José Antonio, López García-Asenjo, María Dolores, Guitián, Sergio, Almenar, Jesús Fernando, González-Palacios, Francisco, Vera, José, Palacios, Manuel, Ramos, Jose Manuel, Gracia Marco, Ana, Lluch, Isabel, Alvarez, Miguel Angel, Seguí, José Ignacio, Mayordomo, Antonio, Antón, José Manuel, Baena, Arrate, Plazaola, Alfonso, Modolell, Amadeu, Pelegrí, Jose Ramón, Mel, Enrique, Aranda, Encarna, Adrover, José Valero, Alvarez, José Luis, García Puche, Pedro, Sánchez-Rovira, Sonia, Gonzalez, José Manuel, López-Vega, M Francisca, Garijo, GEICAM 9906 Study Investigators, [Martín,M] Department of Medical Oncology, Hospital Universitario San Carlos, Madrid, Spain. [López García-Asenjo,JA] Department of Pathology, Hospital Universitario San Carlos, Madrid, Spain. [Rodríguez-Lescure,A] Department of Medical Oncology, Hospital Universitario de Elche, Spain. [Ruiz,A] Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain. [Almenar,S] Department of Pathology, Instituto Valenciano de Oncologia, Valencia, Spain. [Alba Conejo,E] Department of Medical Oncology, Hospital Virgen de la Victoria, Málaga, Spain. [Calvo,L] Department of Medical Oncology, Complejo Hospitalario Juan Canalejo, La Coruña, Spain. [Guitián,MD] Department of Pathology, Complejo Hospitalario Juan Canalejo, La Coruña, Spain. [Ruiz-Borrego,M] Department of Medical Oncology, Hospital Vírgen del Rocío, Sevilla, Spain [Palacios,J] Department of Pathology, Hospital Vírgen del Rocío, Sevilla, Spain. [Muñárriz,B] Department of Medical Oncology, Hospital La Fe, Valencia, Spain. [Vera,F] Department of Pathology, Hospital La Fe, Valencia, Spain. [Rodríguez, CA] Department of Medical Oncology, Hospital Universitario de Salamanca, Salamanca, Spain. [Crespo,C] Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain. [González-Palacios,JF] Department of Pathology, Hospital Ramón y Cajal, Madrid, Spain. [de Álava,E] Department of Pathology, Centro de Investigación del Cáncer, Salamanca, Spain. [Ramos,M] Department of Medical Oncology, Centro Oncológico de Galicia, La Coruña, Spain. [Gracia Marco,JM] Department of Medical Oncology, Hospital de Cabueñes, Gijón, Spain. [Lluch,A] Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain. [Álvarez,I] Department of Medical Oncology, Hospital de Donostia, San Sebastián, Spain. [Seguí,MA] Department of Medical Oncology, Hospital Parc Taulí, Sabadell, Spain. [Mayordomo,JI] Department of Medical Oncology, Hospital Clínico Lozano Blesa, Zaragoza, Spain. [Antón,A] Department of Medical Oncology, Hospital Miguel Servet, Zaragoza, Spain. [Baena,JM] Department of Medical Oncology, Complejo Hospitalario Puerta del Mar, Cádiz, Spain. [Plazaola,A] Department of Medical Oncology, Instituto Oncológico de Guipúzcoa, San Sebastián, Spain. [Modolell,A] Department of Medical Oncology, Clínica Corachan, Barcelona, Spain. [Pelegrí,A] Department of Medical Oncology, Hospital Universitario San Joan de Reus, Tarragona, Spain. [Mel,JR] Department of Medical Oncology, Complejo Hospitalario Xeral Calde, Lugo, Spain. [Aranda,E] Department of Medical Oncology, Hospital Provincial de Córdoba, Córdoba, Spain. [Adrover,E] Department of Medical Oncology, Hospital General de Alicante, Alicante, Spain. [Valero Álvarez,J] Hospital Provincial de Zamora, Spain. [García Puche,JL] Department of Medical Oncology, Hospital San Cecilio de Granada, Granada, Spain. [Sánchez-Rovira,P] Department of Medical Oncology, Hospital Ciudad de Jaén, Jaén, Spain. [González,S] Department of Medical Oncology, Mutua de Terrasa, Terrasa, Spain. [López-Vega,JM] Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain., and Department of Medical Oncology, Hospital Ciudad de Jaén, Jaén, Spain
Subjects: Oncology, medicine.medical_treatment, Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Supervivencia sin Enfermedad, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases::Receptor Protein-Tyrosine Kinases::Receptor, erbB-2 [Medical Subject Headings], Antineoplastic Combined Chemotherapy Protocols, Estimación de Kaplan-Meier, Receptor erbB-2, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Administration Schedule [Medical Subject Headings], Hazard ratio, Pronóstico, Epirrubicina, Prognosis, Immunohistochemistry, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Carcinoma, Ductal::Carcinoma, Ductal, Breast [Medical Subject Headings], Receptors, Estrogen, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Neoplasm Staging [Medical Subject Headings], Chemicals and Drugs::Biological Factors::Biological Markers::Tumor Markers, Biological [Medical Subject Headings], Receptors, Progesterone, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Alicyclic::Cycloparaffins::Cyclodecanes::Taxoids::Paclitaxel [Medical Subject Headings], medicine.medical_specialty, Paclitaxel, Fluorouracilo, Axillary lymph nodes, Resultado del Tratamiento, Anciano, Disease-Free Survival, Drug Administration Schedule, Breast cancer, Carcinoma Lobular, Named Groups::Persons::Age Groups::Adult [Medical Subject Headings], Adjuvant therapy, Humans, Cyclophosphamide, Aged, ERBB2 protein, human, medicine.disease, Carcinoma, Lobular, Check Tags::Female [Medical Subject Headings], Modelos de Riesgos Proporcionales, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Histocytological Preparation Techniques::Staining and Labeling::In Situ Hybridization::In Situ Hybridization, Fluorescence [Medical Subject Headings], Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis::Disease-Free Survival [Medical Subject Headings], Cancer Research, Receptor, ErbB-2, Kaplan-Meier Estimate, Antineoplásicos Fitogénicos, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Carcinoma, Lobular [Medical Subject Headings], Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Pyrimidinones::Uracil::Fluorouracil [Medical Subject Headings], Infusions, Intravenous, In Situ Hybridization, Fluorescence, Carcinoma, Ductal, Breast, Neoplasias de la Mama, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Estrogen [Medical Subject Headings], Middle Aged, Chemotherapy regimen, Treatment Outcome, medicine.anatomical_structure, Female, Fluorouracil, Breast disease, Infusiones Intravenosas, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Phytogenic [Medical Subject Headings], Epirubicin, medicine.drug, Adult, Protocolos de Quimioterapia Combinada Antineoplásica, Hibridación Fluorescente In Situ, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Halogenated::Mustard Compounds::Nitrogen Mustard Compounds::Phosphoramide Mustards::Cyclophosphamide [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Progesterone [Medical Subject Headings], Breast Neoplasms, Ciclofosfamida, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Models, Theoretical::Models, Statistical::Proportional Hazards Models [Medical Subject Headings], Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biochemistry::Immunochemistry [Medical Subject Headings], Predictive Value of Tests, Internal medicine, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Polycyclic Hydrocarbons, Aromatic::Naphthacenes::Anthracyclines::Daunorubicin::Doxorubicin::Epirubicin [Medical Subject Headings], Biomarkers, Tumor, medicine, Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Neoplasm Staging, Proportional Hazards Models, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings], Receptores de Progesterona, Chemotherapy, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Kaplan-Meier Estimate [Medical Subject Headings], business.industry, Esquema de Medicación, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Administration Routes::Infusions, Parenteral::Infusions, Intravenous [Medical Subject Headings], Antineoplastic Agents, Phytogenic, Estadificación de Neoplasias, Receptores Estrogénicos, Surgery, Marcadores Biológicos de Tumor, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], business, Carcinoma Ductal de Mama, Inmunohistoquímica
Abstract: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; BACKGROUND Taxanes are among the most active drugs for the treatment of metastatic breast cancer, and, as a consequence, they have also been studied in the adjuvant setting. METHODS After breast cancer surgery, women with lymph node-positive disease were randomly assigned to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or with FEC followed by weekly paclitaxel (FEC-P). The primary endpoint of study-5-year disease-free survival (DFS)-was assessed by Kaplan-Meier analysis. Secondary endpoints included overall survival and analysis of the prognostic and predictive value of clinical and molecular (hormone receptors by immunohistochemistry and HER2 by fluorescence in situ hybridization) markers. Associations and interactions were assessed with a multivariable Cox proportional hazards model for DFS for the following covariates: age, menopausal status, tumor size, lymph node status, type of chemotherapy, tumor size, positive lymph nodes, HER2 status, and hormone receptor status. All statistical tests were two-sided. RESULTS Among the 1246 eligible patients, estimated rates of DFS at 5 years were 78.5% in the FEC-P arm and 72.1% in the FEC arm (difference = 6.4%, 95% confidence interval [CI] = 1.6% to 11.2%; P = .006). FEC-P treatment was associated with a 23% reduction in the risk of relapse compared with FEC treatment (146 relapses in the 614 patients in the FEC-P arm vs 193 relapses in the 632 patients in the FEC arm, hazard ratio [HR] = 0.77, 95% CI = 0.62 to 0.95; P = .022) and a 22% reduction in the risk of death (73 and 95 deaths, respectively, HR = 0.78, 95% CI = 0.57 to 1.06; P = .110). Among the 928 patients for whom tumor samples were centrally analyzed, type of chemotherapy (FEC vs FEC-P) (P = .017), number of involved axillary lymph nodes (P < .001), tumor size (P = .020), hormone receptor status (P = .004), and HER2 status (P = .006) were all associated with DFS. We found no statistically significant interaction between HER2 status and paclitaxel treatment or between hormone receptor status and paclitaxel treatment. CONCLUSIONS Among patients with operable breast cancer, FEC-P treatment statistically significantly reduced the risk of relapse compared with FEC as adjuvant therapy. Yes
Published: 2008
Full Text: View/download PDF

49. Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells

Author: Margarita Aguilera, Carmen Griñán-Lisón, José Manuel Entrena, María Ángel García, Juan A. Marchal, Gema Jiménez, Cynthia Morata-Tarifa, Manuel Picon-Ruiz, [Morata-Tarifa,C, Jiménez,G, García,MA, Griñán-Lisón,C, Picon-Ruiz,M, Marchal,JA] Biopathology and Medicine Regenerative Institute (IBIMER), University of Granada, Granada, Spain. [Morata-Tarifa,C, Aguilera,M, Marchal,JA] Biosanitary Institute of Granada (ibs.GRANADA), University Hospitals of Granada-Univesity of Granada, Granada, Spain. [Jiménez,G, Marchal,JA] Department of Human Anatomy and Embryology, University of Granada, Granada, Spain. [García,MA] Department of Oncology, University Hospital Virgen de las Nieves, Granada, Spain. [Entrena,JM] Institute of Neuroscience, Biomedical Research Center, University of Granada, Granada, Spain. Animal Behavior Research Unit, Scientific Instrumentation Center, University of Granada, Granada, Spain. [Aguilera,M] Department of Microbiology, University of Granada, Granada, Spain. [Picon-Ruiz,M] Braman Family Breast Cancer Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA., and This work was supported in part by grants from the Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (FEDER funds, projects n°. PI10/02295 and PI10/02149), the Fundación Progreso y Salud, Consejería de Salud, Junta de Andalucía (Ministry of Health, Government of Andalucia, project number PI-0533-2014) and by Consejería Economía, Innovación, Ciencia y Empleo, Junta de Andalucia (Ministry of Economy, Innovation, Science and Employment, Government of Andalucia, excellence project number CTS-6568) providing a fellowship granted to GJ.
Subjects: 0301 basic medicine, Pathology, Phenomena and Processes::Genetic Phenomena::Phenotype [Medical Subject Headings], Colorectal cancer, Claudinas, Ratones, Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings], Anatomy::Cells::Stem Cells::Neoplastic Stem Cells [Medical Subject Headings], Índice de masa corporal, Metastasis, Anatomy::Body Regions::Breast [Medical Subject Headings], Mice, 0302 clinical medicine, Immunophenotyping, Vimentina, Neoplasms, Regulación hacia arriba, Organisms::Eukaryota::Animals [Medical Subject Headings], Caracoles, Cell Self Renewal, Neoplasm Metastasis, Side-Population Cells, Tumor Stem Cell Assay, Recurrencia local de neoplasia, Multidisciplinary, Transición epitelial-mesenquimal, Mama, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Benzimidazoles [Medical Subject Headings], Cell Transformation, Neoplastic, Phenotype, 030220 oncology & carcinogenesis, Neoplasias de la mama, Neoplastic Stem Cells, Heterografts, Fenotipo, medicine.medical_specialty, Epithelial-Mesenchymal Transition, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Endopeptidases::Serine Endopeptidases::Trypsin [Medical Subject Headings], Biology, Article, 03 medical and health sciences, Cancer stem cell, Cell Line, Tumor, Xenoinjertos, medicine, Cell Adhesion, Animals, Humans, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Equipment and Supplies::Transplants::Heterografts [Medical Subject Headings], Neoplasias del colon, Epithelial–mesenchymal transition, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Células madre neoplásicas, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings], Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Up-Regulation [Medical Subject Headings], Gene Expression Profiling, Cancer, Diseases::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local [Medical Subject Headings], Organisms::Eukaryota::Animals::Invertebrates::Mollusca::Gastropoda::Snails [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Cell Adhesion Molecules::Cadherins [Medical Subject Headings], medicine.disease, Tripsina, Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs [Medical Subject Headings], Disease Models, Animal, 030104 developmental biology, Tumor progression, Cancer cell, Animales, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Colonic Neoplasms [Medical Subject Headings], Cancer research, Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Transdifferentiation::Epithelial-Mesenchymal Transition [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Claudins [Medical Subject Headings], Chemicals and Drugs::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Vimentin [Medical Subject Headings], Biomarkers, Cadherinas
Abstract: Cancer stem cells are responsible for tumor progression, metastasis, therapy resistance and cancer recurrence, doing their identification and isolation of special relevance. Here we show that low adherent breast and colon cancer cells subpopulations have stem-like properties. Our results demonstrate that trypsin-sensitive (TS) breast and colon cancer cells subpopulations show increased ALDH activity, higher ability to exclude Hoechst 33342, enlarged proportion of cells with a cancer stem-like cell phenotype and are enriched in sphere- and colony-forming cells in vitro. Further studies in MDA-MB-231 breast cancer cells reveal that TS subpopulation expresses higher levels of SLUG, SNAIL, VIMENTIN and N-CADHERIN while show a lack of expression of E-CADHERIN and CLAUDIN, being this profile characteristic of the epithelial-to-mesenchymal transition (EMT). The TS subpopulation shows CXCL10, BMI-1 and OCT4 upregulation, differing also in the expression of several miRNAs involved in EMT and/or cell self-renewal such as miR-34a-5p, miR-34c-5p, miR-21-5p, miR-93-5p and miR-100-5p. Furthermore, in vivo studies in immunocompromised mice demonstrate that MDA-MB-231 TS cells form more and bigger xenograft tumors with shorter latency and have higher metastatic potential. In conclusion, this work presents a new, non-aggressive, easy, inexpensive and reproducible methodology to isolate prospectively cancer stem-like cells for subsequent biological and preclinical studies., Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (FEDER funds) PI10/02295 PI10/02149, Fundacion Progreso y Salud, Consejeria de Salud, Junta de Andalucia (Ministry of Health, Government of Andalucia) PI-0533-2014, Consejeria Economia, Innovacion, Ciencia y Empleo, Junta de Andalucia (Ministry of Economy, Innovation, Science and Employment, Government of Andalucia) CTS-6568
Published: 2016

50. Integral strategy to supportive care in breast cancer survivors through occupational therapy and a m-health system: design of a randomized clinical trial

Author: Manuel Arroyo-Morales, Francisco Álvarez-Salvago, Irene Cantarero-Villanueva, Noelia Galiano-Castillo, Lydia Martín-Martín, Carolina Fernández-Lao, Mario Lozano-Lozano, Carmen Sánchez-Salado, [Lozano-Lozano, Mario] Univ Granada, Dept Phys Therapy, Granada, Spain, [Martin-Martin, Lydia] Univ Granada, Dept Phys Therapy, Granada, Spain, [Galiano-Castillo, Noelia] Univ Granada, Dept Phys Therapy, Granada, Spain, [Alvarez-Salvago, Francisco] Univ Granada, Dept Phys Therapy, Granada, Spain, [Cantarero-Villanueva, Irene] Univ Granada, Dept Phys Therapy, Granada, Spain, [Fernandez-Lao, Carolina] Univ Granada, Dept Phys Therapy, Granada, Spain, [Arroyo-Morales, Manuel] Univ Granada, Dept Phys Therapy, Granada, Spain, [Lozano-Lozano, Mario] Mixed Univ Sport & Hlth Inst iMUDS, Granada, Spain, [Cantarero-Villanueva, Irene] Mixed Univ Sport & Hlth Inst iMUDS, Granada, Spain, [Fernandez-Lao, Carolina] Mixed Univ Sport & Hlth Inst iMUDS, Granada, Spain, [Arroyo-Morales, Manuel] Mixed Univ Sport & Hlth Inst iMUDS, Granada, Spain, [Galiano-Castillo, Noelia] Univ Granada, Inst Biomed Res Ibs GRANADA, Univ Hosp Complex Granada, Granada, Spain, [Cantarero-Villanueva, Irene] Univ Granada, Inst Biomed Res Ibs GRANADA, Univ Hosp Complex Granada, Granada, Spain, [Fernandez-Lao, Carolina] Univ Granada, Inst Biomed Res Ibs GRANADA, Univ Hosp Complex Granada, Granada, Spain, [Arroyo-Morales, Manuel] Univ Granada, Inst Biomed Res Ibs GRANADA, Univ Hosp Complex Granada, Granada, Spain, [Sanchez-Salado, Carmen] Virgen de las Nieves Hosp, Breast Oncol Unit, Granada, Spain, Spanish Ministry of Economy and Competitiveness (Plan Estatal de I + D + I), Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III, Fondos Estructurales de la Union Europea (FEDER), Spanish Ministry of Education, [Lozano-Lozano,M, Martín-Martín,L, Galiano-Castillo,B, Álvarez-Salvago,F, Cantarero-Villanueva,I, Fernández-Lao,C, Arroyo-Morales,M] Department Physical Therapy, University of Granada, Granada, Spain. [Lozano-Lozano,M, Arroyo-Morales,M] Mixed University Sport and Health Institute (iMUDS), Granada, Spain. [Galiano-Castillo,N, Arroyo-Morales,M] Institute for Biomedical Research ibs.GRANADA, University Hospital Complex of Granada/ University of Granada,Granada, Spain. [Sánchez-Salado,C] Breast Oncology Unit, Virgen de las Nieves Hospital, Granada, Spain., and The study was funded by the Spanish Ministry of Economy and Competitiveness (Plan Estatal de I + D + I 2013-2016), Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI14/01627), Fondos Estructurales de la Unión Europea (FEDER) and by the Spanish Ministry of Education (FPU14/01069).
Subjects: medicine.medical_treatment, Physical fitness, Hospital Anxiety and Depression Scale, Anatomy::Body Regions::Breast [Medical Subject Headings], law.invention, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Study Protocol, 0302 clinical medicine, Mobile applications, Randomized controlled trial, Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Muscle Strength::Hand Strength [Medical Subject Headings], law, Depresión, Neoplasms, 030212 general & internal medicine, Survivors, Breast, Phenomena and Processes::Metabolic Phenomena::Body Composition [Medical Subject Headings], Rehabilitation, Health Policy, Mama, Ingestión de energía, Femenino, Middle Aged, Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Energy Intake [Medical Subject Headings], Telemedicine, Humanos, Computer Science Applications, 030220 oncology & carcinogenesis, Neoplasias de la mama, Body-composition, Arm, Brazo, Anxiety, Female, medicine.symptom, Fuerza de la mano, Anatomy::Body Regions::Extremities::Upper Extremity::Arm [Medical Subject Headings], Occupational therapy, Adult, Quality of life, medicine.medical_specialty, Health Informatics, Intervention, Breast Neoplasms, Validity, Ansiedad, 03 medical and health sciences, Breast cancer, medicine, Adjuvant therapy, Humans, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Emotions::Anxiety [Medical Subject Headings], Composición corporal, Exercise, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Aged, Cognición, Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Cognition [Medical Subject Headings], Curative treatment, business.industry, medicine.disease, Check Tags::Female [Medical Subject Headings], Physical therapy, Physical-activity, Surgery, Quality-of-life, European-organization, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Behavioral Symptoms::Depression [Medical Subject Headings], business
Abstract: Background: Technological support using e-health mobile applications (m-health) is a promising strategy to improve the adherence to healthy lifestyles in breast cancer survivors (excess in energy intake or low physical activity are determinants of the risk of recurrence, second cancers and cancer mortality). Moreover, cancer rehabilitation programs supervised by health professionals are needed due to the inherent characteristics of these breast cancer patients. Our main objective is to compare the clinical efficacy of a m-health lifestyle intervention system alone versus an integral strategy to improve Quality of Life in breast cancer survivors. Methods: This therapeutic superiority study will use a two-arm, assessor blinded parallel RCT design. Women will be eligible if: they are diagnosed of stage I, II or III-A breast cancer; are between 25 and 75 years old; have a Body Mass Index > 25 kg/m2; they have basic ability to use mobile apps; they had completed adjuvant therapy except for hormone therapy; and they have some functional shoulder limitations. Participants will be randomized to one of the following groups: integral group will use a mobile application (BENECA APP) and will receive a face-to-face rehabilitation (8-weeks); m-health group will use the BENECA app for 2-months and will received usual care information. Study endpoints will be assessed after 8 weeks and 6 months. The primary outcome will be Quality of Life measured by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core and breast module. The secondary outcomes: body composition; upper-body functionality (handgrip, Disability of the Arm, Shoulder and Hand questionnaire, goniometry); cognitive function (Wechsler Adult Intelligence Scale, Trail Making Test); anxiety and depression (Hospital Anxiety and Depression Scale); physical fitness (Short version of the Minnesota Leisure Time Physical Activity Questionnaire, Self-Efficacy Scale for Physical Activity); accelerometry and lymphedema. Discussion: This study has been designed to seek to address the new needs for support and treatment of breast cancer survivors, reflecting the emerging need to merge new low cost treatment options with much-needed involvement of health professionals in this type of patients. Trial registration: ClinicalTrials.gov Identifier: NCT02817724 (date of registration: 22/06/2016)., The study was funded by the Spanish Ministry of Economy and Competitiveness (Plan Estatal de I + D + I 2013-2016), Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI14/01627), Fondos Estructurales de la Unión Europea (FEDER) and by the Spanish Ministry of Education (FPU14/01069). This is part of a Ph.D. Thesis conducted in the Clinical Medicine and Public Health Doctoral Studies of the University of Granada, Spain.
Published: 2016

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

82 results on '"Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources